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ABSTRACT
MICRORNA-186 AND METASTATIC PROSTATE CANCER
Dominique Zilpha Jones
May 30, 2016

MicroRNA (miR) dysregulation alters cancer-associated gene expression, which
contributes to cancer pathogenesis. For example, miR-186 over expression lead
to enhanced proliferation and migration in pancreatic cancer cell models.
However, the role of miR-186 in prostate cancer (PCa) remains controversial.
Previously, miR-186-5p was up-regulated in PCa patient serum (stage III/IV)
compared to controls. Furthermore, miR-186-5p was up-regulated in metastatic
PCa (PC-3, MDA PCa 2b, LNCaP) relative to normal prostate epithelial cells
(RWPE1). We hypothesized miR-186 inhibition will reduce aggressive PCa using
metastatic cell models. To test this, we evaluated whether miR-186-5p inhibition
would reduce aggressive PCa behavior and overexpression induce malignant
transformation in normal cells.

Cell proliferation (BrdU incorporation), invasion (reduced growth factor matrigel),
colony formation (soft agar) and cell death (trypan blue exclusion) were
examined in miR-186-5p inhibited PCa cells (PC-3, MDA PCa 2b) and
overexpressed RWPE1 cells. Aberrant gene expression was evaluated in stable
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PC-3 and RWPE1 cells to identify miR-186 candidate targets via microarray and
qRT-PCR analyses using published reports, miR databases and statistical
filtering (FDR p-value ≤ 0.05 and ±1.2 fold change).

MiR-186-5p inhibition reduced proliferation (27-46%) in PCa (PC-3, MDA
PCa 2b), cellular invasion (66%) in PC-3 cells and anchorage independent
growth (28-64%) in PC-3 cells and post-DHT (10 nM) treatment in MDA PCa 2b
cells. Over 2,343 genes were differentially expressed in stably miR-186 inhibited
PC-3 and overexpressed RWPE1 cells relative to controls. Out of 23 selected
candidates, AKAP12 gene and protein was up-regulated in miR-186-5p inhibited
PC-3 cells. MiR-186-5p overexpression decreased AKAP12 protein in HEK 293T
cells. Additional in vitro as well as in vivo studies are needed to further elucidate
the role of additional targets in PCa. Ultimately, the identification of novel
biomarkers may improve detection and effective treatment of aggressive PCa.
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CHAPTER I
INTRODUCTION

Prostate Cancer as a public health problem
Prostate cancer (PCa) is the leading cancer and the 2nd leading cause of
cancer related deaths among men in the U.S. [1]. Ninety-one percent of PCa
cases are treatable among men diagnosed with localized or regional disease as
evidenced by 100% 5-year survival rates [1]. This 5-year survival rates drop
drastically to 28% for metastatic PCa [2]. Once PCa spreads to the bone and
other organs, it is not responsive to conventional treatment strategies.

To

compound the problem further, 25% of all cases diagnosed with stage I-III
disease will experience disease recurrence within five years post treatment.

PCa Risk Factors
There are a number of well-established and probable risk factors that
contribute to the development of PCa. These established risk factors include
older age (age ≥ 50 years), family history among 1st or 2nd degree relatives, low
socioeconomic status, sedentary lifestyle, poor diet, genetic predispositions,
hormone

imbalances

(androgen,
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testosterone,

androgen

sensitivity), chronic inflammation, and African heritage. Data shows elevated
risks of PCa development are generally associated with the aforementioned risk
factors and especially men of African descent. Based on 30 years of record
keeping, there is significant a racial disparity associated with PCa.

PCa Health Disparities
African American men are 2.5 times more likely to die from PCa relative to
American men of European descent [1, 3]. A number of studies have attempted
to determine biological explanations for this disparity through the evaluation of
clinical prognostic/diagnostic factors [e.g., prostate specific antigen (PSA), PSA
density, tumor stage], hormone levels, and the expression of apoptotic and
metastatic-related

genes

[4-11].

Unfortunately,

no

definitive

molecular

mechanisms have been identified contributing to this strong disparity between
African and European American men. Thus, further investigation into the
molecular mechanisms associated with racial disparity is warranted to increase
our understanding of this disease and develop customized targeted therapies for
diverse populations. Although, this dissertation does not focus on race/ethnic
specific biomarkers, we sought to understand the biology of a specific genomic
biomarker within PCa cell lines common to both African-American and EuropeanAmerican men diagnosed with metastatic and/or non-metastatic disease.

PCa Staging and Risk Stratification
PCa is a heterogeneous abnormal growth or neoplasm with distinct
categories of pathologic stages. These varying pathological stages help inform
2

medical and scientific personnel of the extent to which the cancer progressed
and guides treatment strategies. There are four tumor stages, three lymph nodal
stages (N stages) and three metastatic stages (M stages). The first tumor stage
(T1) of disease involves the tumor found in a surgical procedure called
transurethral resection of the prostate (TURP) and less than 5% is cancer (T1a)
or more than 5% is cancer (T1b) or tumor discovered during biopsy (T1c). In the
second stage (T2), the tumor is located in half (or less) of one side of the
prostate (T2a), one half (or more) on one side (T2b) or both sides (T2c) and has
not extended beyond the prostate. For the third stage (T3) of PCa, tumor growth
has extended outside of the prostate, but not to seminal vesicles (T3a) or has
invaded seminal vesicles but not the lymph nodes (T3b). In stage four (T4),
tumor growth is outside of the prostate and tumor cells have migrated to distant
organs (i.e., lymph nodes, liver, bone), which is commonly referred to as
metastasis.

For lymph nodal staging, Nx means no testing has been performed

to detect cancer in the lymph node. N0 indicates the cancer has not reached any
lymph node. N1 means the cancer has spread to the lymph nodes. For the
degree of metastasis, the first level, Mx, indicates no testing has been performed
to detect cancer in distant lymph nodes. Mb indicates cancer has metastasized to
the bone. The last level, Mc, means the cancer has spread to other areas (e.g.,
lungs, brain, liver). The most common biological patterns of PCa metastasis are
metastasis of tumor cells to the bone (90%), liver (65%), lymph nodes (59%) and
lung (38%), respectively [12].
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There are common classification and risk stratification systems utilized for
PCa. These classification and risk stratification systems were used to determine
biospeciemens collected from patients in this study with aggressive and less
aggressive disease. The first is the Gleason grade system, which aids in the
evaluation of prostate biopsies and determine disease prognosis for men with
PCa [13]. Gleason grades range from 1 (normal tissue) through 5 (abnormal
tissue). Different areas of a tumor often have different grades and two grades
that characterize majority of tumor. The sum of the two grades is called a
Gleason score or sum. A Gleason score of ≤ 7 describes well to moderate
differentiated tissue or low aggressive disease. A Gleason score range of 8 ≤ for
poorly differentiated tissue or aggressive disease.

Two common PCa risk stratification systems are the D’Amico risk criteria
and National Comprehensive Cancer Network (NCCN) guidelines. Both the
D’Amico and NCCN use PSA levels and Gleason scores to classify disease
aggressiveness. The D’Amico risk criteria was established in 1998 and later
adopted by the American Urological Association and European Association of
Urology. This system is used to determine low, intermediate and high risk
individuals diagnosed with non-metastatic disease [14]. Patients diagnosed
according to following criteria; low risk [tumor stage T1/T2a, and PSA ≤10 ng/ ml,
and Gleason Score ≤ 6], intermediate risk [tumor stage T2b, and/or PSA 10–20
ng/mL and/or Gleason Score 7] and high-risk [tumor stage ≥T2c, PSA >20 ng/mL
or Gleason Score 8–10].

4

In the NCCN guidelines, there is a further breakdown of low and high-risk
individuals and includes metastatic patients [14]. Low risk is divided into not very
low risk [T1-T2a and Gleason Score 2–6 and PSA ≤10] and very low risk [T1c
and Gleason Score ≤ 6 and PSA <10 and 3 > biopsy cores positive and ≤ 50%
cancer in each core]. Intermediate risk is classified as patients diagnosed with
T2b or T2c and/or Gleason Score = 7 and/or PSA >10–20. Lastly, high risk is
divided into not very high risk [T3a or PSA >20 or Gleason Score 8–10] and very
high risk [T3b-4].

Pathogenesis of PCa
The prostate gland is oval in shape anatomically located interior to the
bladder. The urethra tube runs directly through the middle of the gland. The
gland is divided into three different zones, transition, central and peripheral. The
peripheral zone is the largest of the three zones with contains 66% of the fluid
producing glands. The gland is composed of three types of cells consisting of
glandular, muscle, and fibrous cells. Gland cells produce the fluid component of
semen. Muscle cells control urine flow and ejaculation. Fibrous cells provide
structural support of the gland.
In the normal prostate epithelium, there are several major processes that
lead to prostate carcinogenesis such as chronic inflammation, oxidative
stress/DNA damage and genomic alterations [15, 16]. Oxidative stress and DNA
damage contributes to the pathogenesis of PCa [16]. Oxidative stress results
from an imbalance in reactive oxygen species (ROS) and detoxifying enzyme

5

levels via the accumulation of ROS. Furthermore, oxidative stress can induce
damages in lipids, proteins and most importantly DNA via suppression of the
expression of anti-oxidant enzymes and induction of DNA adducts in PCa. Also,
genomic changes such as loss of tumor suppressors, NKX3.1 and PTEN,
TMPRSS2-ERG translocations and up-regulation of oncogene, c-Myc, EZH2 and
Akt/mTOR and MAPK signaling are commonly detected in PCa Lastly, chronic
inflammation mainly attributed to bacterial or viral agents, dietary factors (i.e.,
heterocyclic amines), genetic variations, amyloids, physical trauma, hormonal
changes, and urine reflux has been previously implicated in PCa [17-21]. Chronic
inflammation can transition into proliferative inflammatory atrophy (PIA)
characterized by focal atrophic lesions and influx of inflammatory cells and
stromal fibrosis [18, 21-23]. PIA lesions frequently developed into prostatic
intraepithelial neoplasia (PIN) evident by histopathological studies [21, 22]. High
grade PIN is widely accepted as the precursor of prostate carcinoma evident by
numerous reports that show high grade PIN is strongly associated with prostate
carcinoma in prostatic tumor tissue [22, 24-27].
However recently, cancer research has implicated non-coding RNA
species called miRNAs as massive regulators of gene expression in
tumorigenesis. Dysregulation of these gene regulators could lead to the induction
of oxidative stress, genomic changes and DNA damage in cancers such as
prostate. Thus, this dissertation evaluates the biological and genetic contributions
of a differentially expressed miRNA to the prostate tumor phenotype via changes
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in tumor cellular behavior (i.e., growth, proliferation, invasion, anchorage
independent growth) and gene expression profiles.

Metastatic Disease
Beyond tumorigenesis, metastasis is a complex process with that
dramatically increases the risk of death for cancer patients and proposes a major
issue in clinical management of PCa and all cancers. The metastatic process
shown in Figure 1 initially involves the enhanced proliferation of primary tumor
cells, invasion of tumor cells into adjacent surrounding tissues and basement
membrane and then detachment from the primary tumor [28]. These cells are
considered to have undergone epithelial mesenchymal transition (EMT). Next,
tumor cell invasion of and survival in the circulation system and lymphatic
channels also known as intravasation, arrest within a distant organ, extravasate
into surrounding tissue and colonization at a secondary site [28]. Mesenchymal
epithelial transition (MET) is required for tumor cells to establish a secondary
tumor site.
There are several models of metastasis, which include progression,
transient compartment, fusion, gene transfer, early oncogenesis, and genetic
predisposition [28]. The progression model proposed by Peter Nowell (1976) has
been the most widely accepted model and has been supported by a number of
studies. This model suggests that a series of mutational events occurs in
subpopulations of the primary tumor or disseminated cells and results in a small
fraction of cells acquiring full metastatic potential [29]. The rationale behind the

7

progression model is that primary tumor cells have a low probability to acquire all
of the multiple alterations required for successful metastasis [29]. So only a few
cells will successful metastasis. Although the progression model is supported by
some studies, none of the proposed models fully explain all of the different
clinical cases observed in metastasis. Some research suggest that metastatic
pattern may be due to secretion of chemokines from different tissues to attract
tumor cells and the expression different chemokine receptors on specific organs
also known as the “homing theory” [30]. Driving migration from the primary tumor
site, tumor cells quickly exhaust local nutrient supply and are forced to relocate to
another

nutrient-rich

environment.

Chemokines

may

act

as

local

chemoattractants to direct tumor cells to specific organs rich with their respective
ligands during metastasis [12, 31, 32].

PCa Treatment Options
Treatment options are recommended based on patient age and disease
aggressiveness. Initial and primary treatment for 52% of men 64 years old or
younger with localized and regional disease is a surgical procedure called radical
prostatectomy, which involves the removal of the prostate and surrounding tissue
[2]. This same patient population also receives a treatment combination of radical
prostatectomy and radiation therapy.

For men 65-74 years old, radiation therapy is commonly used to treat PCa
due the detection of aggressive disease. In patients older, surgery and/or
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radiation are not common treatment options. Active surveillance is most likely
recommended for older men with less aggressive disease. However, hormone
therapy is the first line treatment option for any patient with metastatic disease.
Newer hormone therapies (abiraterone acetate, enzalutamide) have shown to be
effective against metastatic disease [2]. Abiraterone acetate (brand name:
Zytiga) is a steroidal androgen synthesis inhibitor. Abiraterone, the active form of
Abiraterone acetate, decreases circulating levels of androgens through the
inhibition of CYP17A1 activity. However, Enzalutamide (brand name: Xtandi) is a
non-steroidal pure antiandrogen that reduces PSA levels by preventing the
androgen receptor from binding to DNA and co-activator proteins. As previously
mentioned, hormone-resistant and/or hormone refractory PCa is not responsive
to androgen deprivation therapy. Available treatment options for early stages of
disease include withdrawal of anti-androgen, estrogen compounds, adrenal
suppressants, chemotherapy (i.e., docetaxel) , immunotherapy (i.e., sipuleucel-T)
and radiotherapy (i.e., Radium-223) as well as combination treatments [33].
These treatment strategies are fairly effective for local/regional disease; however,
once PCa spreads to the bone and other organs, it is not as responsive to these
conventional treatment methods. Therefore, it is imperative to develop improved
targeted treatment strategies against advanced PCa.

Chapters 2-4 of this

dissertation focus on the identification, validation and characterization of a
biomarker related to the beginning stages of aggressive disease (i.e., invasion,
anchorage independent growth) in androgen-sensitive and -insensitive PCa cell
lines.

9

Figure 1. The Pathogenesis of Cancer Metastasis. This diagram was adapted from
Fidler et al. 2003 Nature Reviews Cancer 3, 453-458 (June 2003) doi:10.1038/nrc1098.
(http://www.nature.com.echo.louisville.edu/nrc/journal/v3/n6/fig_tab/nrc1098_F2.html)
Metastasis is a lethal disease in all malignancies and one canonical pathway of
metastasis pathogenesis is displayed above. Tumor cells establish a primary tumor site
and are provided nutrients to support growth and proliferation through angiogenesis via
the integration of vascular network of blood vessels. Tumor growth leads the detachment
and invasion of tumor cells into surrounding tissue and lymphatic system. Tumor cells
escape the primary site into the blood circulation system where they interact with
platelets, lymphocytes, other blood components and travel to distant organs. Tumor cells
adhere to the vessel wall of distant organs and undergo extravasation to establish a
microenvironment. Tumor cells proliferate via angiogenesis to establish a secondary
tumor site.
10

PCa screening tools
The prostate specific antigen (PSA) test and digital rectal exam (DRE) are
the primary screening tools used to detect PCa in the U.S. The PSA test
measures the serum level (nanogram per milliliter) of the prostate specific
antigen, a protein exclusively produced by cells in the prostate gland. PSA is a
serine protease produced at high levels by normal prostate and malignant PCa
cells. Historically, men with elevated PSA serum levels (PSA ≥ 4 ng/ml) were
linked to a high risk of PCa development [6, 34]. The PSA test has a specificity
range of 38.9-93.8% and sensitivity range of 20.5-83.4% dependent upon PSA
cutoff values and type of assay standardization [35-37]. Furthermore, different
variations of the PSA test such as PSA density, PSA velocity and percentage of
free PSA were developed to aid in clinical decisions about PCa detection[36-38].
However, the appropriate thresholds for some of these tests remain to be
determined for the detection of PCa. The wide spread use of PSA testing has led
to a dramatic increase in PCa detection among U.S. men. Unfortunately, the
frequent utilization of PSA testing has led to the over-diagnosis and
overtreatment of localized disease, which is consistently observed in PCa
screening studies [39-45].

Two major PCa screening trials, the European Randomized Study of
Screening for PCa (ERSPC) and Prostate, Lung Colorectal and Ovarian (PLCO)
Cancer Screening Trial, have influence the field’s perspective on the
effectiveness of PSA testing to detect cancer and reduce mortality [40, 44, 46]. In
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the PLCO study, no significant difference was observed in the mortality rates of
U.S. men receiving PSA/digital rectal exam (DRE) screenings relative to men
with usual care after a 13 year-follow-up [44, 46]. In contrast, the ERSPC study
observed that PSA-based screening was associated with a 20% reduction in PCa
mortality after a 9-year follow-up among European men [40].

However, the use of the PSA test was strongly associated with a 50% rate
of over-diagnosis of PCa in the screening group [40]. Additionally, PSA testing
was associated with 12-13% false-positive results based upon data from the
ERSPC and PLCO studies [40, 44, 46]. Unfortunately, it is well known now that
the PSA test has a number of biological stimulants (e.g., bacterial infection, BPH,
age) other than cancer that elevate PSA levels (PSA ≥ 4ng/ml) in men. Most PCa
biopsies performed due to elevated PSA levels reveal BPH and inflammatory
prostatitis. Although BPH does not cause PCa, its similar symptoms to PCa can
sometimes lead to PCa misdiagnoses [47, 48]. The PLCO and ERSPC studies
along with other reports failed to determine an overwhelming benefit for PSA
testing in patients. It remains unclear whether PSA testing significantly lowers
PCa mortality. This evidence has led the United States Preventive Services Task
Force and American Urological Association to recommend against the use of the
PSA test.

12

Future PCa biomarkers
Consequently, the PSA test is now considered an unreliable tool for PCa
detection. Thus, novel biomarkers that are stably expressed in prostate tissue
and biological fluids (e.g., serum, plasma) are desperately needed to clinical
decisions about PCa detection and determining an individual’s risk of developing
non-metastatic versus metastatic disease. Additionally, these biomarkers will aid
in the field of precision medicine to make inform clinical decisions about which
patients will receive a biopsy and/or aggressive treatment. Single nucleotide
polymorphisms (SNPs), known as genetic variations inherited in cancerassociated genes, were once viewed as potential tools to aid in clinical decisions.
However, there is very limited evidence of the use of SNPs in a clinical setting
and how they have improved clinical decisions. Recently, cancer researchers
have turned their attention to more clinically relevant biomarkers (i.e.,
microRNAs, lncRNAs).

MicroRNAs regulate normal cellular growth and development processes
as well as disease regulated processes (i.e., autoimmune disease, diabetes,
Parkinson’s disease, cancer). Relative to current PCa screening tools,
microRNAs are ideal candidates to predict the presence of cancer and aid in the
diagnosis of disease states and disease recurrence in patients due to their
unique expression profiles that correspond to different tumor stages, Gleason
scores, and metastatic status in cancer in tissue and biological fluids [49-52].
Numerous published reports show miRNAs are stably expressed in tumor
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derived cells, plasma, serum and tissue, and consistently distinguish between
different disease stages compared with non-cancerous biospecimens [53]. The
non-invasive detection of highly sensitive non-coding RNA expression in
biological fluids would greatly improve disease detection and prognosis of
metastatic disease. MicroRNA expression profiles can provide more informative
knowledge about the intrinsic signaling pathways that favor or suppress
tumorigenesis [53, 54]. Ultimately, the utilization of miRNA expression profiles
will aid in the pursuit of precision medicine and efforts to improve cancer care in
patients [55, 56]. Thus, the focus of this dissertation is centered on discovering
micro-RNA profiles of PCa and determining their functional role in the process of
oncogenic transformation.

Biogenesis of microRNAs and their function
MicroRNAs are short endogenous RNA species stably expressed in
plant/mammalian cells, biological fluids (e.g., serum, plasma, urine) and tissue.
These RNA species are primarily transcribed from miRNA genes by RNA
polymerase II as primary transcripts (pri-miRNAs) and subsequently cleaved by
RNase III class enzyme, Drosha-DGCR8 (Pasha), in the cellular nucleus to
produce ~70 nucleotide long hairpin structure also known as precursor miRNA
(pre-miRNA) [57]. The Exportin-5-Ran-GTP complex transports the pre-miRNA to
the cytoplasm and further cleaved by the Dicer-TRBP complex into a mature
miRNA duplex. The functional strand of the mature miRNA duplex is incorporated
into the RNA-induced silencing complex (RISC) with the Argonaute (AGO2)
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protein. The mature miRNA transcript is 17-25 nucleotides in length. Normally,
the passenger strand is marked for degradation of the miRNA transcript. Mature
miRNA transcripts usually bind to the 3’UTR of their mRNA target with the
assistance of AGO2 to negatively regulate mRNA translation. MiRNAs have
thousands of mRNA targets, which contribute to their regulation of 60% of gene
expression

via

translational

repression

of

mRNA

to

protein,

mRNA

cleavage/degradation and de-adenylation [57].
Since their discovery in the early 1990s by the laboratories of Drs. Ruvkun
and Ambros through the present, these naturally occurring, short, non-coding
RNA species have been demonstrated to be influential mediators of gene
expression in multicellular organisms. Lin-4 was the first and origin miRNA
discovered in 1993 through genetic testing in nematodes or microscopic worms.
Further studies revealed a regulatory function for this small RNA. MiRNAs
regulate cellular development, behavior and differentiation in the normal cells of
multicellular organisms [58, 59]. However, these non-coding RNAs are mostly
absent in unicellular organisms such as mouse embryonic stem cells. Majority of
mammalian miRNA genes are located within the introns of host genes and coexpressed their host genes as well. Their primary function is the promotion of
cellular differentiation in normal cells, which is essential for multicellular
organisms. For instance, during early zebrafish development most miRNAs are
not expressed, but in later development miRNAs have tissue-specific expression.
MiRNAs are widely conserved in plant and mammalian cells with a high
abundance per cell [59]. Furthermore, miRNAs have been implicated in diverse
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biological functions such as programmed cell death, early and late vertebrate
development. For instance, some miRNAs regulate the Notching signaling
pathway, which is essential for proper patterning and development. Majority of
mammalian miRNA genes are located within the introns of host genes and coexpressed their host genes as well. Yet within the last decade, numerous studies
have shown the dysregulation of various microRNAs (miRNAs/miRs) within
diseases such as PCa [53, 54, 60-65]. The differential expression of miRNAs in a
variety of solid tumors demonstrate an opportunity for miRNAs to serve as
promising biomarkers and/or therapeutic targets due to their detectability in
human tissue and biological fluids and strongly influence of cancer hallmarks.
MiRNAs may serve as promising non-invasive tools to aid in the improvement of
cancer diagnosis, prognosis, clinical management, and prevention strategies.

MicroRNAs in PCa
A number of miRNAs are differentially expressed in PCa [53, 54, 60-65].
Non-coding RNAs such as miRNAs exert their effects through the modulation of
gene expression to either promote or repress tumorigenesis and disease
progression in various cancers, including prostate [66, 67]. To date, there are
approximately 120 clinical trials evaluating miRNA expression profiles in relation
to cancer [68]. However, less than five percent (~4.2%) of these clinical trials are
investigating miRNA profiles associated with PCa development, progression and
treatment.
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Dysregulation of miRNA expression contributes to the pathogenesis of PCa
through their regulation of target genes involved in cellular behaviors (e.g.,
proliferation, motility, invasion, metastasis, angiogenesis). Fifty percent or more
of human miRNA genes are located in fragile sites, breakpoint regions and
regions of loss of heterozygosity and/or amplification, which can lead to the
dysregulation of miRNAs. Oncogenic miRNAs are commonly up-regulated in
PCa in support of tumorigenesis. In contrast, tumor suppressor miRNAs are
down-regulated to allow the tumor phenotype to persist and prosper. However,
miRNAs do not always function the same way in every cancer type. Sometimes
oncogenic miRNAs also play a dual role as a tumor-suppressor within the same
cancer or other tumor types. Tumor suppression-related miRNAs can promote
tumorigenesis in other cancer types. Recently, studies demonstrate some
miRNAs function in a dual capacity as both oncogene and tumor-suppressor
within PCa [51, 69, 70].
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Figure 2. Intracellular Biogenesis of microRNA. This image was adapted from Winter et.
al Nat Cell Biol. 2009 Mar;11(3):228-34. doi: 10.1038/ncb0309-228. The microRNA gene
is transcribed by RNA polymerase II and/or III into the primary microRNA transcript (primiRNA) in the nucleus. Pri-miRNA transcript is cleaved by the microprocessor complex
Drosha-DGCR8, into a precursor hairpin (~70nts) and exported into the cytoplasm by
Exportn-5 Ran-GTP. RNase, Dicer, and TAR RNA binding protein (TRBP) complex with
cleaves the precursor hairpin into a double stranded into a microRNA duplex.

The

leading miRNA strand is incorporated into the RISC complex and co-associated with
Argonate 2 (Ago2) protein. Mature microRNA transcript commonly binds to the 3’UTR of
target mRNA transcript and promote mRNA degradation, translational repression and/or
deadenylation.
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Oncogenic miRNAs
Some oncogenic miRNAs that promote tumorigenesis in PCa include
miRs-18a, -21, -32, -96, -106b-25 cluster, -125b, -221 and -222 [53, 71]. For
instance, overexpression of miR-221/222 was observed in androgen insensitive
metastatic PC-3 cells [72]. Inhibition of these miRNAs resulted in the reduction of
colony formation by 4.5-fold in metastatic PC-3 cells [72] . In contrast,
overexpression of miRs-221and -222 enhanced cellular proliferation by 2-fold
and colony formation by 3-fold in metastatic androgen sensitive LNCaP cells via
down-regulation of p27Kip1(CDKN1B), a major cyclin dependent kinase inhibitor.
Mutation or loss expression of p27 can lead to uncontrolled cellular proliferation.

MiR-125b is another oncogenic miRNA in PCa. MiR-125b expression was
up-regulated in androgen independent PCa LNCaP sublines, cds1 and cds2, and
prostatic tumor tissue compared to PCa LNCaP cells and benign tissue,
respectively [73]. Overexpression of miR-125b in cds1 cells significantly
increased cellular proliferation via down-regulation of BAK1, a pro-apoptotic
gene.

MiR-21 is a well-known oncogenic miRNA not only in PCa, but in other
solid tumors as well. Inhibition of miR-21 expression in metastatic androgenindependent DU145 and PC-3 cells significantly reduced cell motility 72 and 48
hrs post-transfection, respectively [74]. MARCKS was identified as a direct target
of miR-21 evident by the up-regulation of MARCKS protein expression in a dose-
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dependent treatment with anti-sense miR-21 in both DU145 and PC-3 cells.
Additionally, inhibition of miR-21 via the anti-sense miR-21 significantly reduced
the cellular invasion of DU145 cells relative to cells transfected with the antisense control (p-value = 0.00079). This report suggests that cell motility
reduction in DU145 and PC-3 cells is due to the up-regulation of MARCKS, a
gene involved in the regulation of the actin cytoskeleton.

The miR-106b-25 cluster is a group of miRNAs including miRs-106b, -93
and -25. Several reports implicate that the miR-106b-25 cluster plays an
oncogenic role in PCa. The miR-106b-25 cluster is up-regulated in metastatic
PCa cell lines and malignant tissue relative to normal cells and tissue [75, 76].
For instance, Poliseno and associates (2010) observed that transient
overexpression of the miR-106b-25 cluster down-regulated the protein
expression of PTEN, a major tumor suppressor, by 40% in metastatic DU145
cells [76]. In the same report, inhibition of the mir-106b-25 cluster and other
miRNAs (miRs-19a, -22) reduced cellular growth in DU145 cells after 6 and 7
days relative to controls. Also, stably miR-106b-25 cluster overexpressing DU145
cells increased tumor growth in nude mice relative to PIG retroviral vector as the
empty vector control. Furthermore, MCM7, the host gene of the miR-106b-25
cluster, exhibited an oncogenic function via the increase of colony formation
relative

to

empty

vector

and

known

oncogenes,

c-MYC

and

RAS.

Overexpression of MCM7 and miR-106-25 cluster members enhanced the
transformation of wild type mouse embryonic fibroblasts (MEFs) relative to miR-
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106-25 cluster alone. In another study, overexpression of the miR-106b-25
cluster in 22Rv1 cells significantly increased ECM binding and colony formation
in soft agar [75]. Additionally, miR-106b, one of the miR-106b-25 cluster
members, modestly reduced CASP7 protein levels in PCa xenograft 22Rv1,
normal prostate epithelial RWPE1 and LNCaP cells. However, only the inhibition
of miR-106b reduced ECM binding and colony formation in soft agar relative to
the control and double inhibition of miR-106b and CASP7 in DU145 cells. This
observation indicates that there are other miR-106b targets involved in altering
ECM binding and anchorage independence in PCa. Further, in the same study,
PCa patients who exhibited a high expression of miR-106b in their tumor tissue
showed early biochemical recurrence compared to patients with a low expression
(p-value = 0.014). Liang and co-workers (2014) observed that 24 hrs of hypoxia
induced the expression of the miR-106b-25 cluster and reduced the gene and
protein expression of REST (RE-1 silencing transcription factor), a tumor
suppressor, in LNCaP cells [77]. Moreover, ectopic expression of miR-106b-25
cluster down-regulated REST protein expression in metastatic androgenindependent PC-3 cells as well.

In PCa, miR-96 also promotes the tumor phenotype via its effects on
cellular proliferation and colony formation. In a report by Yu and colleagues
(2014), transient overexpression of miR-96 significantly enhanced cellular
proliferation and colony formation in LNCaP cells relative to negative control [78].
Inhibition of miR-96 in metastatic PC-3 cells reduced cell proliferation and colony
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formation in the LNCaP cells. In both cell lines, FOXO1, a tumor suppressor
gene was identified a target of miR-96. This report suggests that the suppression
of cell proliferation and colony formation in PC-3 cells and the increased in these
cellular behaviors in LNCaP cells were primarily due to the up-regulation and
down-regulation of FOXO1 protein level, respectively. In a recent study, Siu and
co-workers (2015) identified AKT1S1 as a target of miR-96 in established clonal
PTEN/TP53 double knockout AC1and AC3 cell lines, which exhibited a high
expression of miR-96. Additionally, the expression of miR-96 and AKT1S1 is
mediated by TGFβ signaling. TGFβ treatment (10ng/ml) increased miR-96
expression and reduced AKT1S1 expression in PC-3 and relative to vehicle
controls.

MiRs-32 and -148a promote prostate tumorigenesis through their
regulation of cell cycle and cell growth. In a study by Jalava and colleagues
(2012), overexpression of miR-32 and/or miR-148a significantly increased the
growth of LNCaP cells [79]. Further analysis revealed that a significant
population of LNCaP cells transfected with miR-148a were in the DNA synthesis
(S) phase of the cell cycle. Moreover, overexpression of miR-32 was shown to
down-regulate mRNA and protein expression of BTG2 in LNCaP cells. Whereas,
PIK3IP1 was identified as a direct target of miR148a via its transcript and protein
down-regulation in miR-148a overexpressing LNCaP cells. In the same study,
BTG2 staining was lower in castration-resistant PCa (CRPC) (n = 94) tissue
specimens relative to PCa specimens (n =170) and associated with advanced
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disease (pT3 vs pT2) among cancer patients. In fact, the absence of BTG2 was
strongly associated with a shorter progression-free survival of PCa relative to
patients with BTG2 expression.
MiR-18a is another miRNA that plays an oncogenic role in PCa. It is upregulated in metastatic PCa cell lines and tumor tissues relative to normal
prostate epithelial cells and adjacent tissue [80]. Hsu and co-workers (2014)
identified STK4, a tumor suppressor gene, as a putative target of miR-18a
evident by the down-regulation of STK4 mRNA and protein expression in ectopic
miR-18a expressing PC-3 and DU145 cells. Inhibition of miR-18a significantly
reduced colony formation and cell proliferation in 22Rv1 cells. Tumor growth of
anti-miR-18a 22Rv1 cells implanted in nude mice was reduced relative to the
growth of anti-miR control cells.

Tumor suppressor miRNAs
In contrast, tumor suppressive miRNAs (e.g., miRs -29b, -34, -101, -1263p, -145, 146a, -200 family, -675) play an important role in the repression of the
tumor phenotype associated with PCa [53, 71]. For instance, Ru and associates
(2012) observed miR-29b was down-regulated in androgen insensitive- and
sensitive-PCa cell lines, PC-3 and LNCaP, and tumor tissue relative to
immortalized normal prostate epithelial cells and non-tumor tissue [81].
Overexpression of miR-29b impairs wound healing and decreases cellular
invasion in PC-3M cells, a highly metastatic PCa cell line derived from PC-3
cells. Ectopic miR-29b expression significantly reduces the number of
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metastases in vivo. In the same report, Snail, a major EMT marker, was identified
as a direct target of miR-29b due to a decrease in Snail protein expression in
miR-29b overexpressing PC-3M cells. Furthermore, miR-29b inhibition resulted
in an up-regulation of Snail protein expression in LNCaP cells.

MiR-34a is a mediator of p53 that acts as a tumor suppressor in PCa. It is
significantly under-expressed in laser captured micro-dissected (LCM) malignant
tissue (n = 10) and metastatic PC-3 cells compared with adjacent normal tissue
and normal epithelial prostate cells, respectively [82]. Cellular invasion and
colony formation in soft agar was suppressed in stably miR-34a transfected PC-3
cells. Moreover, the tumor growth of stably miR-34a transfected PC-3 cells was
reduced in nude mice. PC-3 cells overexpressing miR-34a exhibited a higher
apoptotic population relative to the negative control. Overexpression of miR-34a
down-regulated the protein expressions of c-Myc oncogene and metastasis
mediator RhoA. The report suggests that miR-34a-induced reduction of cellular
invasion, colony formation and tumor growth via the induction of apoptosis and
down-regulation of c-Myc.

In a recent report (2014), miR-146a was shown to function as a tumor
suppressor in PCa [83]. Stable miR-146a overexpression significantly inhibits
anchorage independent growth in the prostate epithelial non-metastatic P69 and
highly metastatic M12 (a subline of P69) cell lines relative to vector control. In
contrast, miR-146a inhibition in both cell lines increased colony formation in soft

24

agar. In M12 cells, miR-146a overexpression enhanced both cellular proliferation
and invasion compared with the vector control. The inhibition of miR-146a
produced the reverse effects on these cellular processes. Similar effects were
observed in relation to cell proliferation in PC-3 and P69 cells relative to vector
control. Additionally, Rac1 was identified as a direct target of miR-146a evident
by the down-regulation of Rac1 protein level in both P69 and M12 cells.
Moreover, the expression of miR-146a was down-regulated and Rac1 was upregulated in tumor tissue (n = 28) relative normal tissue (n = 28), which exhibits
an inverse relationship between their expression profiles. In an earlier report,
miR-146a was significantly under-expressed in hormone-refractory PCa cell lines
(LNCaP, C4-2B, PC-3) and tumor tissue relative to androgen-dependent cell
lines (LNCaP, PC-3-AR9) and non-cancerous tissue [84]. Forced overexpression
of miR-146a down-regulated ROCK1, an oncogene, protein expression in PC-3
cells.

MiR-145 is a severely under-expressed miRNA in PCa cells and functions
as a tumor suppressor.

For instance, one report observed that miR-145

expression was significantly down-regulated in metastatic PCa cells (i.e., DU145,
LNCaP, PC-3) relative to normal epithelial PWR-1E [85]. Also, low expression of
miR-145 was detected in prostate tumor tissue compared with normal adjacent
tissue. Moreover, miR-145 overexpression reduced cell viability in PC-3 cells in a
time dependent manner within 72 hrs.
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The miR-200 family is a well-known tumor suppressor family in PCa.
Forced expression of miR-200b in PC-3 cells significantly decreased the
tumorigenic potential in an orthotropic PCa model relative to parental PC-3 and
negative control cells [86]. Tumor tissue obtained from this model exhibited a
reduction in cellular proliferation via staining for Ki-67, a proliferation marker,
relative to controls. Furthermore, overexpression of miR-200b significantly
decreased angiogenesis evident by a reduction in microvascular density and cell
invasion of within miR-200b positive PC-3 tumors to negative control [86]. Also,
overexpression of miR-200b negatively influences the EMT via down-regulation
of mRNA and protein expression of ZEB1, a potent EMT mediator, in PC-3 cells.
MiR-200c is low in LNCaP and DU145 cells [87]. A loss of miR-200c expression
was observed in PC-3B1, derived from SCID mice bone marrow injected with
PC-3 cells, and PC-3 due to DNA hyper methylation of miR-200c of CpG islands.

MiR-101 is another miRNA that functions exclusively as a tumor
suppressor in PCa. In a report by Varambally and associates (2009), ectopic
expression of miR-101 decreased cellular invasion and tumor growth of
metastatic DU145 cells relative to control miR and empty vector, respectively
[88]. Additionally, DU145 tumor growth reduction was accompanied by a
decrease in EZH2 protein expression. EZH2, a histone methyltransferase, is
commonly elevated in aggressive and localized PCa. In contrast, miR-101 is
normally under-expressed in metastatic PCa (n = 32) relative to benign controls
(n =26). This inverse relationship between miR-101 and EZH2 suggests that
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EZH2 may be a potential target of miR-101. The report further suggests that the
loss of miR-101 expression allows for the unrestricted up-regulation of EZH2 to
maintain the tumor phenotype of DU145 cells.

MiR-675 also plays a tumor suppressor role in PCa. Derived from long
non-coding RNA (lncRNA) H19, miR-675 is significantly under-expressed in
highly metastatic M12 cells relative to non-metastatic prostate epithelial P69 cell
line [89]. Inhibition of miR-675 expression in P69 cells resulted in a significant
increase of cellular migration. In contrast, miR-675 overexpression dramatically
reduced cellular migration of metastatic PC-3 cells, but not M12 cells. In P69
cells, miR-675 overexpression led to a decrease in the protein expression of
TGFBI, an extracellular matrix protein. TGFBI also known as transforming growth
factor β induced protein is highly expressed in metastatic PCa and has been
previously implicated in the promotion of cell adhesion, motility, invasion and
metastasis in other cancers [89].

Dual role miRNAs in PCa
Interestingly, there are only two miRNAs (miRs-133, -375) that have been
identified to exhibit both an oncogenic and tumor suppressor role in PCa [51, 69,
70]. MiR-133b was significantly under-expressed in PCa tumor specimen (n = 69)
compared normal adjacent tissue (n = 69) [69]. A low tumor to normal tissue
miR-133b ratio was indicative of a shorter disease recurrence-free survival in
patients compared with patients with a higher ratio. Moreover, a univariate
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analysis revealed a marginal association between miR-133b and a decrease in
risk of biochemical recurrence (HR = 0.16; 95% CI = 0.02-1.06; p-value = 0.06).
Overexpression of miR-133b in androgen-independent PC-3 cells significantly
reduced cellular proliferation 96 and 144 hrs post-transfection relative to miRcontrol. MiR-133b overexpressing PC-3 cells treated with recombinant human
TRAIL (20ng/ml) showed a significant induction of apoptosis, which suggests
miR-133b promotes cellular death. However in another study by Li and
associates (2014), overexpression of miR-133b in androgen-dependent PCa cell
lines (LNCaP, 22Rv1) significantly enhanced cell proliferation. Indeed, ectopic
miR-133b expression decreased the apoptotic cell population in LNCaP cells
relative to negative control. In contrast, forced miR-133b overexpression
increased the apoptotic cell population in PC-3 cells. MiR-133b expression was
the lowest in less aggressive LNCaP cells and highest in aggressive PC-3 cells.
Additionally, DHT treatment (100nM) within 48 hrs induced an increase in miR133b expression in LNCaP cells relative to vehicle control. Androgen-sensitivity
mediates miR-133b expression levels and its effect on tumor phenotypes.

MiR-375 also has a dual function in PCa dependent on androgen
sensitivity status. Costa and colleagues (2015) observed that miR-375 is
significantly up-regulated in prostatic tumor tissue (n =114) relative to normal
tissue (n =15) [70]. Moreover, higher levels of miR-375 were expressed in cases
with higher Gleason scores (Gleason score ≥ 7) and advanced disease (pT3b)
relative to patients with lower Gleason scores (Gleason score < 7) and tumor
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stages (pT2 n = 58, pT3a n = 24). Ectopic miR-375 expression induced apoptosis
and reduced cellular proliferation and invasion in metastatic PC-3 cells. In normal
prostate epithelial RWPE1 cells, miR-375 overexpression decreased cell
proliferation. However, this observation did not reach a level of significance.
Mechanistically, overexpression of miR-375 down-regulated the CCND2
transcript, a regulator of the cell cycle, which is also normally under-expressed in
PCa. This suggests that miR-375 expression promotes cell cycle arrest in both
metastatic PCa cells and normal epithelial cells. The aforementioned studies on
miR-133b and miR-375 support the concept that miRNAs can have a dual
function within one disease type. These studies aid in the understanding of how
to appropriately target miRNAs that play both an oncogenic and tumor
suppressive roles to identify robust markers in PCa.

Clinical Applications of microRNAs
Clinical trials are critically evaluating the role of miRNA expression in
relation to PCa and their therapeutic use against disease progression.
Unfortunately, a small percentage (4.2%) of clinical trials is evaluating miRNA
expression profiles in PCa. Currently, there are six clinical trials investigating
miRNA expression in relation to high-risk PCa, androgen deprivation therapy,
therapies

(i.e.,

abiraterone

acetate,

enzalutamide, radiotherapy)

against

metastatic hormone-resistant disease and high-risk PCa [NCT01220427,
NCT02366494, NCT01503229, NCT02471469, NCT01444820, NCT02391051].
Three of the six clinical trials are currently recruiting study participants and two
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trials are ongoing. Currently, no data have been published in relation to any of
the clinical trials. In a phase 2 clinical trial, the efficacy of abiraterone acetate
treatment against metastatic and hormone-resistant PCa is being evaluated by
the University of Washington [NCT01503229]. This study is utilizing miRNA
expression profiles to monitor molecular changes in tumor metastases.

In a

phase 3 clinical trial, investigators are evaluating acute and delayed genitourinary and gastrointestinal toxicity in high-risk prostate adenocarcinoma patients
treated

with

hypofractionated

and

conventional

radiation

therapy

[NCT01444820]. As secondary outcome of this study, the expression of Xchromosome-linked micro-RNAs will be evaluated in response to radiation.

Chemopreventive agents that alter miRNA expression offer other clinical
applications for miRNAs as well [85, 90-98]. For instance, Geinstein (50 µM), a
dietary isoflavone, up-regulates the gene and protein levels of ARHI, a tumor
suppressor gene, via down-regulation of oncogenic miRs-221 and -222 in
metastatic PC-3 cells [94]. Another chemopreventive agent, Resveratrol is a
natural phytoalexin that down-regulates oncogenic miRNAs (miRs-7, -17, -18b 20a, -20b -106a, -106b, -129, -185, -764*) and up-regulates tumor suppressor
miRNAs (miRs-149, -150, -575, -671-5p, -939, -1290) in metastatic LNCaP cells
[93]. Epigallocatechin-3-gallate (EGCG), a major polyphenol in green tea, upregulates tumor suppressor miR-330 expression in hormone-refractory PCa
xenograft model relative to vehicle controls [95]. Chemopreventive agents that
enhance the expression of tumor suppressor miRNAs and repress the
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expression of oncomiRs may serve as excellent therapeutic agents against
cancer to reduce disease burden in patients. Ultimately, miRNA profiles could be
utilized to monitor physiological changes in response to disease progression
and/or conventional treatments to evaluate the effectiveness of therapeutic
agents and patient response to therapies [99-112].
This research project seeks to provide insight on the role of an
understudied miRNA, miR-186, in prostate tumorigenesis. In this study, elevated
expression levels of miR-186-5p were detected in PCa patients diagnosed with
tumor stage I, III and IV relative to disease-free individuals. Furthermore, its
expression was up-regulated in androgen sensitive and insensitive metastatic
PCa cell lines relative normal epithelial cells. However, only two reports have
evaluated miR-186 expression in PCa [63, 113]. The studies present conflicting
data on the expression of miR-186-5p in prostate tumor tissue. Furthermore, the
aforementioned studies do not provide a definitive function of miR-186-5p in
PCa.
To address this gap research and define the true role of miR-186-5p in
PCa, we characterized the expression of miR-186-5p in vitro and determine the
impact of miR-186-5p expression on the prostate tumor phenotype and epithelial
PCa cells. Moreover, we identified a potential mRNA target regulated by miR186 in PCa. Characterization of miR-186 in vitro will serve as the foundation of
future studies evaluating the role of miR-186 prostate tumorigenesis.
Our

study

findings

suggest

that

miR-186-5p

inhibition

reduces,

proliferation, anchorage independent growth and invasion in metastatic PCa (i.e.,
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PC-3, MDA PCa 2b) and also miR-186 overexpression in normal epithelial cells
(i.e., RWPE1) proliferation and increased cell death. These tumor specific effects
reveal miR-186-5p inhibition reduces prostate tumor phenotype aggressiveness
and miR-186-5p is potentially oncogenic and supports prostate tumorigenesis via
its endogenous up-regulation. Furthermore, we showed miR-186-5p inhibition led
to the up-regulation of tumor suppressor gene, AKAP12. Ultimately, the detection
of elevated miR-186-5p serum levels in combination with current PCa screening
tools may improve the detection of aggressive disease and identification of highrisk patients. Additionally, miR-186-5p and its regulated genes may serve as
potential therapeutic targets for current therapeutic agents to modulate and
improve treatment efficacy.
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CHAPTER II
DIFFERENTIAL EXPRESSION OF MIRNAS IN THE SERUM OF PROSTATE
CANCER PATIENTS
Introduction:
The prostate specific antigen (PSA) test and digital rectal exam are gold
standards for PCa detection. However, these tools demonstrate a marginal or no
impact on prostate mortality rates among men in the U.S. and Europe. In 2009,
two major epidemiological studies, the Prostate Lung Colorectal and Ovarian
(PLCO) Screening Trial and European Randomized Study of Screening for PCa
(ERSPC), evaluated the effectiveness of PSA testing and DRE against PCa
mortality [40, 44, 46].

Based upon the data collected from these and other

studies, the use of PSA testing by physicians or urologists has been discouraged
for patients due to the recommendations made by the American Urological
Association and the U.S. Preventive Services Task Force. Therefore, additional
biomarkers are needed to aid in the improvement of PCa detection.
As described in Chapter 1, miRNA dysregulation has been shown to play
a pivotal role in the development and/or disease progression of PCa [71, 114,
115, 116 ]. These non-coding RNAs bind to the 3’UTR region of their mRNA
targets

and

invoke

post-transcriptional

33

changes

such

as

degradation,

repression of translation to protein, and deadenylation of mRNA targets.
MicroRNAs target a vast number of mRNA transcripts. Consequently,
microRNAs influence about 30-60% gene expression in tumor-associated
processes (e.g., proliferation, motility, invasion, metastasis, angiogenesis) [53,
54, 60-65]. For instance, aberrant miRNA expression in PCa can distinguish
between clinical features such as poorly and moderate differentiated tumor
tissue, primary, metastatic disease, non-recurrent disease and biochemical
recurrent patients in PCa [52, 117]. MiRNAs may serve as potential prognostic
and diagnostic markers to aid in the detection and clinical management of PCa
[62, 113]. Additionally, these short, non-coding RNAs can also be utilized as
complementary tools for current screening procedures in PCa detection due to
their ability to reflect the physiological changes in cancer, high stability and
detectability in mammalian cells, tissue and different biological fluids [52, 65,
118].

MiRNAs generally participate in the regulation of cellular homeostasis, as
previously discussed in Chapter 1. However in cancer, they can function as
either oncogenes, tumor suppressors or both-depending on tumor type and
hormonal sensitivity in some cancers such as PCa. MiRNAs are found in cells,
tissues and biological fluids (saliva, urine, plasma, and serum). Changes in
miRNA expression profiles have been linked to disease progression and different
tumor stages of disease in PCa. These non-coding RNAs are highly stable and
detectable in tissue, cell lines and biological fluids for hrs and/or days after
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synthesis. The stability of miRNAs are attributed to the complex they form with a
protein called Argonaute (AGO2), which prevents degradation of miRNAs [119].
During miRNA biosynthesis, miRNAs form a complex with AGO2 and this
complex facilitates the degradation of target mRNA transcript and/or repression
of translation to protein.

A population of miRNAs are secreted from various cell types (i.e., tumor
cells) and released into the extracellular space [120]. Commonly referred to as
circulating miRNAs, miRNAs in biological fluids are released via exosomes (50100 nm), microvesicles (100-1000 nm), or are complexed to AGO2 and/or in high
density lipoprotein particles shed from various cell types. Circulating miRNAs
travel through the extracellular space and where they can be released into
plasma, serum, saliva and/or urine [118].

These extracellular vesicles are

mediate cell-to-cell communication and transport genetic information (i.e.,
miRNAs, mRNA) between different cells [118]. Reports suggest circulating
miRNA expression profiles correspond to distinct stages in PCa [52, 117, 121].
Due to their high stability, detectability in biological fluids strong correlation to
physiological changes, miRNAs are ideal candidates for disease detection and
prognosis in PCa. However, there are major issues associated with the extraction
of circulating miRNAs and the normalization methods required for their
quantitative analyses in biological fluids, namely serum.
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Challenges of miRNA detection
MiRNA expression profiles have the potential to serve as prognostic and
diagnostic markers in PCa. However, the low abundance of miRNA in serum and
use of different normalization techniques for miRNA expression across different
solid tumor types plague miRNA detection. MiRNA extraction from serum yield
low abundance of circulating miRNA and sometimes there are difficulties
quantifying nucleic acid concentrations via spectrophotometry. Highly robust and
sensitivity quantitation methods are needed to measure the concentration miRNA
in serum. Currently, there are no endogenous controls for miRNA expression
normalization in serum. In the literature, various normalization techniques for
miRNA expression are used in different tumor types [118]. However, there is
overlap between some cancer types. In breast, lymphoma, colon and oral
cancer, miR-16 and 18s are used as controls to normalize miRNA expression in
serum. In contrast, RNU6B is used as a control for miRNA expression in the
serum of gastric and colon cancer patients. In PCa, reports by Brase et al.
(2010) and Mitchell et al. (2008) spike denatured serum samples with cel-miRs39, -54 or 238 to normalize miRNA profiles [52, 122]. No control has been
determined as the best overall control for miRNA expression among cel-miRs-39,
-54 or 238 in PCa. In other PCa studies, RNU6B, median Ct value and absolute
quantification are normalization techniques for serum and/or plasma samples
[60]. Ultimately, the utilization of various normalization procedures could lead to
great inconsistencies among serum-based miRNA expression profiles in prostate
and other cancers.
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Circulating miRNAs as prognostic and diagnostic tools
Circulating miRNAs non-invasively discriminate between PCa and healthy
individuals as well as localized versus metastatic disease. Several reports have
demonstrated miRNA expression profiles correspond to specific disease stages
and advanced disease [52, 65, 117, 123, 124]. MiRs-141 and -375 were
significantly up-regulated in prostatic tumor tissue (n=36) relative to benign
prostate tissue (n=36) (p-value < 0.001) [52]. These miRNAs were also elevated
in the serum of PCa patients with lymph node metastasis score N1 (n = 43)
compared to those without lymph node spread (n =23) (p-value < 0.05). In this
study, miRNA expression was normalized using miRs-cel-39, cel-54, and cel-238
in serum to control for RNA extraction efficiency and cDNA synthesis. However,
only miR-141 was significantly higher in patients with aggressive disease
(Gleason Score > 8) relative to intermediate differentiated tumor tissue (Gleason
Score = 7) (p-value < 0.05). Additionally, miR-375 expression was significantly
higher in metastatic PCa serum samples compared with localized disease serum
(FDR p-value = 0.036). In a recent report (2013), elevated serum levels of miR141 corresponded to a greater number of bone metastases (metastases > 5) in
hormone-naive PCa (p-value = 0.028), hormone-sensitive (p-value = 0.014) and
hormone-refractory (p-value = 0.028) PCa patients relative to patients with lower
metastases (3 > metastases) [123]. Serum-based miRNA expression profiles in
the previous study were normalized to Sp6 and miR-cel-39. Circulating
oncogenic miRs-195, -26a, and let7i were significantly up-regulated in the serum
of PCa patients (n = 37) compared to BPH patients (n = 18) (p-value = 0.015-
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0.048) [65]. The expression of all miRNA expression profiles in the serum was
normalized to miR-cel-39. Furthermore, this study suggests that these miRNAs
may serve as monitoring tools in disease management since the removal of the
prostate dramatically reduced the expression these circulating miRNAs.
Furthermore, miRNAs can distinguish between patients with advance disease
and low-grade disease. In a report by Mihelich and associates (2015), 14
miRNAs (miRs-let-7a, -103, -107, -130b, -106a, -26b, -451, -223, -93, -24, 30c, 874, -100, -146a) predicted the absence of high-grade PCa (Gleason grade 4
and/or 5) in the plasma of BPH (n = 50) and low-grade PCa (Gleason grade =3)
patients (n = 50) with a negative predictive value of 0.938 and positive predictive
score of 0.366 (p-value < 0.05) [117]. MiRNA expression profiles analyzed in
serum were normalized to Sp6 and miR-cel-39 expression. A negative predictive
value is the probability that patients with a negative screening test truly have a
negative disease diagnosis. However, a positive predictive score is the
probability that patients truly have a positive diagnosis. In the same study, 8
miRNAs accurately predicted a subset of PCa patients at low risk of biochemical
recurrence with a negative predictive value of 0.941. The data suggest that these
8 miRNAs may serve a pre-surgical predictor of disease recurrence.

In

metastatic castration resistant PCa patients (n = 25), the up-regulation of miR423-3p in plasma was significantly associated with high Gleason score (Gleason
Score ≥ 8), lymph nodal N1 status, and biochemical recurrence (PSA ≥ 0.2
ng/mL on two occasions after prostatectomy) relative to patients with localized
disease (n = 25) (p-value < 0.004) [124]. Similarly to previous studies, circulating
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miRNA expression profiles were normalized to miR-cel-39, Sp6, and Sp3,
respectively.
In this study, we evaluated the expression of 377 mature microRNAs in
the serum of European-American PCa patients diagnosed with tumor stage I, III
and IV disease. The goal of this evaluation was to identify differentially expressed
circulating miRNAs in the serum that influence PCa development and/or
aggressive disease. Fortunately, we identified two up-regulated circulating
miRNAs (miRs-106b-5p and -186-5p) in the serum of PCa patients relative to
non-cancerous controls. Moreover, we evaluated the expression of a serumbased miRNA, miR-186-5p, in different prostate tumor cell lines. Circulating
miRNAs reflect physiological changes associated with the disease states within
PCa. The study findings identified an up-regulated circulating miRNA, miR-1865p, in PCa patient serum, which was also up-regulated in three metastatic PCa
cell lines (i.e., PC-3, LNCaP, MDA PCa 2b). This miRNA may play a role in
aggressive tumor phenotype associated prostate tumorigenesis and serve as a
potential prognostic marker for the clinical management of PCa.
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Methods:
Human Serum Biospecimens
Serum (0.5-1 ml) from 15 men with PCa and 5 non-cancerous individuals
was collected from patients prior to any therapy and obtained by BioServe
Biotechnologies Biorepository (Beltsville, MD). Samples were divided into noncancerous controls (n=5), patients diagnosed with PCa stage I (n=5), stage III
(n=5), and stage IV (n=5). De-identified clinical characteristic data was provided
for each patient by BioServe Biotechnologies (Beltsville, MD). Descriptive
statistics were performed to determine patient median age, age range, median
weight, weight range, body mass index (BMI) median, and BMI range. A high
percentage of PCa patients had a smoking history (66.7%) and tumor
classification of adenocarcinoma (60%). Statistical analyses for age, PSA levels
and BMI were performed using the Wilcoxon Rank-Sum test and cut-off
significance level of p-value ≤ 0.05.

microRNA Isolation from Serum
Total isolation of microRNA was performed using the miRVana microRNA
Isolation kit (Catalog # AM 1561, Thermo Fisher Scientific, Waltham, MA). Serum
(250 µl) samples from 20 patients were transferred to phase tubes. Trizol LS
Reagent (1 ml) was added to each sample in 1.5 ml tubes in a chemical hood
and pipetted up and down 30 times at room temperature. Each sample was
spiked with 2ul of cel-miR-39 (1nM, internal control miRNA) and incubated at
room temperature for 5 minutes (mins). Pure ACS grade 98% chloroform (200 µl)
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was added to each sample and shaken up and down for 15 seconds (secs).
Samples were immediately transferred to phase lock tubes and incubated for 5
mins at room temperature. Samples were centrifuged at 12,000xg at 4 oC for 15
mins. Aqueous phase (400 µl) of each sample was transferred to new 1.5ml
tubes and 100% isopropanol (500 µl, 1.25x times aqueous phase volume) was
added to each sample. Samples were pipetted up and down several times, each
mixture (700 µl) was applied to a filter cartridge and centrifuged at 10,000 xg for
30 secs. This step was continued until each sample was completely filtered
through at room temperature. Flow-through was discarded after each
centrifugation. Sample filters were washed with wash solution 1 (700 µl) one time
and wash solution 2/3 (500 µl) two times using centrifugation at 10,000xg for 30
secs at room temperature. Filters were centrifuged an additional time at 10,000xg
for 1 minute to remove residual fluid and transferred to new 1.5ml tubes.
Nuclease-free H2O preheated at 95oC was applied to each filter and incubated
for 5 mins. Total RNA was eluted using centrifugation at 12,000 xg for 1 minute
to room temperature. Serum samples were stored at -80oC until further use.
Statistical analysis for miRNA validation was performed using Unpaired Student
T-test and cut-off significance level of p-value ≤ 0.05

miRNA Expression
Reverse transcription of total RNA (10 ng) was performed using TaqMan
microRNA Reverse Transcription kit, miRNA specific RT primers and Peltier
Thermal Cycler (PTC 200). Cycling cDNA was synthesized using the following
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cycling conditions 16oC for 30 mins, 42oC for 30 mins, 85oC for 5 mins and hold
indefinitely at 4oC. qRT-PCR was performed using miRNA specific PCR TaqMan
Assays (Life Technologies) and the following cycling conditions: hold for 2 mins
at 50oC, 10 mins at 95oC for 1 cycle, 15 secs at 95oC and 1 minute at 60oC for
40 cycles. Amplification of cDNA was performed using the Applied Biosystems
Step One PCR system (Applied Biosystems, Carlsbad, CA).

The relative

expression of microRNA compared with U44 snRNA was calculated using 2 -∆∆Ct
method.

Taqman Array Human MicroRNA
Expression profiling for miRNA was performed using the Taqman Array
Human MicroRNA Pool A Cards v.2 (Thermo Fisher Scientific, Waltham, MA,
Carlsbad, CA) according to the manufacturer’s recommendations. The array card
consisted of 377 miRNA assays, three endogenous controls (RNU6, RNU44 and
RNU48) and one negative control unrelated to human (ath-miR-159a). Each
total RNA sample was diluted to 2 ng/µl using nuclease-free water. Diluted RNA
samples were reverse transcribed to produce cDNA in a 7.5 µl reaction using the
TaqMan miRNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham,
MA, Carlsbad, CA) in addition to Megaplex RT Primers Human Pool A 10X
(Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA). Samples were preamplified using TaqMan PreAmp Master Master Mix 2X and Megaplex PreAmp
Primers Human Pool A (Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA)
in a 25 µl reaction. The pre-amplification conditions were initiated in PCR tubes
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at were 95°C for 10 min, 55°C for 2 mins and 72°C for 2 mins followed by 12
cycles of 95°C for 15 secs and 60°C for 4 mins and followed by 99.9°C for 10
mins and held at 4°C. Pre-amplified products were diluted with 75 µl of TE (0.1X,
pH 8.0) and stored at -15°C. Then samples were thawed and added into a PCR
reaction mix and 100 µl of mix was dispensed into each port of the TaqMan
MicroRNA array. Then array was centrifuged for 2 times at 1200 rpm for 1
minute, sealed and placed into the ABI 7900 Real Time PCR system.

Taqman Array Human MicroRNA Statistical Analysis
MicroRNA expression profiles of 377 targets (Pool A TLDA card) in total
RNA derived from PCa serum (n = 15) and non-cancerous controls (n = 5) were
evaluated using R-programming software. MicroRNA profiles were normalized to
the global median Ct value for each array (global Ct median value - target Ct
value). After global normalization, missing Ct values associated targets were
imputed using k nearest neighbor (kNN) imputation. miRNA expression profiles
with too many missing values were screened off and not included in final
analysis. Differentially up-regulated and down-regulated miRNAs for each each
PCa stage vs. controls were determined using moderated t-tests and ANOVA in
the R package limma [125-127]. Statistical analyses on miRNA expression
profiles were adjusted for multiple hypothesis testing using the False Discovery
Rate (FDR) method. MicroRNA profiles that reached statistical significance (FDR
p-value ≤ 0.05) were further analyzed individually.
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Table 1. Characteristics of Human Cell lines. Cell lines utilized in the current
study are described in the table above. Tumor grade was not available for
22Rv1, C4-2B and MDA PCa 2b PCa cell lines.
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Cell Culture
Immortalized European American metastatic (PC-3, DU145) and normal
prostatic epithelial cell lines (RWPE1, RWPE2) were obtained from American
Type Culture Collection (ATCC) (Manassas, VA). E006AA and MDA-PCa-2b
cells were obtained from Drs. Shahriar Koochekpour and Deepak Kumar. All cell
lines were grown and maintained in a humidified incubator at 37 oC with 5% CO2.
E006AA is an immortalized androgen-dependent human primary PCa
epithelial cell line derived from a 50 year old African American male diagnosed
with stage 2 (T2aN0M0) localized PCa. This cell line was obtained from Dr.
Shahriar Koochekpour at Roswell Park Cancer Institute (Buffalo, NY). The
E006AA cell line was sub-cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) medium supplemented with 10% of fetal bovine serum (FBS), 1% of 200
nM L-glutamine [100x] (Catalog# 25030-081, Thermo Fisher Scientific, Waltham,
MA) and 1% of antibiotic [10,000 I.U./ml of penicillin, 10,000 µg/ml of
Streptomycin, 25 µg/ml Amphoterricin B] (Catalog # 30-004-Cl, Mediatech Inc.,
Manassas, VA).

MDA-PCa-2b is an androgen dependent human immortalized epithelial
cell line derived from a 63-year old African American male diagnosed with lung
and bone metastasis. The cell line was obtained from Dr. Deepak Kumar at the
University of the District of Columbia (Washington, D.C.). MDA-PCa-2b cells
were sub-cultured in Kaighn’s modified Ham’s F-12K medium (Catalog #21127022, Thermo Fisher Scientific, Waltham, MA) supplemented with hydrocortisone
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(100 pg/ml) (Catalog# H0396-100MG, Sigma) and human recombinant epidermal
growth factor (EGF) (10 ng/ml), FBS (20%) and antibiotic [10,000 I.U./ml of
penicillin, 10,000ug/ml of Streptomycin, 25 µg/ml Amphoterricin B ] (Catalog #
30-004-Cl, Mediatech Inc., Manassas, VA).

PC-3 is an androgen-independent immortalized human epithelial cell line
derived

from

a

62-year

old

European

American

male

with

prostatic

adenocarcinoma grade IV and bone metastasis. PC-3 cells were sub-cultured in
Kaighn’s modified Ham’s F-12K medium (Catalog #21127-022, Thermo Fisher
Scientific, Waltham, MA) supplemented with 10% of FBS, 1% of 200nM Lglutamine [100x] (Catalog# 25030-081, Thermo Fisher Scientific, Waltham, MA)
and 1% of antibiotic [10,000 I.U./ml of penicillin, 10,000 µg/ml of Streptomycin, 25
µg/ml Amphoterricin B] (Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA).

LNCaP clone is an androgen dependent human immortalized epithelial
cell line derived from a 50-year old European American male diagnosed with left
supraclavicular lymph node metastasis. LNCaP cells were sub-cultured in RPMI
1640 (Catalog # 11875-093, Thermo Fisher Scientific, Waltham, MA)
supplemented with 10% of FBS, 1% of 200 nM L-glutamine [100x] (Catalog#
25030-081, Thermo Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000
I.U./ml of penicillin, 10,000 µg/ml of Streptomycin, 25 µg/ml Amphoterricin B]
(Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA).

46

22Rv1 is an immortalized human prostate carcinoma epithelial cell line
derived from a CWR22 xenograft. After castration –induced regression and
relapse of parental androgen-dependent CWR22 xenograft, cells were serially
propagated in mice. The cell line was obtained from Dr. Deepak Kumar at the
University of the District of Columbia (Washington, D.C.). 22Rv1 cells were subcultured in RPMI 1640 (Catalog # 11875-093, Thermo Fisher Scientific, Waltham,
MA) supplemented with 10% of FBS, 1% of 200 nM L-glutamine [100x] (Catalog#
25030-081, Thermo Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000
I.U./ml of penicillin, 10,000ug/ml of Streptomycin, 25 µg/ml Amphoterricin B]
(Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA).

C4-2B is a bone metastatic subline derived from C4-2 cells orthotopically
injected into castrated male mice. C4-2B cells were extracted from large ossesus
tumors in mice. C4-2B cells were sub-cultured in T-medium supplemented with
10% of FBS, 1% of 200 nM L-glutamine [100x] (Catalog# 25030-081, Thermo
Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000 I.U./ml of penicillin,
10,000 µg/ml of Streptomycin, 25ug/ml Amphoterricin B] (Catalog # 30-004-Cl,
Mediatech Inc., Manassas, VA). T-medium is composed of the following:
Kaighn’s modified Ham’s F-12K medium, Dulbecco’s Modified Eagle’s medium,
200 µg/ml of Biotin (Catalog# 84639, Sigma Aldrich, St. Louis, MO), 200 ng/ml
3,3,5-triloda-l-thyronine sodium salt (Catalog# 16397, Sigma Aldrich, St. Louis,
MO), 5mg/ml of transferrin (Catalog# T8158, Sigma Aldrich, St. Louis, MO), 10
mg/ml of adenine hydrochloride (Catalog# A9795, Sigma Aldrich, St. Louis, MO)
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and 2.5ml of ITS Liquid Media Supplement (100X) (Catalog# 13146, Sigma
Aldrich, St. Louis, MO).

DU145 is an androgen-independent immortalized human epithelial cell line
derived from a 69 year old European American male with prostate carcinoma and
brain metastasis. DU145 cells were sub-cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) medium supplemented with 10% of fetal bovine serum (FBS),
1% of 200 nM L-glutamine [100x] (Catalog# 25030-081, Thermo Fisher Scientific,
Waltham, MA) and 1% of antibiotic [10,000 I.U./ml of penicillin, 10,000 µg/ml of
Streptomycin, 25 µg/ml Amphoterricin B ] (Catalog # 30-004-Cl, Mediatech Inc.,
Manassas, VA).

RWPE-1 is an immortalized normal human prostate epithelial cell line
obtained from a European American donor and immortalized with human
papillomavirus 18. RWPE-2 is an immortalized normal prostate epithelial cell line
derived from RWPE1 cells and transformed by v-ki-Ras. Both RWPE1 and
RWPE2 were sub- cultured in Keratinocyte-SFM (Catalog # 17005-042, Thermo
Fisher Scientific, Waltham, MA) supplemented with bovine pituitary extract (BPE)
(50 µg/ml), human recombinant epidermal growth factor (EGF) (5 ng/ml), and 1%
of antibiotic [10,000 I.U./ml of penicillin, 10,000ug/ml of Streptomycin, 25 µg/ml
Amphoterricin B] (Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA).
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microRNA Isolation from cell lines
Total isolation of mRNA and microRNA was performed using the miRVana
microRNA Isolation kit (Catalog# AM 1561, Thermo Fisher Scientific, Waltham,
MA). Cells were seeded at an optimal cell density into 60 mm plates in growth
medium. Cells were washed once with 1X PBS (2 ml), lysed in dishes with
mirVana lysis buffer (600 µl), harvested with cell scraper and pipetted into 1.5ml
tubes. Cells were vortexed for 30 secs to completely lyse cells. Homogenate
additive (1/10 of cell lysate volume) was added to cell lysates and vortexed for 30
secs. Samples were incubated on ice for 10 mins and equal volume of
acid/phenol chloroform mixture was added to each tube. Samples were vortexed
for 60 secs and separate into aqueous and organic phases through centrifugation
at 10,000xg for 5 mins at 4oC using Eppendorf Centrifuge 5810R. Aqueous
phase (≥ 400 µl) was pipetted into new 1.5ml tubes and 100% EtOH (1.5 x
aqueous layer volume) was added to each tube. Samples were added to filters in
new collection tubes, centrifuged at 10,000 xg for 30 secs. Samples were
processed at room temperature and flow-through was discarded after
centrifugation. Filters were washed once with 700 µl of wash 1 solution and
centrifuged at 10,000 xg for 30 secs. Filters were washed twice with 500µl of
wash 2/3 solution and centrifuged at 10,000 xg for 30 secs. Filters were
centrifuged at 10,000 xg for 1 minute to remove residual fluid and transferred to
new collection tubes. Elution buffer (60 µl) was added to the center of each filter
and incubated for 5 mins. miRNA was eluted through centrifugation at 10,000 xg
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for 1 minute at room temperature. Samples were placed on ice and RNA
concentrations were determined using a Nanodrop Spectrophotometer.
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Results:
Population Description
Serum was collected from PCa patients diagnosed with tumor stage I, III,
IV and disease free patients that self-identified as men with European ancestry
as reported in Table 2. Controls were received a diagnosis of a normal prostate
at the time of serum collection. PCa cases (n = 15) had an age range of 47-72
and a median age of 69. Non-cancerous controls had an age range of 56-71 and
a median age of 69. No significance difference was observed between the
median age of cases and controls (p-value = 0.726). The prostate serum antigen
(PSA) median among cases was significantly higher relative to non-cancerous
controls (p-value = 0.048). Sixty percent (n = 9) of the cases were identified as
adenocarcinoma and 40% (n = 6) of the cases were not reported or classified.
Sixty-seven percent of the PCa patients (n =10) had a history of smoking;
however the smoking status among the controls was not available for this study
population. Relative to the controls, no difference was detected between PCa
patient BMI median relative to controls. Majority of the cancer patients received
at least 2 types of therapy (73.3%) against PCa, which include chemotherapy (n
= 2, 13.3%), radiation (n = 8, 53.3%), surgery (n = 7, 46.7%), and hormonal
therapy (n =14, 93.3%).
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Table 2. Population Description of PCa Patients. Clinical data for patients from Bioserve
is displayed in the above table. Patients (n=20) self-identified as European American
males. Majority of PCa cases were diagnosed with adenocarcinoma (60%), had a
smoking history (66.7%) and received 2 or more therapies. Relative to controls, cases
had higher median serum PSA level, weight and BMI value relative to controls.
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Differentially expressed serum-based miRNAs in PCa
MicroRNA profiling was performed using total RNA from collected from
serum of PCa patients diagnosed with stages I (n = 5), III (n = 5) and IV (n = 5)
relative to non-cancerous controls (n = 5), as described in Chapter 2 methods
section. MicroRNA array profiling measured the expression of 377 miRNAs in the
serum of PCa patient diagnosed with localized disease (stage I), pre-metastatic
and bone metastatic disease (Stage IV) relative to non-cancerous controls (n =
5), as summarized in Figure 3. After global normalization of miRNA profiles, array
analysis revealed 26 miRNAs were differentially expressed in PCa patients.
Relative to non-cancerous controls, 17 miRNAs (miRs-18a, -122, -133a, -145, 150, -186, -191, -197, -296, -342-3p, -374, -454, -484, -518d, -744, -885-5p, -let7b) were down-regulated in serum from PCa patients, shown in Table 3. In
contrast, nine miRNAs (miRs-21, -92a, -99b -106b, -142-3p, -185, -302b, -320, 520e) were up-regulated in PCa serum relative to controls (Table 2). However,
only 6 miRNAs (miRs-106b-5p, -186-5p, -302b-3p, -342-3p, -520e, -885-5p) were
adherent to the following selection criteria; FDR p-value ≤ 0.05 and fold change
(0.5 > FC, FC ≥ 2). These miRNAs were selected for further validation via qRTPCR using singleplex Taqman miRNA assays.
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Figure 3. Heatmap of Differentially expressed miRNAs in PCa serum. Color scheme for
heatmap: orange (no change), red (high expression) and yellow (low expression). The
expression of 377 miRNAs in the serum of patients with diagnosed with tumor stage I, III
and IV PCa and non-cancerous controls.
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Table 3. Differentially expressed miRNAs in PCa serum. After global normalization, 26
miRNAs were differentially expressed in PCa serum relative to non-cancerous controls.
Relative to non-cancerous controls, only 9 miRNAs were up-regulated in PCa stage I, III
and IV disease. The remaining 17 miRNAs were down-regulated in PCa serum. After
adjusting for multiple hypothesis testing (false discovery rate [FDR] p-value ≤ 0.05), only
6 miRNAs were determined to be differentially expressed in prostate serum. Significant
FDR p-values are bolded in the above table.
55

Validation of miRNAs
The expression of miRs-106b-5p, -186-5p, -302b-3p, -342-3p, -520e, and
-885-5p was measured in two independent total RNA isolations from serum
(Table 2). All miRNA expression was normalized to a spiked-in external control,
miR-cel-39 and analyzed using specific miRNA Taqman qRT-PCR assays. No
differences were detected in the expression of cel-miR-39 in serum between noncancerous and PCa cases (Figure 5). Among the selected miRNAs, the
expression of miRs-520e and 302b were below the detectable level (Ct value <
37 or undetermined) in PCa patient and non-cancerous control serum. The
expression of miR-885-5p was inconsistent between total RNA isolations for
patients and controls (Figure 8). Therefore, this miRNA was not further validated
in vitro. MiR-342-5p was up-regulated in PCa serum relative to non-cancerous
controls. Unfortunately, this up-regulation was not statistically significant.
However, miRs106b-5p and -186-5p were significantly up-regulated in PCa
serum relative to non-cancerous controls in both independent isolations (Figures
6-7). MiR-186-5p was selected for further validation and characterization in vitro
to determine its role in PCa due to the limited evidence available on this miRNA
in PCa.
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Figure 4. Flowchart of miRNA profiling for serum-based miRNAs. The expression of 377
mature miRNA profiles was evaluated in the serum of PCa patients (n = 15) and noncancerous controls (n= 5). MiRNA profiles were normalized to global median Ct value
among all the miRNA profiles. Next, miRNA profiles associated with missing values (≥
50) were imputed using K nearest neighbor imputation program. After global
normalization, the array determined that 26 miRNAs were differentially expressed in PCa
serum relative to non-cancerous controls. After adjusting for multiple hypothesis testing
using the false discovery rate (FDR) (FDR p-value ≤ 0.05), 6 miRNAs were determined
to be differentially expressed serum-based miRNAs. Selected miRNAs were individually
validated in the serum of PCa and controls. After validation, the expression of only two
miRNAs (-106b-5p, -186-5p) remained consistent.
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Figure 5. Ct values of MiR-Cel-39 (cel-39) in PCa serum and non-cancerous controls.
MiR-Cel-39 is a non-human synthetic miRNA was used as an external control for miRNA
isolation from serum. Cel-39 was spiked into denatured serum to control for the
normalization of miRNA expression in non-cancerous controls and PCa patients. No
significance differences were determined in the Ct values between controls and cases
(p-value = 0.116). Statistical analysis was performed using a non-parametric one way
ANOVA test and Dunn’s multiple hypothesis test and significance cut-off p-value ≤ 0.05.
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Figure 6. MiR-106b-5p expression in PCa serum. Expression of miR-106b-5p and -186
was validated in two independent isolations of miRNA from serum. MiRNA expression
was measured in total RNA derived from PCa serum (n = 15) relative to non-cancerous
controls (n = 5). A) MiR-106b-5p was up-regulated by 3.1-11.8-fold in patients diagnosed
with tumor stage I, II, and III disease relative to non-cancerous controls in the 1st
isolation (p-value > 0.02). B) MiR-106b-5p was up-regulated in only tumor stage I and III
disease relative to controls. Statistical analysis was performed using Unpaired t-test and
significance level of 0.05 (*p-value < 0.05, **p-value < 0.01, ***p-value < 0.0002).
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Figure 7.

MiR-186-5p expression in PCa serum. Expression of miRs-186-5p was

validated in two independent isolations of miRNA from serum. MiRNA expression was
measured in total RNA derived from PCa serum (n = 15) relative to non-cancerous
controls (n = 5). A) MiR-186-5p was significantly up-regulated by 2.6-8.1-fold in tumor
stage I and II serum from both isolations relative to non-cancerous controls (p-value <
0.03). B) However, miR-186 expression was only significantly elevated by 7.9-fold in
stage IV disease in the second isolation relative to non-cancerous controls (p-value =
0.02). Statistical analysis was performed using Unpaired t-test and significance level of
0.05 (*p-value < 0.05, ***p-value < 0.002).
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Figure 8. MiR-885-5p expression in PCa serum. Expression of miR-885-5p was
validated in two independent isolations of miRNA from serum. MiRNA expression was
measured in total RNA derived from PCa serum (n = 15) relative to non-cancerous
controls (n = 5). A) MiR-885-5p was significantly down-regulated by 46-57% in patients
diagnosed with stage I and II disease relative to non-cancerous controls (p-value = 0.020.0034). B) However, in the second isolation miR-885-5p expression was up-regulated
by 2.5-7.4 fold in stage III disease relative to non-cancerous patients (p-value = 0.005).
Statistical analysis was performed using Unpaired t-test and significance level of 0.05
(*p-value < 0.02, ** p-value < 0.004).
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Figure 9. Mature miR-186-5p expression in androgen dependent and independent PCa
cell lines. The relative expression of miR-186-5p was measured in normal prostate
epithelial cells (RWPE1, RWPE2), non-metastatic (E006AA), prostate carcinoma
xenograft (22Rv1), bone (PC-3), lymph node (LNCaP), brain (DU145) metastatic PCa
cells using specific Taqman primers and qRT-PCR. MiR-186 expression was not
significantly higher in RWPE2, E006AA, 22Rv1, and DU145 cell lines relative RWPE1
cells. However, miR-186-5pwas up-regulated by 3.2-16.2-fold in three metastatic PCa
cell lines (LNCaP, MDA PCa-2b, PC-3) relative to normal prostate epithelial RWPE1
cells. Metastatic PC-3 cells exhibited a 16-fold increase, the highest expression, in the
expression of miR-186-5p relative to normal prostate epithelial cells (p-value = 0.0002).
MiRNA expression was normalized to endogenous control miR, RNU44, and measured
in three independent experiments. Statistical analysis of experiments was performed
using one way ANOVA (** p-value < 0.01, *** p-value < 0.0003).
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Figure 10. Ct values of RNU6 and RNU44 in normal prostate epithelial and PCa
cell lines. A) Higher Ct values were detected for RNUB6 in normal epithelial and
PCa cell lines (p-value = 0.571). B) However, lower Ct values (higher expression)
were detected for RNU44 in normal epithelial and PCa cell lines relative to
RNU6. The Ct value of RNU44 in PC-3 cells was significantly higher relative to
C4-2B (p-value = 0.0061). Statistical analysis was performed using a nonparametric one way non-parametric ANOVA test and Dunn’s multiple hypothesis
test and significance cut-off p-value ≤ 0.05 (** p-value < 0.007).
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Expression profile of miR-186-5p in metastatic and non-metastatic PCa cell lines
The expression of miR-186-5p was measured in androgen sensitive
metastatic (i.e., LNCaP, C4-2B, 22Rv1, MDA-PCa-2b), androgen sensitive nonmetastatic (i.e., E006AA) and insensitive metastatic (DU145, PC-3) PCa cell
lines relative to normal epithelial prostate cells (RWPE1) and k-Ras transformed
normal epithelial cells (RWPE2) using qRT-PCR. These cell lines are also
described in Table 1. MiRNA expression was normalized to the expression of
endogenous control miR RNU44 in PCa cell lines. RNU44 was selected as an
endogenous control miR as supposed to RNU6 due to lower Ct values, which are
indicative of higher expression in normal epithelial and PCa cell lines used in this
study (Figure 10). Expression of miR-186-5p was not significantly up-regulated in
transformed normal epithelial (RWPE2), prostate carcinoma xenograft (22RV1),
metastatic PCa (DU145) and non-metastatic PCa (E006AA) cells relative to
RWPE1 cells. However, miR-186-5p was significantly up-regulated by 3.2-16.2fold in metastatic PCa cells (LNCaP, MDA-PCa-2b and PC-3) relative to the
control cell line (RWPE1), as shown in Figure 9 (p-value < 0.01). In LNCaP cells,
miR-186-5p expression was up-regulated by 3.4-fold relative to normal epithelial
cells (p-value = 0.009). Additionally, the miR-186-5p was up-regulated by 3.2fold in MDA PCa 2b cells relative to RWPE1 cells (p-value = 0.005). Interestingly,
miR-186-5p expression was most pronounced in androgen insensitive metastatic
PC-3 cells with a 16.2-fold increase relative to RWPE1 cells (p-value = 0.0002).
However, miR-186-5p expression in PCa cell lines did not exhibit a dependence
on androgen sensitivity status.
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Discussion:
Circulating non-coding RNAs (e.g., mRNAs) in serum play a pivotal role in
many cancers, including PCa.

MiRNAs are essential regulators of genes

involved in various hallmarks of cancer. At the beginning of this study, there were
limited reports on the expression of circulating miRNAs in PCa. To address this
research gap, we initiated a pilot study to evaluate whether circulating miRNAs
were differentially expressed in the serum collected from PCa patients diagnosed
with non-metastatic and metastatic disease relative to disease-free men. In the
current study, six circulating miRNAs (-106b-5p, -186-5p, -302b-3p, -342-3p, 520e, -885-5p) were differentially expressed in the serum of PCa patients using a
intermediate high-throughput Taqman array cards. Two circulating miRNAs (106b-5p, 186-5p) were up-regulated in the serum of PCa patients when
compared

to

controls,

following

qRT-PCR.

Since

miR-106b-5p

was

characterized as an oncogenic miRNA with several direct gene targets using
PCa cell models, further analysis was focused on miR-186 [75, 76, 96, 128, 129].
In addition to the up-regulation of miR-186 in the serum of PCa patients, we also
demonstrated miR-186 was up-related in a few metastatic PCa cell models (PC3, MDA-PCA-2b, LNCaP).
Some discrepancies were detected in the expression of circulating
miRNAs between the microarray and individual qRT-PCR analyses. For instance,
miR-186-5p was down-regulated in the serum of PCa patients using the
microarray data but up-regulated following qRT-PCR. Discrepancies between the
micro-array and qRT-PCR were presumably attributed to the difference in
normalization techniques (i.e., global normalization and miR-cel-39 external
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control) used for these two genomic approaches.

In particular, analysis of

miRNA using Taqman array requires global normalization; whereas, qRT-PCR
required the use of an external control (i.e. miR-39) that was spiked in the serum
samples. However, qRT-PCR findings that used an external control were
considered more reliable than Taqman Array data.

Global normalization of

Taqman array data was heavily reliant upon median Ct values of all miRNAs
analyzed, which may lead to false positive results or mis-interpretation of the
directionality of the expression of circulating miRNAs. Normalization of qRT-PCR
data of circulating miRNAs using miR-cel-39 as an external control helped to
control for sample losses during the total RNA isolation, cDNA generation,
miRNA isolation steps. Since there is no appropriate endogenous control for
circulating miRNAs, previously published reports suggest the use of synthetic
miRNA Caenorhabditis elegans 39 to normalize circulating miRNA profiles
among PCa patients [52, 117, 123, 124]. Consequently, miR-cel-39 was used in
the current study to normalize miRNA expression in serum due to its common
use in literature in relation to PCa.

Although there are no published reports on the expression of miR-186 in
the serum from PCa patients and appropriate controls, miR-186-5p expression
has been evaluated in two independent prostate tumor tissue-based studies with
mixed results [63, 113]. In one study, miR-186-5p was significantly downregulated in fresh frozen tumor tissue (n = 50) relative to benign hyperplasia (n =
30) and matched non-malignant tissue (n = 50) among German men [113]. This
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study failed to remove surrounding normal tissue from cancerous tissue using
micro-dissection, which may have skewed miR-186-5p expression within a nonpure population of tumor tissue.
Commensurate with our serum based findings, Ambs and colleagues
(2008)

observed

an

up-regulation

of

miR-186-5p

expression

in

laser

microdissected tumor tissue of prostate patients diagnosed with extraprostatic
disease (i.e., extension of the tumor outside or independent of the prostate)
relative to patients with no extraprostatic disease among European (n = 30) and
African American (n = 30) men [63]. Unlike the previous report among German
PCa patients, this 2008 study evaluated miR-186-5p expression using microdissected tissue, which provides a pure population of tumor cells in which the
miRNA profiles are not contaminated, skewed or diluted by normal surrounding
tissue (personal communication with Dr. Lacey McNally, University of Louisville).
Therefore, miR-186-5p expression in the Ambs study rather than the German
study was given more consideration in relation to our study findings.

Previously, miR-186-5p expression has been reported as up-regulated in
several different malignancies [99-104, 130]. Furthermore, miR-186 has
demonstrated an oncogenic function via its down-regulation of anti-tumor
associated genes in cancer. For instance, miR-186 overexpression led to the
down-regulation of tumor suppressors, FOXO1 and NR5A2, in vitro in
endometrial and pancreatic cancer, respectively [100, 103]. Additionally in
cervical cancer cells, miR-186 overexpression down-regulated the gene
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expression of pro-apoptotic gene, P2X7 [101]. However, the role of miR-186 in
cancer may be tumor specific because it appears to have a tumor suppressor
role in other cancers [106-112]. In the next chapter of this dissertation, we
demonstrate inhibition of miR-186 corresponds with a suppression of cellular
proliferation, anchorage independent growth and cellular invasion suggest miR186 exhibits an oncogenic role in PCa within our metastatic PCa cell models.

We have considered study limitations, strengths and future directions.
The analysis of circulating miRNA expression was restricted by a small sample
size of PCa patient serum. To our knowledge, our lab is the first to demonstrate
the up-regulation of miRNA-186-5p in the serum of PCa patients as well as
metastatic cell models. Given the discrepancy in the directionality of the Taqman
array and qRT-PCR of serum-based miRNAs, we speculate global normalization
may not be the best normalization technique for circulating miRNAs in PCa. We
propose normalization of circulating miRNA profiles using an external control like
miR-cel-39 may be more appropriate than a global normalization used for the
Taqman array analysis. To prevent future issues in miRNA profiling during highthroughput

analysis,

we

will

include

miR-cel-39

and

other

synthetic

Caenorhabditis elegans miRNAs within customized microarrays to normalize the
expression of serum-based miRNAs. In future studies, we will confirm the upregulation of miR-186-5p and other oncomiRs in serum and matched microdissected PCa tumor samples relative to age-matched controls using
ethnically/racially diverse sub-groups. Additionally, we will evaluate miR-186-3p,
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the passenger strand of miR-186, expression to determine whether only miR186-5p is uniquely up-regulated in PCa serum and cell lines. The up-regulation of
miR-186 based on disease-state or disease aggressiveness within independent
studies may support it’s utility as a prognostic tool.

Circulating non-coding RNAs (i.e., miRNAs) have the great potential to
serve as clinical biomarkers capable of distinguishing between lethal and nonlethal disease. In addition, miRNA’s have the capacity to monitor physiological
changes and evaluate the effectiveness of different therapies against PCa in
patients. For instance, after prostate patients underwent a radical prostatectomy
the serum-based expression of oncogenic miRs-195, -26a and -let-7i
dramatically reduced in patients. Moreover, several studies demonstrate that
miRNA expression profiles relate to early stage, advanced, and recurrent disease
[52, 65, 117, 121, 123, 124]. MiRNA expression profiles that correspond to
specific disease stages provide an opportunity to improve current prognostication
and clinical management strategies. Furthermore, miRNA expression may help
enhance the capacity of current PCa tools, namely PSA test and digital rectal
examination to identify individuals with a high-risk of developing aggressive or
recurrent disease as well as those who may benefit from more aggressive
treatment or follow-up care.

Ultimately, miRNAs may serve as non-invasive

biomarkers with the capacity to improve PCa prognostication, treatment and
clinical management strategies.
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CHAPTER III
THE IMPACT OF MIR-186 ON THE PROSTATE CANCER PHENOTYPE IN
VITRO

Introduction:
MiRNAs are differentially expressed in tumor cells and greatly influence
several cellular hallmarks of cancer (i.e., proliferation, migration, anchorage
independent growth and invasion) via their regulation of target mRNAs [73, 75,
79, 81, 89]. Specifically, miR-186 expression alters tumor cellular behavior in
vitro in several malignancies including bladder, pancreatic, ovarian and lung
[103, 106, 107, 112, 130, 131]. MiR-186 is an intronic miRNA located on
chromosome 1 at 1p31.1 within the ZRANB2 gene locus. This miRNA is
differentially expressed in various tumor types including PCa [63, 99-104, 106113]. In some cancers, miR-186 plays an oncogenic role due its overexpression,
but in other neoplasms miR-186 functions as a tumor suppressor. Previously, we
demonstrated an up-regulation of miR-186-5p expression levels in the serum of
PCa patients diagnosed with stage I, III and IV disease relative to non-cancerous
controls. Additionally, we also observed a significant up-regulation of miR-186-5p
in metastatic PCa cell lines (LNCaP, MDA PCa-2b, PC-3), but highest in PC-3
relative to normal prostate epithelial RWPE1 cells. However, miR-186-5p has
never

been

characterized

as

an
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oncogenic

miRNA

in

PCa.

Several reports demonstrate miR-186 expression is down-regulated in
cancer-associated fibroblasts, oral squamous, non-small cell lung, colorectal,
bladder and ovarian cancer [106-112, 130, 131]. In two reports, miR-186 was
under-expressed in non-small lung cancer (NSCLC) tumor tissue and cell lines
(A549, NCI-H358, H157, H1299) relative to adjacent normal tissue and normal
bronchial epithelial cells (16HBE) [106, 107]. In the same studies, overexpression
of miR-186-5p inhibited cellular migration and invasion in NSCLC cell lines [106,
107]. Overexpression of miR-186 in bladder cancer cell lines (i.e., HT-1346, RT4)
lead to a decrease in cellular proliferation, and invasion [130]. Furthermore in a
recent report (2015), miR-186 expression was significantly low in cisplatinresistant epithelial ovarian cancer (EOC) cell lines (i.e., ACRP, C13*,
OVCAR3/DDP) relative to cisplatin-sensitive ovarian cancer cell lines (i.e.,
A2780, OV2008, OVCAR3) [112]. Ectopic expression of miR-186 reduced cell
motility via reduction of vimentin and increase of E-cadherin protein expressions
in cisplatin-resistant EOC cell line, ACRP. Additionally, higher miR-186
expression was exhibited in platinum sensitive ovarian tumor tissue from patients
with progression-free survival greater than 6 months. In another study, miR-186
overexpression reduced proliferation and invasion of bladder cancer cells [131].
Collectively, these aforementioned reports suggest that miR-186 plays a tumor
suppressive role in NSCLC, and ovarian cancer.
In

contrast,

miR-186

expression

is

up-regulated

in

endometrial,

pancreatic, esophageal, cervical, head/neck, and non-melanoma skin cancer [99104, 130, 132]. For instance, Zhou and co-workers (2008) observed that miR-186
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expression was up-regulated in HeLa cells, a cervical adenocarcinoma cell line,
relative to human ecto-cervical-vaginal epithelial cells (hEVEC) [101]. MiR-186
expression was also shown to be up-regulated in endometrial tumor tissue and
an endometrial cell line, Ishikawa, relative to controls [100]. In pancreatic cancer,
miR-186 is up-regulated in tumor tissue (surgical specimens T2, T13, T29, T33,
T34, T36-38, T40) and cell lines (BxPC-3, Panc-1, MIA, Hs766T, HPAFII, ASPC1) relative to normal pancreatic tissue and human pancreatic ductal epithelial
(HPDE) cells [102]. In another report, overexpression of miR-186 in pancreatic
cell lines (Panc-1, BxPC-3, and MiaPaca-2) induced cellular proliferation and
migration relative to negative controls [103]. These effects were reversed after
inhibition of miR-186 in pancreatic cell lines. Moreover in the same report, miR186 was significantly up-regulated in the tumor tissue of pancreatic cancer
patients with poor survival (median survival of 13.8 months) relative to patients
with low miR-186 expression with a longer survival time [103]. Additionally,
overexpression of miR-186-5p led to enhanced cell proliferation, anchorage
independent growth and colony formation of J82 bladder cancer cells [130].
Together these reports suggest an oncogenic function for miR-186 demonstrated
via its overexpression in various cancers. However, whether miR-186 plays an
oncogenic or tumor suppressor role in PCa is unknown.
To date, only two reports have evaluated the expression profile of miR186 in PCa tumor tissue [63, 113]. However, these reports conflict with one
another and do not reveal a definitive role of miR-186 in PCa. In a report by
Erdmann and associates (2014), miR-186 expression was significantly down-
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regulated by 2.7-3.4-fold in tumor tissue (n = 50) relative to tumor-free (n = 46)
and benign hyperplasia (n = 30) tissue [113]. Furthermore, AMACR and PSMA
were identified as putative targets of miR-186 in PCa through qRT-PCR and
exemplary scatter plots; however, the study did not confirm the impact of miR186 expression on these targets via western blot or luciferase reporter assays
[113]. In another report, miR-186 expression was up-regulated by 1.3-fold in
tumor tissue with extraprostatic disease (n = 17) relative to tumor tissue without
extraprostatic disease (n = 35) [63]. Due to these conflicting reports, a definitive
role for miR-186 remains to be identified in PCa.
Therefore, we addressed this research gap through the characterization of
the effects miR-186 overexpression in normal cells and inhibition in PCa cell
lines. The different hallmarks of cancer such as enhanced cellular proliferation,
invasion and anchorage independence were evaluated in relation to miR-186-5p
expression in metastatic PCa and normal prostate epithelial cells. We
hypothesized the miR-186-5p inhibition will impede proliferation and invasion to
reduce the aggressiveness of tumor phenotype associated with metastatic PCa.
Furthermore, we hypothesized miR-186-5p overexpression in normal prostate
epithelial cells would lead to the malignant transformation.
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Methods:
Cell Culture
Cell lines (i.e. PC-3, MDA PC 2b, E006AA, RWPE1) previously described
in Chapter 2 were used to perform characterization experiments.

DNA Isolation
Cells were plated in a T75 flask and grown to 80% confluency. Cells were
washed once in 1X PBS (2 ml), trypsinized with 0.05% Trypsin for 5 mins and
trypsin was neutralized with growth medium containing FBS. Cells were
transferred to 15ml tubes and pelleted through centrifugation at 1200 rpm for 5
mins. Cell pellets were washed in 1X PBS (1 ml) and centrifuged at 1200 rpm for
5 mins. Genomic DNA was isolated from cell pellets using the DNeasy Blood and
Tissue kit (Catalog# 69504, Qiagen, Valencia, CA). In brief, ATL buffer (180 µl)
and proteinase K (20 µl) were added to each cell pellet and mixed thoroughly.
Samples were transferred into 1.5ml tubes. Samples were incubated at 56 oC and
constantly tapped until cells lysed completely. AL buffer (200 µl) was added to
each sample and vortexed briefly. Samples were incubated at 56 oC for 10 mins
and 100% EtOH (200 µl) was added to each tube and vortexed for 10 secs.
Samples were applied to DNeasy mini-spin columns in collection tubes and
centrifuged at 6,000xg for 1 minute at room temperature. Mini-spin columns were
transferred to new collection tubes, washed with AW1 buffer (500ul) and
centrifuged at 6,000xg for 1 minute. Samples were transferred to new collections,
washed with AW2 buffer (500 µl) and centrifuged at 16,100xg for 4 mins. Mini-
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spin columns were transferred to new collection tubes and heated AE elution
buffer (100 µl) was added to each column. Samples incubated at room
temperature for 1 mins and DNA was eluted through centrifugation at 6,000 xg
for 1 minute. DNA concentrations were measured using a Nano Dropper
Spectrophotometer.

RNA Isolation
Cells were plated at an optimal cell density in 60mm dishes and incubated
at 37oC for a given time frame. Cells were trypsinized with Trypsin 0.05% for 5
mins, neutralized with growth medium containing FBS and transferred to 15ml
tubes. Cells were centrifuged at 1200rpm for 5 mins. Cell pellet was washed in
1X PBS (1 ml) once and centrifuged at 1200rpm for 5 mins. PBS was removed
and 1 ml of Trizol Reagent (Invitrogen) was added to cell pellets, thoroughly
mixed into solution and transferred to 1.5 ml tubes. Mixture incubated at room
temperature for 5 mins. Chloroform (200 µl/1ml of Trizol) was added to mixture
and shaken for 15 secs and incubated at room temperature for 3 mins. Samples
were centrifuged at 12,000 xg for 15 mins at 4oC. Aqueous phase (≥ 400ul) was
transferred to new 1.5ml tubes and 100% isopropanol (500ul/ 1ml of Trizol) was
added to each tube. Samples were vortexed for 10 secs and incubated at room
temperature for 10 mins. Samples were centrifuged at 12,000xg for 10 mins at
4oC. Supernatant was discarded and RNA pellets were washed in 80% EtOH
(1ml per 1ml of Trizol). Samples were vortexed briefly (10 secs) and centrifuged
at 7500 xg for 5 mins at 4oC. RNA pellets air dried for 5-30 mins and
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resuspended in molecular grade H2O. Samples were incubated at 60oC for 15
mins and RNA concentrations using a Nano drop Spectrophotometer.

microRNA Isolation from cell lines
Total isolation of mRNA and microRNA was performed using the miRVana
microRNA Isolation kit (Catalog# AM 1561, Thermo Fisher Scientific, Waltham,
MA). Cells were seeded at an optimal cell density into 60 mm plates in growth
medium. Cells were washed once with 1X PBS (2 ml), lysed in dishes with
mirVana lysis buffer (600 µl), harvested with cell scraper and pipetted into 1.5ml
tubes. Cells were vortexed for 30 secs to completely lyse cells. Homogenate
additive (1/10 of cell lysate volume) was added to cell lysates and vortexed for 30
secs. Samples were incubated on ice for 10 mins and equal volume of
acid/phenol chloroform mixture was added to each tube. Samples were vortexed
for 60 secs and separate into aqueous and organic phases through centrifugation
at 10,000 xg for 5 mins at 4oC using Eppendorf Centrifuge 5810R. Aqueous
phase ( ≥ 400 µl) was pipetted into new 1.5ml tubes and 100% EtOH (1.5 x
aqueous layer volume) was added to each tube. Samples were added to filters in
new collection tubes, centrifuged at 10,000 xg for 30 secs. Samples were
processed at room temperature and flow-through was discarded after
centrifugation. Filters were washed once with 700 µl of wash 1 solution and
centrifuged at 10,000 xg for 30 secs. Filters were washed twice with 500 µl of
wash 2/3 solution and centrifuged at 10,000 xg for 30 secs. Filters were
centrifuged at 10,000 xg for 1 minute to remove residual fluid and transferred to
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new collection tubes. Elution buffer (60 µl) was added to the center of each filter
and incubated for 5 mins. miRNA was eluted through centrifugation at 10,000 xg
for 1 min at room temperature. Samples were placed on ice and RNA
concentrations were determined using a Nanodrop Spectrophotometer.

Transient Transfection
RWPE-1 and RWPE-2 cells were seeded at a cell density of 8x10 5 into 60
mm dishes and incubated 37oC overnight. Cells were washed twice in PBS
before transfection. Cells were transfected using mirVana miR-186 mimic (19
nM) (Assay# MC11753, Catalog# 4464066, Thermo Fisher Scientific, Waltham,
MA, Carlsbad, CA), mirVana mimic scramble control (19 nM) (Catalog# 4464059,
Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA) and Superfect
transfection reagent (Catalog# 301305 Qiagen, Valencia, CA) according to
manufacturer’s instructions. The miR-186 mimic is a small, chemically modified
double-stranded RNA molecule that mimic the endogenous miRNA and enable
miRNA functional analysis by up-regulation of miRNA activity. The mimic is the
same length as the mature miRNA transcript. In brief, a 10 µM stock solution was
made for the mirVana mimic scramble control (10 pmoles/µl) and mirVana miR186 mimic (10 pmoles/µl). Cells were transfected in 60mm dishes with 50pmoles
of mirVana mimic scramble control and mirVana miR-186 mimic in Superfect
reagent (10 µl), growth medium (600 µl) and 1ml of Opti-MEM Reduced Serum
Media (Catalog# 11058921, Thermo Fisher Scientific, Waltham, MA). After a 2hr
incubation at 37oC, 1ml of growth medium was added each dish. After 24hrs,
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cells were used cellular behavior assays (e.g., cellular proliferation, migration,
invasion, and colonogenic assay).
PC-3 cells were seeded at a cell density of 6x10 5 and MDA-PCa-2b cells
were seeded at a cell density of 8x105 into 60mm dishes and incubated at 37oC
overnight. Cells were transfected using miR-186-5p mirVana inhibitor (33 nM)
(Assay# MH11753, Catalog# 4464084, Thermo Fisher Scientific, Waltham, MA,
Carlsbad, CA), mirVana inhibitor scramble control (33 nM) (Catalog# 4464078,
Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA), JetPrime reagent and
buffer (Catalog# 114-01, Polyplus Transfection, New York, NY) according to
manufacturer’s instructions. MiR-186-5p is a small, chemically modified singlestranded RNA molecule designed to specifically bind to and inhibit endogenous
miRNA molecules and enable miRNA functional analysis by down-regulation of
miRNA activity. The miRNA inhibitor is the reverse complement and same length
as the mature miRNA transcript. In brief, a 10 µM stock solution was made for
the mirVana inhibitor scramble control (10 pmoles/µl) and mirVana miR-186
inhibitor (10 pmoles/µl). Cells were transfected in 60 mm dishes with 72.6pmoles
of mirVana inhibitor scramble control and mirVana miR-186 inhibitor in JetPrime
reagent (2 µl), JetPrime buffer (200 µl) and 1ml of Opti-MEM Reduced Serum
Media (Catalog# 11058921, Thermo Fisher Scientific, Waltham, MA). After a 2-hr
incubation at 37oC, 1ml of growth medium was added each dish. After 24hrs,
cells were used cellular behavior assays (e.g., cellular proliferation, migration,
invasion, and colonogenic assay).

Post-transfection 24hrs, microRNA was
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isolated from cell lines to confirm overexpression and inhibition of miR-186 via
qRT-PCR.
HEK-293T cells were at a cell density of 8x10 5 into 60 mm dishes and
incubated 37oC overnight. Cells were washed twice in PBS before transfection.
Cells were transfected using mirVana miR-186 mimic (19 nM), mirVana mimic
scramble control (19 nM) (Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA)
according to manufacturer’s instructions. In brief, a 10 µM stock solution was
made for the mirVana mimic scramble control (10 pmoles/µl) and mirVana miR186 mimic (10pmoles/µl). Cells were transfected in 60mm dishes with 50pmoles
of mirVana mimic scramble control and mirVana miR-186 mimic in 1ml of OptiMEM Reduced Serum Media (Catalog# 11058921, Thermo Fisher Scientific,
Waltham, MA), JetPrime reagent and buffer (Catalog# 114-01, Polyplus
Transfection, New York, NY) according to manufacturer’s instructions. After a 2hr
incubation at 37oC, 1 ml of growth medium was added each dish. After 24 hrs,
cells were used western blot analyses.

Mir-186 precursor and anti-miR constructs
Genomic DNA from RWPE1 cells was used to clone a 579 bp BamHI/NotI
fragment

consisting

of

the

miR-186

precursor

using

forward

primer

(GCGGATCCGAGCCATGCTTATGCTACTG), and reverse forward (GCGCGG
CCGCCCAGGTATATGGCACAG) via PCR with the following cycling conditions:
95oC for 5 mins for 1 cycle, 95oC for 15 secs, 57.5oC for 30 secs, 72oC for 30
secs followed by 35 cycles and held 4oC. Size of PCR product was confirmed via
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gel electrophoresis and eluted from gel using Gen Elute Agarose Spin Column kit
(Catalog# 56500, Sigma Aldrich, St. Louis, MO). PCR product was cloned into
the pENTR/D-Topo vector (Thermo Fisher Scientific, Waltham, MA) using
Gateway system and spread on kanamycin (50 mg/ml) agar plates. Plasmid DNA
was isolated from bacterial colonies using the QIAprep Spin Miniprep Kit
(Catalog # 27104, Qiagen, Valencia, CA) and sequenced by Eurofins Genomics
(Louisville, KY) to verify correct cloning.

Designed forward and reverse anti-miR-186 oligos from sequence
provided from Thermo Fisher Scientific, Waltham, MA and ordered from Eurofins
Genomics

(Louisville,

KY).

Anti-miR-186

forward

(5’CACCgcGGATCC

TGCTTGTAACTTTCCAAAGAATTCTCTCCTTTTGGGCTTTCTGGTTTTATTTTA
AGCCCAAAGGTGAATTTTTTGGGAAGTTTGAGCT 3’) (1mM) and anti-miR-186
reverse (5’GCGGCCgcAGCTCAAACTTCCCAAAAAATTCACCTTTGGGCTTAA
AATAAAACCAGAAAGCCCAAAAGGAGAGAATTCTTTGGAAAGTTACAAGCA
3’) (1mM) oligos were annealed together with 10X Annealing Buffer (100mM TrisHCl pH 7.5, 1M NaCl, 10mM EDTA pH 7.5) according to cycling conditions: 87 oC
(10o degrees above Tm) for 10 mins, 87-25oC at a rate of 0.1oC/sec, 25oC for 30
mins and hold at 4oC. The annealed anti-miR-186 oligo was run on 0.1% TAE
agarose gel Mir-186 precursor (579bp) and anti-miR-186 (100bp) was shuttled
into pcDNA-DEST47 expression vector and sequenced by Eurofins Genomics
(Louisville, KY) to verify correct cloning. The pcDNA-DEST47-miR-186 mimic
construct was used to stably overexpress miR-186 in RWPE1 and RWPE2 cells
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and the pcDNA-DEST47-Anti-miR-186 construct was used to stably inhibit miR186 in PC-3 cells.

Stable Transfection
RWPE-1 cells were seeded at a cell density of 8x105 into 60 mm dishes
and incubated 37oC overnight. Cells were washed twice in PBS before
transfection.

Cells

were

transfected

using

pcDNA-DEST47-miR-186

overexpression construct (1 µg), pcDNA-DEST47 as the negative control (1 µg)
(Thermo Fisher Scientific, Waltham, MA) and 10 µl of Superfect reagent (Qiagen,
Valencia, CA) according to manufacturer’s instructions. PC-3 cells were seeded
at a cell density of 6x105 into 60mm dishes and incubated 37oC overnight. Cells
were transfected using pcDNA-DEST47-anti-miR-186 construct (1 µg), pcDNADEST47 as the negative control (1 µg) (Thermo Fisher Scientific, Waltham, MA)
and JetPrime reagent (Polyplus Transfection, New York, NY) according to
manufacturer’s instructions. Forty-eight hours post-transfection, growth medium
(3 ml) was replaced and cells were treated with G418 Sulfate (800 µg/ml)
(Catalog# 30-234-CR, MEDIATECH INC) for 10-14 days and then cultured in
G418 Sulfate (400 µg/ml) for expansion.

miRNA Expression
Reverse transcription of total RNA (10ng) was performed using TaqMan
microRNA Reverse Transcription kit, miRNA specific RT primers and Peltier
Thermal Cycler (PTC 200). cDNA was synthesized using the following cycling
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conditions 16oC for 30 mins, 42oC for 30 mins, 85oC for 5 mins and hold
indefinitely at 4oC. qRT-PCR was performed using miRNA specific PCR TaqMan
Assays (Life Technologies) and the following cycling conditions: hold for 2 mins
at 50oC, 10 mins at 95oC for 1 cycle, 15 secs at 95oC and 1 minute at 60oC for
40 cycles . Amplification of cDNA was performed using the Applied Biosystems
Step One PCR system (Applied Biosystems, Carlsbad, CA). The relative
expression of microRNA compared with U44 snRNA was calculated using 2 -∆∆Ct
method.

Cell Proliferation Assays
Trypan Blue Exclusion Assay
Transiently and stably miR-186 transfected cells were seeded at a cell
density of 10x103 or 50x103 into 6-well plates and incubated at 37oC over the
time course of 5-6 days. Cells was washed in PBS (1X) twice, cleaved with
TrypLE Select (Catalog # 12563-029, Thermo Fisher Scientific, Waltham, MA)
and placed in the incubator for 5 mins. Trypsin was neutralized with growth
medium containing FBS and cells were transferred to 15 ml tubes. Cells were
mixed thoroughly and used to make a 1:2 dilution of cells with 0.4 w/v Trypan
Blue solution in PBS (Catalog# 25-900-C1, Mediatech, Manassas, VA). Cell
dilution (10µl) was counted in triplicate at each time interval using a
Hemacytometer.
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5-bromo-2’-deoxyuridine (BrdU) Incorporation
Transiently transfected PC-3 (2x103), MDA PCa 2b (2x103) and RWPE1
(5x103) cells (100 µl/well) were seeded into 96-well black plates and incubated
for 24 hrs at 37oC overnight. Cellular proliferation was measured using the Cell
Proliferation ELISA BrdU colorimetric kit (Catalog # 11647229001, Sigma Aldrich,
St. Louis, MO). The 5-bromo-2’-deoxyuridine (BrdU) labeling solution (1:100, 10
µl/well) in growth medium was added to cells to monitor the incorporation of BrdU
into newly synthesized DNA. Cells were incubated at 37 oC in BrdU labelling
solution for 24hrs. For each experiment, experimental controls consisted of
blanks (medium/BrdU/ BrdU anti-body) and background controls (cells/antibody). After each time intervals, BrdU label was removed from adherent cells.
Cells were incubated in FixDenat solution (200 µl/well) at room temperature for
30 mins and removed thoroughly. Anti-BrdU-POD working solution (1:100) was
added to cells for 90 mins at room temperature and then removed. Cells were
washed three times in PBS 1X solution. Substrate solution was added to each
well and incubated at room temperature for 15 mins. Cellular proliferation was
quantified using the difference in the absorption of BrdU incorporated in the DNA
of newly proliferating cells at the testing wavelength, 370 nm, and the reference
wavelength, 492 nm, using a Biotek Synergy HT plate reader.

ATP Lite Assay
Transiently miR-186 transfected PC-3 cells were seeded at a cell density
of 2x103 (100 µl/well) into 96-well black plates and incubated for 24 hrs at 37oC.
One vial of lyophilized substrate solution was reconstituted in 5 ml of substrate
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buffer solution and gently agitated until solution was homogenous. Mammalian
cell lysis buffer (50 µl) was added to each well of 96-well plates. Plates were
shaken for 5 mins at 700 rpm to lyse cells and stabilize ATP. Immediately before
measurement, substrate solution (50 µl) was added to each well. Cellular viability
and proliferation was measured via luminescence intensity after 72, 96 and 120
hrs using ATPlite Luminescence Assay System Kit (Catalog# 6016941, Perkin
Elmer, Waltham, MA) and Advanced Medical Imaging (AMI) instrument. ATPlite
is an Adenosine TriPhosphate (ATP) monitoring system based on firefly
(Photinus pyralis) luciferase and uses ATP as a marker of cell viability.
Luminescence is emitted from the chemical of ATP with luciferase and Dluciferin. This luminescence assay is the alternative to colorimetric, fluorometric
and radioisotopic assays for the quantitative evaluation of proliferation and
cytotoxicity of cultured mammalian cells.

Anchorage Independent Growth Assay
Sterile 3.5% agar solution in 1X PBS was used to make a 0.7% agar
solution with growth medium. The 0.7% agar-medium solution was used to make
a 0.35% agar-medium solution. The 0.35% agar-medium solution (3 ml) was
added to 6-well plates to form base layer and plates were incubated at 4oC for 60
mins to set agar base. Transiently transfected and/or stable cells (10x10 3 cell
density) in a final volume of 3 ml were gently mixed with 0.7% agar-medium
solution (3 ml) to make a 0.35% agar-medium solution. The cells in the 0.35%
agar-medium solution were added onto the agar base layer in the 6-well plates.
Cells were allowed to incubate at 37oC and form colonies in soft agar for 2-3
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weeks. Colonies were counted at 4X magnification in bright field setting using
bright field microscopy.

5-α-DHT Treatment
5

-alpha

Dihydrotestosterone

(DHT)

(Catalog#

D-073-1ML,

Lot#

FE02101503, Sigma Aldrich, St. Louis, MO) in methanol was purchased at 1
mg/ml (1mM). DHT (100ul) was diluted 1:10 in PBS 1X (900ul) to make a
solution of 100 µM. Next, DHT solution (100 µM) was diluted 1:100 in 5ml of PBS
1X to make s solution of 1uM. DHT solution (1 µM) was diluted 1:10 in 5ml of
PBS 1X. Androgen sensitive MDA PCa 2b cells were transfected with miR-1865p inhibitor (33 nM) and scramble control (33 nM), serum starved for in reduced
Opti-MEM I Reduced serum media (Catalog# 31985070, ThermoFisher
Scientific, Waltham, MA) for 24 hrs and treated with DHT (10 nM) for 24 hrs in
growth medium with FBS. Treated cells were plated in 0.35% soft agar with DHT
(10 nM).

Cellular Invasion Assay
Polyethylene Terephthalate hanging inserts (1.1cm 2) with pore size of
8.0µm and placed in a 12-well plate. Reduced growth matrigel was thawed and
100 µl was added on top of inserts in a 12-well plate. Matrigel was incubated at
37oC for 1hr to form a thin gel layer and cells (25x10 3) in serum-free medium
were seeded on top of matrigel. A solution of growth medium (0.6 ml) containing
FBS and FBS (0.6 ml) was pipetted into the lower chambers of a 12-well plate.
Growth medium and FBS in the lower chamber was used to make contact with
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insert membrane and create a chemoattractant gradient for cells. After 48hrs,
inserts were washed in 1X PBS with sterile q-tip and cells that migrated through
the insert into the lower chamber were washed with 1X PBS. Migrate cells in the
lower chamber were stained with 0.4% crystal violet in ethanol and quantified
using a 10X magnification and bright field microscopy.
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Results:
Mir-186 inhibition induces cellular death in both metastatic PCa and normal
prostate epithelial cells
To determine whether alteration of miR-186 expression modified cellular
death in PCa, we inhibited the expression of miR-186-5p in metastatic PCa cells
(Figure 12A). We also evaluated the effect of cellular behavior in relation to miR186-5p overexpressed in normal prostate epithelial cells (Figure 15A). We
selected RNU44 as a endogenous control miR to normalize miRNA expression
due to its expression being more stable and higher amplification in prostate cells
than RNU6, a commonly used endogenous control miR in other cancers (Figure
10). First, we evaluated the duration of a transient transfection in PC-3 and
RWPE1 cells. We determined that transient transfections last up to 144 hrs post
transfection, which is beyond the time frame for the in vitro studies in this study
(Figures 11, 14). A small chemically modified single-stranded RNA molecule
inhibitor was used to inhibit miR-186-5p expression. The inhibitor is designed to
specifically bind to and inhibit endogenous miRNA molecules and enable miRNA
functional analysis by the down-regulation of miRNA activity. The miRNA inhibitor
is the reverse complement and same length as the mature miRNA transcript. A
small, chemically modified double-stranded RNA molecule was used to
overexpress miR-186-5p. The mimic is designed to mimic the endogenous
miRNA and enable miRNA functional analysis by the up-regulation of miRNA
activity. The mimic is the same length as the mature miRNA transcript. MiR-1865p expression was transiently inhibited in androgen insensitive PC-3 cells and
androgen sensitive MDA PCa 2b cells as shown in Figure 12A. The death rate of
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transfected PC-3 and MDA PCa 2b cells were evaluated for up to 120 hrs using
trypan blue exclusion or cellular death assays as described in Chapter 2
methods. After 5 days, the cellular death of PC-3 and MDA PCa 2b cells treated
with the miR-186-5p inhibitor (33nM) was increased by 20-31% relative to
scramble control (33nM). Cellular death was increased by 28-31% in PC-3
treated with the miR-186 inhibitor relative to scramble control as shown in Figure
12B (p-value ≤ 0.055). In Figure 12B, miR-186 inhibition in MDA-PCa-2b cells
induced cellular death by 20-31% relative to scramble control (p-value = 0.334).
However, cellular death was not significantly reduced in PC-3 and MDA PCa 2b
cells. Next, PC-3 cells were stably transfected with pcDNA-DEST47-anti-miR186
and pcDNA-DEST47 constructs. Stable anti-miR-186 PC-3 cells exhibited a 30%
reduction in miR-186-5p expression relative to empty vector shown in Figure 13A
(p-value = 0.0022). Stable miR-186-5p inhibition in metastatic PC-3 cells resulted
in a 32-51% increased of cell death after 5 days relative to empty vector control
as shown in Figure 13B (p-value ≤ 0.02).
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Figure 11. Stability of transient miR-186 inhibition in PCa cells. PC-3 cells were
transiently transfected with scramble negative control and miR-186 inhibitor for 24hrs.
Expression of miR-186-5p was measured A) 24 and B) 144 hrs post-transfection via
qRT-PCR. Post-transfection, miR-186-5p expression was decreased by 73% (p-value =
0.003) and 50% (p-value = 0.0001), after 24 and 144 hrs, respectively (p-value < 0.004).
We set scramble control to 1 fold change. Data was quantitated from at least three
independent experiments and error bars are the standard deviation between
experiments. Statistical analysis was performed using Unpaired t-test and significance
level of p-value ≤ 0.05 (**p-value < 0.004, ***p-value < 0.0002).
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Figure 12. The effect of transient miR-186-5p inhibition on cell death in PCa. A) PC-3
and MDA PCa-2b cells were transiently transfected with miR-186-5p inhibitor (33nM)
and significantly reduced miR-186-5p expression by 66-73% relative to scramble control
as examined by qRT-PCR (p-value = 0.0061, 0.0002). B) Post-transfection, cellular
death of PC-3 and MDA PCa-2b cells was monitored every 24 hrs up using trypan blue
exclusion assay. MiR-186 inhibition induced cellular death by 31% (Day5) in PC-3 and
by 20-31% (Day5, 6) in MDA PCa-2b cells relative to scramble control (p-value = 0.055,
0.334). Data was quantitated from at least two separate independent experiments and
error bars are the standard deviation between experiments. Statistical analysis was
performed using Unpaired t-test and significance level of 0.05 (***p-value < 0.007).
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Figure 13. The effect of stable miR-186 inhibition on cellular death in PC-3 cells. A) PC3 cells were stably transfected with pcDNA-DEST47-anti-miR-186-5p and pcDNADEST47 constructs using G418 treatment. MiR-186-5p expression was stably reduced
by 30% in PC-3 cells relative to empty vector as revealed by qRT-PCR (p-value =
0.0022). B) Cellular death of stable anti-miR-186 PC-3 cells were monitored every 24hrs.
Cell death was induced by 33-51% in stable anti-miR-186 PC-3 cells relative to empty
vector as examined by trypan blue exclusion assay (p-value ≤ 0.02). Data was
quantitated from one experiment and error bars correspond to between three separate
cell counts standard deviation. Statistical analysis was performed using Unpaired t-test
and significance level of p-value ≤ 0.05 (*p-value < 0.03, **p-value < 0.003, *** p-value <
0.0006)
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Overexpression of miR-186-5p suppresses cellular death in normal prostate
epithelial cells
To determine the impact of miR-186-5p expression on cellular death in
normal prostate cells, miR-186-5p was transiently overexpressed in normal
epithelial RWPE1 cells to evaluate the transformation capacity of potential
oncogenic miR-186-5p alone. The stability of transient miR-186-5p
overexpression was evaluated in normal prostate epithelial cells. Ectopic
expression was observed to last 144 hrs post-transfection, shown in Figure 14.
MiR-186-5p was transiently overexpressed by 761-fold increase in RWPE1 cells
24 hrs post-transfection with miR-186-5p mimic (19nM) relative to scramble
control (19nM) as shown in Figure 15A. The death rate of transfected RWPE1
cells was monitored up to 120 hrs using trypan blue exclusion assays as
described in Chapter 3 methods. Overexpression of miR-186 in normal epithelial
RWPE1 cells significantly induced cellular death by 27% after 5 days relative to
scramble control shown in Figure 15B (p-value = 0.0008). Next, in a more
physiological model miR-186-5p was stably overexpressed in RWPE1 cells by
2.6 fold increase relative to empty vector (Figure 16A). Interestingly, stable
overexpression of miR-186-5p resulted in a more pronounced increase of 5076% in cellular death relative to empty vector control, shown in Figure 16B. After
day 5, the RWPE1 cells expressing the miR-186 mimic construct displayed the
greatest decrease of 76% in cellular death.
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Figure 14. Stability of transient miR-186 overexpression in normal epithelial cells.
RWPE1 cells were transiently transfected with scramble negative control and miR-186
mimic for 24hrs. Expression of miR-186-5p was measured A) 24 and B) 144 hrs posttransfection via qRT-PCR. Post-transfection, miR-186 was up-regulated by 761–fold (pvalue = 0.0426) and 83-fold (p-value = 0.0213) relative to scramble control after 24hrs
and 144hrs, respectively. Data was quantitated from at least three independent
experiments and error bars correspond to standard deviation. Statistical analysis was
performed using Unpaired t-test and significance level of p-value ≤ 0.05 (*p-value <
0.05).
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Figure 15. The effect of transient miR-186-5p overexpression on cellular death in normal
epithelial cells. A) RWPE1 cells were transiently transfected with miR-186-5p mimic and
scramble negative control for 24 hrs. MiR-186-5p expression was up-regulated in
RWPE1 cells relative to negative control as examined by qRT-PCR. B) Post transfection,
cellular death of RWPE1 cells were monitored every 24hrs up to 120hrs using trypan
blue exclusion assay. Overexpression of miR-186 induced cellular death by 27% in
RWPE1 cells relative to negative control (p-value = 0.0008). Data was quantitated from
at least three separate independent experiments and error bars calculated with standard
deviation. Statistical analysis was performed using Unpaired t-test and significance level
of p-value ≤ 0.05 (***p-value < 0.001).
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Figure 16. The effect of stable miR-186-5p overexpression on cell death in normal
prostate epithelial cells. A) RWPE1 cells were stably transfected with pcDNA-DEST47miR-186-5p mimic and pcDNA-DEST47 constructs using G418 treatment. MiR-186 was
stably overexpressed by 2.6-fold in RWPE1 cells relative to empty vector as examined
by qRT-PCR (p-value = 0.0019). B) Cellular death of stable miR-186 mimic RWPE1 cells
every 24hrs up to 120hrs examined by trypan blue exclusion assay. Cellular death was
increased by 50% on Day 5 (p-value < 0.0001) and 76% on Day 6 (p-value =0.009) in
stable miR-186 mimic RWPE1 cells relative to empty vector. Data was quantitated from
one experiment and error bars correspond to the standard deviation between three
separate cell counts. Statistical analysis was performed using Unpaired t-test and
significance level of p-value ≤ 0.05 (**p-value < 0.01, ***p-value < 0.0001).
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MiR-186 alters the capacity of metastatic PCa cells to proliferate in vitro
Self-sustained cellular proliferation is an essential hallmark of cancer.
Malignant cells produce their own growth signals [i.e., tumor growth factor-β
(TGF-β), platelet-derived growth factor (PDGF), epidermal growth factor (EGF)]
to stimulate uncontrolled proliferation in tumorigenesis [133]. To determine the
effect of miR-186-5p expression on proliferation, we evaluated the cellular
proliferation of transiently miR-186-5p inhibited metastatic PCa cells, PC-3 and
MDA PCa 2b, and miR-186-5p overexpressing RWPE1 cells using BrdU assays
as described in Chapter 2 methods. Cellular proliferation in both metastatic PC-3
and MDA PCa 2b cells was reduced significantly shown in Figure 17. Newly
proliferating cells was decreased by 46% in PC-3 cells and 27% in MDA-PCa-2b
cells relative to scramble controls shown in Figures 17A and 17B, respectively.
Additionally, the effect of miR-186-5p on cell viability and proliferation was also
detected in metastatic PC-3 cells using the ATP Lite Luminescence detection kit
as described in the Chapter 2 methods. In Figure 18, a 48-58% reduction in cell
viability and proliferation was detected in metastatic PC-3 cells after 72-120 hrs
relative to scramble control. In contrast, transient miR-186 overexpression
slightly reduced cellular proliferation by 10% in RWPE1 cells relative to scramble
control (Figure 19A). Post-transfection, cellular proliferation was decreased by
24% in E006AA cells treated with miR-186-5p mimic relative to negative control
as shown in Figure 19B (p-value = 0.0055).
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Figure 17. The effect of miR-186 inhibition on cellular proliferation in metastatic PCa.
PC-3 and MDA PCa-2b cells were transiently transfected for 24 hrs with miR-186-5p
inhibitor and scramble negative control. Cellular proliferation of PC-3 and MDA PCa-2b
cells was examined after 24hrs by BrdU colorimetric assays. A) Post-transfection,
cellular proliferation was decreased by 46% in PC-3 cells treated with miR-186-5p
inhibitor relative to scramble control (p-value = 0.032). B) Post-transfection, cellular
proliferation was decreased by 27% in MDA PCa-2b cells treated with miR-186-5p
inhibitor relative to scramble control (p-value = 0.0039). Statistical analysis was
performed using an Unpaired Student’s T test and significance cut-off p-value ≤ 0.05.
Data was quantitated from at least three separate independent experiments and error
bars calculated with standard deviation. Statistical analysis was performed using
Unpaired t-test and significance level of p-value ≤ 0.05 (*p-value, 0.04, **p-value <
0.004).
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Figure 18. Proliferation of miR-186-5p inhibited PC-3 cells. PC-3 cells were transiently
transfected with miR-186-5p inhibitor and scramble control for 24 hrs. Cellular
proliferation of PC-3 cells 72, 96 and 120hrs post transfection evaluated by ATP Lite
assay. MiR-186-5p inhibition reduced proliferation by 22-58% in PC-3 cells relative to
scramble controls (p-value < 0.0001). Cell proliferation was decreased by 58% after
72hrs, 48% after 96hrs and 22% after 120hrs. Data was quantitated from one
experiment and error bars were calculated from the standard deviation of 6 replicates
using the ATPLite assay Statistical analysis was performed using Unpaired t-test and
significance level of p-value ≤ 0.05 (***p-value < 0.0001).
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Figure 19. The effect of miR-186-5p overexpression on proliferation in normal prostate
epithelial and non-metastatic PCa cells. RWPE1 and E006AA cells were transiently
transfected for 24hrs with miR-186-5p mimic and scramble negative control. Cellular
proliferation of RWPE1 and E006AA cells was examined after 24 hrs by BrdU
colorimetric assays. A) Post-transfection, cellular proliferation was decreased by 10% in
RWPE1 cells treated with miR-186-5p mimic relative to negative control (p-value =
0.013). B) Post-transfection, cellular proliferation was decreased by 24% in E006AA
cells treated with miR-186-5p mimic relative to negative control (p-value = 0.0055). Data
was quantitated from three independent experiments and error bars calculated with
standard deviation. Statistical analysis was performed using Unpaired t-test and
significance level of p-value ≤ 0.05 (*p-value < 0.02, **p-value < 0.006).
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MiR-186-5p inhibition alters anchorage independence in metastatic PCa

To evaluate the effect of miR-186 expression on anchorage independent
growth, we seeded transfected normal epithelial (RWPE1), non-metastatic
(E006AA) and metastatic (PC-3, MDA PCa-2b) cells into 0.35% soft agar and
their growth was monitored at 37oC for 2-3 weeks. RWPE1 and E006AA cells
exhibited low miR-186 expression. MiR-186 was transiently overexpressed in
both cell lines and plated into 0.35% soft agar. Over the course of 2-3 weeks,
both RWPE1 and E006AA treated with scramble control and miR-186-5p mimic
exhibited no colony formation (Data not shown).
MiR-186 was up-regulated in metastatic PCa cell lines, PC-3 and MDA PCa2b, relative to normal prostate epithelial RWPE1 cells. We transiently inhibited
the expression of miR-186 in PC-3 and MDA PCa 2b cells and seeded cells into
0.35% soft agar. In Figure 20A, a reduction of 64% in colony formation of
metastatic PC-3 cells treated with the miR-186 inhibitor relative to scramble
control (p-value = 0.0022). MiR-186-5p inhibition did not significantly impede
colony formation in androgen sensitive metastatic MDA PCa 2b cells shown in
Figure 20 B (p-value = 0.335). However, after stimulation of the androgen
receptor with 5-alpha-DHT treatment (10 nM) a modest 28% decrease in colony
formation was observed in MDA PCa 2b cells treated with the miR-186-6p
inhibitor relative to scramble control (p-value = 0.034).
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Figure 20. The effect of miR-186-5p inhibition on anchorage independence in metastatic
PCa. Metastatic PC-3 and MDA PCa 2b cells were transiently transfected with scramble
negative control and miR-186 inhibitor for 24hrs. Post-transfection, cells were grown in
0.35% soft agar for 2-3 weeks at 37oC. Colony formation of PC-3 cells treated with miR186 inhibitor was significantly decreased by 64% relative to scramble control (p-value =
0.0022). In MDA PCa 2b cells, colony formation was slightly reduced by reduced by
12% relative to scramble control (p-value = 0.335). However, stimulation of the androgen
receptor with α-DHT treatment (10nM) after miR-186-5p inhibition did significantly
decrease colony formation in by 28% in MDA PCa 2b cells (p-value= 0.034). Data was
quantitated from at least three independent experiments and error bars calculated with
standard deviation. Statistical analysis was performed using Unpaired t-test and
significance level of p-value ≤ 0.05 (*p-value < 0.04, ***p-value < 0.003).
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Suppression of cellular invasion in metastatic PCa
To determine whether inhibition of miR-186-5p impacted cellular invasion
of metastatic PCa cells, metastatic PC-3 and MDA PCa 2b cells were transiently
transfected with the miR-186-5p inhibitor and scramble for 24hrs. Posttransfection, PC-3 and MDA PCa 2b cells were seeded on top of reduced growth
factor matrigel in 12-well plates. A 1:1 solution of growth medium and FBS was
pipetted into the lower chamber of each well to serve as a chemoattractant for
PCa cells. Reduced growth factor matrigel was used to reduce the influence
growth factors on the cellular invasion of PCa cells. After 48 hrs, the cells were
fixed in 100% methanol and stained in 0.4% crystal violet overnight. In Figure
21A, a significant reduction in cell invasion (66%) was observed in metastatic
PC-3 cells transfected with the miR-186-5p inhibitor relative to scramble control
(p-value = 0.0024). In metastatic MDA PCa 2b cells, miR-186 inhibition reduced
cellular invasion by 38% relative scramble control as shown in Figure 21B (pvalue = 0.0892). Unfortunately, this reduction was not statistically significant
between treatment groups.
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Figure 21. Cellular invasion of miR-186-5p inhibited metastatic PCa cells. PC-3 and
MDA PCa 2b cells were transiently transfected with scramble control and miR-186-5p
inhibitor for 24 hrs. Post-transfection, cells were seeded on top of reduced growth factor
matrigel. After 48 hrs, cells were fixed in methanol and stained with 0.4% crystal violet.
A) Cell invasion was reduced by 66% in metastatic PC-3 cells treated with the miR-1865p inhibitor relative to the scramble control (p-value = 0.0024). B) However, miR-186-5p
inhibition did not significantly reduced cell invasion in MDA PCa 2b cells (p-value =
0.0892). Data was quantitated from at least three independent experiments and using an
average of 3 different fields of view at 10X magnification. Statistical analysis was
performed using an Unpaired Student’s T test and significance level of p-value ≤ 0.05
(**p-value < 0.003).
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Discussion:
Aberrant expression of intronic miR-186 has been implicated in various
solid tumor malignancies [99-104, 106-112, 130, 131]. The influence of miR-1865p expression on tumor cellular behavior has undergone characterization in a
limited number of cancers [103, 106, 107, 112, 130, 131]. For instance, miR186-5p overexpression enhanced the cellular proliferation, migration, colony
formation and anchorage independent growth of pancreatic and bladder cancer
cells [103, 130]. However, there are no published reports on the role of miR-1865p in relation to different cancer hallmarks using PCa cell models (i.e.,
proliferation, invasion, anchorage independent growth). We hypothesized miR186-5p inhibition would impede the tumor phenotype in metastatic cells and miR186-5p overexpression would increase the aggressiveness of non-metastatic
cells and induce malignant transformation of normal epithelial cells. In the current
study, inhibition of miR-186-5p led to a reduction in cell proliferation, invasion,
and anchorage independent growth in metastatic PCa cells but not nonmetastatic cell models. Moreover, miR-186 overexpression increased cellular
death and proliferation in normal prostate epithelial cells.

These findings

implicate an oncogenic role for miR-186-5p in both metastatic PCa and normal
epithelial cells.
In vitro characterization of miR-186-5p revealed pertinent information
related to its effects on PCa and normal cell behavior. For instance, cell death
was not significantly affected by transient miR-186-5p inhibition in metastatic PC3 and MDA PCa 2b PCa cell lines. However, stable miR-186 inhibition
significantly increased cell death in PC-3 cells. This data suggests permanent
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rather than transient knockdown of miR-186 in the cellular genome in PCa cells
may lead to a significant increase in cell death metastatic PC-3 PCa cells.
Additional studies are needed to assess whether permanent miR-186 inhibition
will influence cellular death in other metastatic cell lines (e.g., MDA PCa 2b).
Moreover, transient inhibition of miR-186-5p significantly reduced the proliferative
capacity of metastatic PC-3 and MDA PCa 2b PCa cells. In agreement with our
in vitro data, miR-186-5p inhibition was also associated with a decrease in
cellular proliferation of pancreatic and bladder cancer cell lines [103, 130].

Initially, miR-186-5p overexpression was expected to increase the cellular
death and proliferation of normal prostate epithelial RWPE1 cells. However, in
the current study, transient overexpression of miR-186-5p led to a decrease in
proliferation and increase in cell death in RWPE1 cells. Similar to our findings,
overexpression of another oncogenic miRNA, miR-375 in RWPE1 cells resulted
in a reduction of cell proliferation, presumably due to an increase in cellular death
[70]. However in the current study, cellular death has not been identified as the
biological explanation for reduced proliferation yet. We speculate reduction in
cellular proliferation in miR-186 overexpressed RWPE1 cells may be attributed to
increased cellular death; however, subsequent studies are needed to test this
hypothesis.

In addition, we cannot rule out the possibility that miR-186-5p

overexpression in the normal epithelial cell lines may lead to necrosis or
autophagy. Ultimately, miR-186-5p overexpression alone was not sufficient for
malignant transformation in the normal epithelial cells. In order for malignant
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transformation to take place in the normal epithelium, multiple genomic changes
and insults induced by oxidative stress, and mutations in major tumor
suppressors (i.e., PTEN, p53, NKX3.1) and oncogenes (i.e. c-Myc) must occur
based upon Knudson hypothesis or multiple hits hypothesis. Knudson hypothesis
is a theory that a single cell must undergo a series of mutational events to
achieve malignancy. The accumulation of genetic changes and insults will lead to
DNA damage and ultimately genetic instability that will make normal cells more
susceptible to malignant transformation. Thus, multiple genetic insults may
increase RWPE1 cells susceptibility to malignant transformation via miR-186
overexpression.
Unexpectedly,

miR-186-5p

overexpression

reduced

the

cellular

proliferation of non-metastatic E006AA cells. We speculated that miR-186-5p
overexpression would increase the aggressiveness of these non-metastatic cells.
E006AA cells are androgen sensitive and possess a wild type p53 protein, but
null for PTEN protein [134]. Although miR-186-5p was severely overexpressed in
E006AA cells, it is possible that androgen receptor stimulation may be required
to increase sensitivity or susceptibility to miR-186-5p overexpression to enhance
proliferation. Furthermore, p53 may combat tumor aggressive effects exerted by
miR-186-5p overexpression. Future studies should address whether miR-186-5p
oncogenic function may be restricted to metastatic or advanced disease or
require androgen receptor stimulation to exert its effects in PCa.
Interestingly, the suppression of three different cancer hallmarks (i.e.,
proliferation, invasion and anchorage independent growth) was primarily
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observed in transiently miR-186-5p inhibited metastatic PC-3 cells. The PC-3
cells exhibited the highest expression of miR-186-5p compared to the other PCa
cells. It is possible that this cell line was more sensitive to miR-186-5p inhibition
due to a dependence on miR-186-5p expression to maintain its malignant
transformation. Therefore, any reduction of miR-186-5p expression in PC-3 cells
suppresses the tumor phenotype of these cells.
Anchorage independent growth and cell invasion are characteristics of
advanced disease as well as assessments of the neoplastic nature of tumor
cells. To our knowledge, there are no published reports on the influence of miR186-5p on anchorage independent growth using cancer cell models. Transient
inhibition of miR-186-5p alone was sufficient to decrease anchorage independent
growth in androgen insensitive metastatic PC-3 cells, but not MDA PCa 2b cells.
However, miR-186-5p inhibition of MDA PCa 2b cells after androgen receptor
stimulation via 5-alpha DHT treatment (10 nM) lead to a reduction in anchorage
independent growth. Normally androgen receptor stimulation induces cellular
proliferation and/or growth. It may be possible that DHT treatment sensitizes
MDA PCa 2b cells to the effects of miR-186-5p inhibition. This observation
implicates an involvement of androgen receptor signaling in androgen sensitive
cells for miR-186 to exert its effects on anchorage independent growth. Although,
miR-186-5p expression does not appear to be dependent on androgen receptor
sensitivity status based upon its expression in our PCa cell lines.

But this

observation implies miR-186-5p may be influenced by androgen sensitivity.
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Moreover, overexpression of miR-186-5p in RWPE1 and non-metastatic E006AA
cells did not promote anchorage independent growth in soft agar.
The current study revealed transient inhibition of miR-186-5p reduced cell
invasion in androgen insensitive PC-3 cells. However, we did not observe a
reduction in cell invasion of androgen sensitive MDA PCa 2b cells. However, we
cannot rule out the possibility that androgen stimulation of miR-186 inhibited
MDA PCa 2b cells will lead to a reduction in cellular invasion. Similar to the
impact of DHT on anchorage independent growth of miR-186 inhibited MDA PCa
2b cells, it is plausible androgen receptor signaling is essential for miR-186-5p
effects on tumor cellular behavior using androgen sensitive PCa cell models.
MiR-186-5p expression has been previously shown to alter cell invasion in two
studies. Contrary to our findings, these reports suggest a tumor suppressor role
for miR-186-5p demonstrated by a decrease in cell invasion via miR-186
overexpression in bladder and NSCLC cancer. However, our study suggests an
oncogenic role for miR-186-5p in PCa.
Collectively, in vitro studies in bladder and pancreatic cancer and our
study findings support an oncogenic role for miR-186-5p. Overexpression of miR186-5p in pancreatic and bladder cancer cells led to the enhancement of the
tumor phenotype (i.e., increased proliferation, colony formation, invasion).
Inhibition of miR-186-5p in pancreatic and PCa cells in the current study led to a
reduction in the tumor phenotype. Although there is conflicting data on miR-1865p expression in bladder cancer, more consideration was given to the report that
suggested an up-regulation of miR-186 based their analysis of miR-186-5p in
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tumor tissue carefully selected by NIH’s The Cancer Genome Atlas and the
procurement bladder cell lines from a reliable repository, ATCC [130, 131].
However, several studies propose a tumor suppressor role for miR-186-5p. Only
two studies have evaluated miR-186-5p expression in NSCLC tissue and cell
lines [106, 107]. Both reports failed to analyze miR-186-5p expression in laser
captured micro-dissected tumor tissue. Moreover, one report does not explain
the collection process for their matched tumor and normal tissue biospecimens
as well. Additionally, both studies only evaluated miR-186-5p in 4 out of the 12
common NSCLC cell lines in the literature [106, 107, 135]. Additionally, each
study evaluated miR-186-5p expression in different normal bronchial epithelial
cell lines (16HBE, BEAS-2B) as controls to compare with miR-186-5p expression
in NSCLC cell lines [106, 107, 135]. In another report, miR-186-5p was only
evaluated in ovarian tumor tissue (stage IIIC, IV), but not normal adjacent tissue
[112]. Furthermore, this study failed to analyze miR-186 in micro-dissected tumor
tissue as well. Collectively based upon the aforementioned failures, these reports
may have slightly skewed results in relation to miR-186.
We have considered the limitations, strengths and future directions of the
current study. The characterization of miR-186-5p using PCa and normal
epithelial cell models was restricted to the available cell lines in the current
laboratory and laboratories of collaborators. In the current study, possible
mechanisms responsible for miR-186-5p up-regulation in PCa were not
evaluated.
mechanisms

Therefore,
(e.g.,

future

studies

dysregulation

of
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will

elucidate

miRNA

potential

machinery

biological

components,

hypomethylation) responsible for the up-regulation of mature miR-186-5p in
serum and metastatic PCa cells. Previously, the up-regulation of miRNA
machinery such as RNase enzymes, Dicer and/or Drosha, have been associated
with miRNA dysregulation in cancer [136-139].

It is possible that the up-

regulation of Dicer and Drosha may contribute to elevated levels of miR-186-5p
observed in not only PCa, but several other malignancies (i.e., pancreatic,
bladder,

cervical,

Epigenetic

changes

and
(i.e.,

endometrial)
global/regional

as
hypomethylation

well.
and

hyperacetylation) may also attribute to the up-regulation of oncogenic miRNAs..
In cancer, hypomethylation of promoter regions of oncogenic-related genes may
allow high expression of oncomiRs such as miR-186-5p. Additionally,
hyperacetylation may be another mechanism responsible for miRNA upregulation. During hyperacetylation, the chromatin structure relaxes and exposes
the DNA wrapped around histones. This may present an opportunity for
transcription factors that positively regulate miR-186-5p to bind to DNA regulatory
elements and induce miR-186-5p expression. Thus the investigation of miRNA
biogenesis machinery and epigenetic changes may lead to additional biological
explanations for miR-186-5p up-regulation in PCa.
In the current study, there was no change in anchorage independent
growth of miR-186 inhibited MDA-PCA-2b cells; however, we observed a
significant decrease in anchorage independent growth following stimulation of
miR-185 inhibited MDA-PCA-2b cells with DHT (an androgen stimulator).
Therefore, future studies will assess whether miR-186-5p inhibition suppresses
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the cell growth, proliferation, invasion of androgen sensitive cells (e.g., LNCaP,
MDA-PCa-2b) following DHT treatment. Moreover, additional in vitro and in vivo
studies are needed to assess whether miR-186-5p overexpression and inhibition
alters cellular proliferation, anchorage independent growth, cell invasion, tumor
growth, and tumor metastasis using other androgen sensitive metastatic PCa cell
lines (i.e., TSU-Pr1, MDA PCa-2a, ALVA-101) as well as xenograft cell lines (i.e.,
VCaP, DuCaP) Furthermore, our study suggests miR-186 may target genes
involved in proliferation, anchorage independent growth and invasion in
metastatic PCa cell models.

Consequently, additional in vitro studies are

needed, similar to those in Chapter 4, to identify and validate miR-186 targets
responsible for attenuating aggressive tumor behavior in metastatic PCa cell
models with and without androgen stimulation. Our laboratory also has interest
in retrospective studies to assess whether miRNA-186 or other oncomiRs
detected in serum or micro-dissected prostate tumor specimen may correspond
with higher risk of biochemical or disease recurrence among PCa patients
following a radical prostatectomy. Given the assumption that the aforementioned
pre-clinical and serum/tissue based studies demonstrate miR-186 inhibition may
reduce tumor burden and metastatic potential, future clinical trials can test the
therapeutic benefit of miR-186 inhibitor alone or in combination with immuno- or
chemotherapy. Although toxicity and efficacy of miRNA inhibitors have not been
evaluated in clinical trial studies to treat metastatic PCa, miR mimics have
transitioned from the bench to the bedside. Currently, there are two phase I
clinical trials evaluating the toxicity and efficacy of tumor suppressor miRNA
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mimics, miRs-16 and -34, as therapeutic agents to treat advance disease in liver
and non-small lung cancer [NCT01829971, NCT02369198]. These clinical trials
present promise for the utilization of miRNA inhibitors as potential therapeutic
agents to treat cancer as well. Adverse side effects are expected with miRNA
mimics or inhibitors; however, this concern is typical for any therapeutic agent.
To potentially mitigate these adverse effects of miRNA mimics or inhibitors, these
therapeutic agents should be directly administered to prostate tumor cells located
in the prostate and/or distant organs using a biomarker targeting system. This
system would consist of the miR-186-5p inhibitor encapsulated within a biodegradable nanoparticle attached to a substrate and/or ligand that binds to a
protein and/or receptor specifically and highly expressed in prostate tumor cells.
Collectively, the aforementioned proposed studies may assist with the
identification and validation of miRNAs as well their inhibitors/mimics as
prognostic, therapeutic and clinical management tools necessary to reduce the
burden of aggressive PCa.
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CHAPTER IV
IDENTIFICATION AND VALIDATION OF MIR-186 GENE TARGETS

Introduction:
MicroRNAs regulate a vast number of mRNA targets to exert their
effects on cellular processes in normal and tumor cells. Commonly, miRNAs bind
to the 3’UTR of mRNA transcripts. However, some studies have revealed
miRNAs also bind to the 5’UTR of as well and do not rely solely on complete
complement binding to regulate target genes. Aberrant gene expression profiles
in PCa are partially attributed to the dysregulated miRNAs that regulate them.
MiR-186 has been implicated as a tumor suppressor in oral squamous, non-small
cell lung, colorectal and ovarian cancer [106-112]. However, miR-186 has also
been linked to an oncogenic role in several malignancies as well [63, 99-104,
106-108, 140, 141]. Although the aforementioned reports exhibit that miR-186-5p
expression is up- and/or-down-regulated in some cancers, miR-186-5p
characterization in vitro studies in our lab (Chapters 2 and 3) support an
oncogenic role for miR-186 in PCa. Elevated levels of this miRNA are associated
several cancers, which further support an oncogenic function for miR-186-5p.
Moreover, some aforementioned reports have identified tissue specific targets of
miR-186. However, targets for miR-186-5p in PCa cells have not been validated
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[63, 113]. Thus, the identification of miR-186-5p targets in PCa would provide
mechanistic evidence to elucidate the potential role of miR-186-5p in PCa.

miRNA-186 and its gene targets in cancer
Several miR-186 gene targets have been identified and validated in
various solid tumors. Additionally, the biological outcomes via overexpression
and/or inhibition of miR-186-5p were evaluated in different cancers as well.
Forced expression of miR-186 down-regulates the gene and/or protein
expression of pro-apoptotic gene, P2X7, tumor suppressor-related genes
(NR5A2, FOXO1, AKAP12, PPM1B), glucose transporter GLUT1, PTTG1, and
oncogenic genes (ROCK1, NSBP1), which are direct miR-186 targets as shown
in Table 4 [100, 101, 103, 105-108]. Among the cancers that under-express miR186-5p, several targets have been validated in the literature [106-112, 131]. For
instance, overexpression of miR-186 inhibits cellular migration, invasion and
glucose uptake of cancer cells via down-regulation of pituitary tumor transforming
1 (PTTG1), Rho-associated protein kinase (ROCK1) and GLUT1 expression in
NSCLC and cancer associated fibroblasts, respectively [106-108]. In one study,
ectopic expression of miR-186 decreased ROCK1 and PTTG1 protein
expression in HEK 293T and NSCLC cell line, A549, respectively. Sun and coworkers (2014) observed that miR-186 overexpression decreases GLUT1 gene
and protein expression [108].

In another study, overexpression of miR-186

resulted in a down-regulation of oncogenic-related gene, NSBP1, in HT-1376
bladder cancer cells [131].
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However, miR-186 also plays an oncogenic role in several cancers (i.e.,
pancreatic, cervical, bladder, and endometrial) via the down-regulation of anticancer-related genes [100, 101, 103, 105, 130]. For instance, overexpression of
miR-186 was associated with a decrease in the mRNA expression of proapoptotic P2X7 gene in HEK 293T cells. Furthermore in HEK 293T cells, miR-186
inhibition resulted in an increase of P2X7 gene expression relative to controls. In
another report, ectopic miR-186 expression suppressed the protein expression of
tumor suppressor, FOXO1, in endometrial cancer HEC-1B cells [100]. Whereas,
inhibition of miR-186 led to an increase in the protein expression of FOXO1 and
p27, a mediator of cell cycle arrest and senescence, in endometrial cancer
Ishikawa cells [100, 101]. Moreover, Goeppert and associates (2010)
demonstrated that overexpression of miR-186 in HEK 293 cells reduced gene
expression and luciferase activity of AKAP12, a tumor suppressor in liver cancer
[105]. In two other reports, miR-186-5p overexpression in pancreatic (i.e., Panc1, BxPC-3, and MiaPaca-2) and bladder (i.e., J82) cancer cells led to the downregulation of tumor suppressor genes, NR5A2 and PPM1B, relative to controls,
respectively [103, 130]. Unfortunately, no definitive miR-186-5p targets have
been validated in PCa due to limited reports [99-112, 130, 131]. Therefore, we
performed experiments to define targets of miR-186-5p in PCa cells.
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Table 4. Validated Gene Targets of miR-186 in Cancer. Aberrant expression of
miR-186 detected via qRT-PCR in 14 different studies for several malignancies.
Six studies

show

miR-186-5p

up-regulated

in

pancreatic,

endometrial,

esophageal, and cervical cancer. In contrast, other studies detected miR-186-5p
down-regulated in non-small cell lung, oral squamous, and ovarian cancer.
However, conflicting miR-186-5p expression data exists in relation to bladder and
PCa.
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We hypothesized based our in vitro studies that overexpression of miR186-5p would lead to the down-regulation of tumor suppressor genes in PCa.
AKAP12 was validated as a direct target of miR-186-5p in a metastatic PCa cell
line, PC-3. In previous reports, AKAP12 has been identified as a tumor
suppressor in gastric and PCa [142, 143]. Transient ectopic expression of miR186-5p down-regulated AKAP12 endogenous protein expression in HEK 293T
cells. Additionally, transient miR-186-5p inhibition in PC-3 cells lead to a slight
up-regulation of endogenous AKAP12 protein. Furthermore, this tumor
suppressor gene may be considered as a potential target of future therapeutic
agents against PCa.
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Methods:
Cell Culture
Cell lines (PC-3, RWPE1) used to analyze gene expression profiles
altered by miR-186-5p overexpression and/or inhibition were previously
described in Chapter 3 methods.

HEK 293T is an immortalized and transformed human epithelial embryonic
kidney cell line with a SV40 T-antigen derived from a human fetus. 293T cells
were sub-cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) medium
supplemented with 10% of FBS, 1% of 200nM L-glutamine [100x] (Catalog#
25030-081, Thermo Fisher Scientific, Waltham, MA) and 1% of antibiotic [10,000
I.U./ml of penicillin, 10,000ug/ml of Streptomycin, 25ug/ml Amphoterricin B]
(Catalog # 30-004-Cl, Mediatech Inc., Manassas, VA).

microRNA Isolation from cell lines
miRNA isolation from cells protocol was previously described in Chapter 3
methods.

Transient and Stable Transfection
Transient and stable transfection protocols were previously described in
Chapter 3 methods.

HEK-293T cells were at a cell density of 8x10 5 into 60 mm dishes and
incubated 37oC overnight. Cells were washed twice in PBS before transfection.
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Cells were transfected using mirVana miR-186 mimic (19 nM), mirVana mimic
scramble control (19 nM) (Thermo Fisher Scientific, Waltham, MA, Carlsbad, CA)
according to manufacturer’s instructions. In brief, a 10 µM stock solution was
made for the mirVana mimic scramble control (10 pmoles/µl) and mirVana miR186 mimic (10pmoles/µl). Cells were transfected in 60mm dishes with 50pmoles
of mirVana mimic scramble control and mirVana miR-186 mimic in 1ml of OptiMEM Reduced Serum Media (Catalog# 11058921, Thermo Fisher Scientific,
Waltham, MA), JetPrime reagent and buffer (Catalog# 114-01, Polyplus
Transfection, New York, NY) according to manufacturer’s instructions. After a 2hr
incubation at 37oC, 1 ml of growth medium was added each dish. After 24 hrs,
cells were used western blot analyses.

miRNA Expression
miRNA expression procedure was p previously described in Chapter 3
methods.

Human Gene Expression Array
Total RNA was isolated from a total of 24 samples described as metastatic
PC-3 cells with transient (n = 3) and stable inhibition of miR-186 (n = 3), normal
epithelial RWPE1 cells with transient (n = 3) and stable overexpression of miR186 (n = 3) and their respective controls, scramble control (transient) (PC-3 n =
3; RWPE1 n = 3) and empty vector control (stable) (PC-3 n = 3; RWPE1 n = 3).
Ectopic and inhibition expression of miR-186 in the cell lines were performed
independently in triplicate. RNA sample purity and integrity was assessed using
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the Agilent 2100 Bioanalyzer instrument. RNA quality (A260/A280) was evaluated
using a Nanodropper spectrophotometer.
According to the instructions of the 3’IVT Plus Reagent kit (Catalog# 902416,
Affymetrix Inc., Santa Clara, CA), sample and stock preparations were performed
in non-stick nuclease-free tubes. Serial dilutions for the poly-A control was
prepared in the following order: 1st dilution was a 1:20 dilution of poly-A control
stock (2µl) pipetted into poly-A control dilution buffer (38 µl), 2nd dilution was a
1:50 dilution of the 1st dilution (2 µl) pipetted into poly-A control dilution buffer (98
µl), 3rd dilution was 1:50 dilution of the 2nd dilution (2 µl) pipetted into poly-A
control dilution buffer (98 µl), 4th dilution was a 1:4 dilution of the 3 rd dilution (5 µl)
pipetted into poly-A control dilution buffer (15 µl) and 2 µl of the 4th dilution poly-A
RNA solution was added to each total RNA (250 ng) sample. The First-Strand
Master mix [x26, 3’ First-Strand buffer (4 µl), 3’First-Strand Enzyme (1 µl)] was
made, mixed thoroughly by gently vortexing tubes, centrifuged briefly to collect
mixture at the bottom of the tubes and placed on ice. First-Strand master mix (5
µl) was added to each sample, mixed thoroughly by gently vortexing tubes and
centrifuged briefly to collect mixture at the bottom of the tubes. For the firststrand synthesis reaction, samples were incubated for 2 hrs at 42oC and at least
2 mins at 4oC. Immediately after incubation, samples were centrifuged briefly to
collect cDNA at the bottom of tubes and placed on ice for 2 mins. The SecondStrand master mix [x26, 3’ Second-Strand Buffer (5 µl), 3’ Second-Strand
Enzyme (2µl), Nuclease-free H2O (13 µl)] was made, mixed thoroughly by gently
vortexing tubes, centrifuged briefly to collect mixture at the bottom of the tubes
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and placed on ice. Second-Strand master mix (20 µl) was added to each FirstStrand cDNA sample (10 µl), gently vortexed and centrifuged briefly. Samples
were incubated for 1hr at 16oC, 10 mins at 65oC and held at 4oC for at least 2
mins in a thermocycler. After incubation, samples were immediately centrifuged
and placed on ice. In Vitro Transcription (IVT) master mix [x26, 3’ IVT Biotin
Label (4 µl), 3’ IVT Buffer (20 µl), 3’ IVT Enzyme (6 µl)] was prepared at room
temperature, gently vortexed and centrifuged briefly. IVT master mix (30 µl) was
transferred to each Second-Stranded cDNA sample, gently vortexed and
centrifuged briefly to collect reaction at the bottom of tube. Samples were
incubated for 16hrs at 40oC and held at 4oC to synthesize complementary RNA
(cRNA) using a thermocycler. After incubation, samples were centrifuged briefly
and placed on ice. Purification beads and cRNA were equilibrated to room
temperature. Purification beads (100 µl) were added to each cRNA sample (60
µl) in 96-well plate. Each mixture was pipetted up and down 10 times and
incubated for 10 mins at room temperature to facilitate cRNA binding to beads.
Plate was moved to a magnetic stand to capture beads. Supernatant was
carefully aspirated off beads and discarded after 5 mins. Purification beads were
washed with 80% EtOH (200µl) for an incubation period of 30 secs three times.
After the final wash, 80% EtOH was slowly aspirated off and discarded without
disturbing the purification beads. Beads were air dried on the magnetic stand for
5 mins until no liquid is visible. Plate was removed from magnetic stand and preheated (65oC) nuclease-free H2O (27 µl) was added to each sample. After a 1
minute incubation, samples were pipetted up and down 10 times or until beads
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were fully resuspended into solution. Plate was moved to magnetic stand for 5
mins to capture purification beads. Supernatant (eluted cRNA) for each sample
was transferred to nuclease-free tubes and placed on ice. The quality and yield
of cRNA was measured using a nanodrop spectrophotometer. Purified cRNA
was fragmented by divalent cations and elevated temperature. Labeled cRNA
(12 µg) was transferred to nuclease-free tubes and brought up to required
volume (25.6 µl) with nuclease free H2O. 3’ Fragmentation buffer (6.4 µl) was
added to each sample for a total volume of 32 µl, gently vortexed and centrifuged
briefly. Samples were incubated for 35 mins at 94oC and held at 4oC for at least 2
mins in a thermocycler. After incubation, samples were centrifuged briefly and
placed on ice. Agilent Bioanalyzer was used to check fragmentation of cRNA.
GeneChip PrimeView Human Gene Expression arrays were removed from 4 oC
storage and allowed to equilibrate to room temperature. Hybridization oven was
pre-heated at 45oC, pre-hybridization buffer was allowed to equilibrate to room
temperature and 20X hybridization controls (bioB, bioC, bioD, cre) were heated
at 65oC for 5 mins in a thermocycler. For the 100 format, a hybridization master
mix [x25, control oligo B2 (3nM, 3.3 µl), 20X hybridization controls (10µl), 2X
hybridization mix (100µl), DMSO (20 µl), nuclease-free H2O (40 µl)] was made to
add to fragmented and biotin-labeled cRNA (10 µg) to make hybridization cocktail
for a total volume of 200ul. Hybridization cocktail was gently vortexed and
centrifuged briefly. Each array was processed one at a time. Array was vented
from the insertion of a pipette tip into the upper right septum and filled with prehybridization buffer (130 µl) from the bottom left septum and placed in pre-heated
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oven (45oC) for 10 mins. Pre-hybridization buffer was removed from array.
Hybridization cocktail was incubated for 5 mins at 99oC and 5 mins at 45oC in a
thermocycler. After incubation, samples were centrifuged briefly. Array was
refilled from the lower bottom septum with hybridization cocktail (130 µl) avoiding
insoluble matter. Both septa were covered with ½” tough spots to minimize
evaporation and/or leaks. Array was loaded into the hybridization oven and
incubated at a rotation of 60rpm for 16hrs at 45 oC. Array was removed from the
oven and tough-spots were removed from the array. Hybridization cocktail was
extracted from the array and refilled with wash buffer A. Array was allowed to
equilibrate at room temperature before washing and staining protocol. In the
fluidics station, stain cocktail 1 (600 µl) was placed in stain holder 1, statin
cocktail 2 (600µl) was placed on stain holder 2 and array holding buffer (800 µl)
was placed in buffer holder 3. Array was washed and stained according to array
type, the type of hybridization components and fluidics protocol FS450_0002.
Each array was analyzed by gene chip scanner (Affy.Command console Version
3.3).

Statistical Analysis of Human Gene Expression Array
Statistical analysis of gene expression data from arrays was performed
using the Partek Genomics Suite 6.6 software (St. Louis, MO). Gene expression
profiles differentially expressed by 1.2-fold change with their corresponding pvalue were identified in metastatic PC-3 cells and normal epithelial RWPE1 cells.
Genes overexpressed in PC-3 cells and under-expressed in RWPE1 cells were
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identified as potential miR-186 targets. Next, gene expression profiles were
adjusted by multiple hypothesis testing using a false discovery significance level
of ≤ 0.05. Principal component analyses for gene expression in the PC-3 and
RWPE1 cell lines and experimental groups were performed to determine the
spread between biological replicates and each experimental group.

miR-186 Target Selection
MiR-186 potential targets were selected from differential expressed genes
in stable anti-miR-186 PC-3 and stable ectopic miR-186 expressing RWPE1
cells. Genes down-regulated in stable RWPE1 cells and up-regulated in stable
PC-3 cells by ± 1.2 fold change. Expression profiles were adjusted for multiple
hypothesis testing using the FDR cut off p-value of 0.05. Genes that survived
multiple hypothesis testing were further filtered using in silico tools (MetaCore,
Ingenuity, microrna.org) and validated targets in the literature to determine direct
and indirect targets of miR-186. After filtering, 21 genes were selected to be
potential direct targets. Also, two additional targets were selected as potential
indirect target of miR-186.

mRNA Expression
Total RNA (500ng or 1µg) was reverse transcribed using qScriptTM cDNA
SuperMix (Catalog# 95048-025, Quanta Biosciences). Quantitative real-time
PCR (qRT-PCR) of synthesized cDNA was performed using a 2hr cycling
protocol on Applied Biosystems Step Up Real or 7900 PCR system and
PerfeCTa SYBR Green FastMix ROX (Catalog# 95073-012, Quanta
124

Biosciences) according to the manufacturer’s instructions. The relative
expression of mRNA transcripts were normalized to GAPDH expression and
calculated using 2-∆∆Ct method. Primers used in gene expression analysis are the
following: AKAP12 (Catalog# PPH06033A, Qiagen, Germantown, MD) and
TRIB3 (Catalog# PPH05870C, Qiagen, Germantown, MD). Gene expression was
measured using the following cycling conditions: 10 mins at 95oC for 1 cycle, 15
secs at 95oC and 1 minute at 60oC for 40 cycles, then melting curve 15 secs at
95oC, 1 minute at 60oC, +0.3oC per second and 15 secs at 95oC.

Western Blot Analysis
HEK 293T and PC-3 cells were seeded in 60 mm dishes. HEK 293T cells
were transiently transfected with negative scramble control (19 nM) and miR-186
mimic (19 nM). PC-3 cells were transiently transfected with negative scramble
control (33 nM) and miR-186 inhibitor (33nM). Whole cell protein lysates were
collected 24, 48, 72, 96 hrs post-transfection in Radio-Immunoprecipitation Assay
(RIPA) buffer (Catalog #R0278, Sigma Aldrich, St. Louis, MO) supplemented with
1:100 dilution of 100mM sodium orthovanadate (Catalog# 567540-5GM, Sigma
Aldrich, St. Louis, MO) and 1:100 dilution of protease inhibitor cocktail (Catalog#
P8340, St. Louis, MO). Protein concentrations were determined by Bradford
assay (Catalog# 5000001, Bio-Rad, Hercules, CA). Cell lysates were separated
by MP TGX 4-20% gels (Catalog# 4561094, Bio-Rad, Hercules, CA) and
transferred to PVDF membranes (Catalog# 1704272, Bio-Rad, Hercules, CA)
using the Trans-Blot Turbo system (Bio-Rad, Hercules, CA). Protein expression
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of AKAP12 and TRIB3 was measured using primary monoclonal mouse AKAP12
antibody (Catalog# WH0009590M1-100, Sigma Aldrich, St. Louis, MO), primary
monoclonal

mouse

TRIB3

antibody

(Catalog#

sc-390242,

Santa

Cruz

Biotechnology, Dallas, TX), and secondary anti-mouse antibody (Catalog# 7076,
Cell Signaling, Danvers, MA). Anti-B-actin (Catalog# A5316, Sigma Aldrich, St.
Louis, MO) at a 1:5,000 dilution was used as a loading control. Anti-AKAP12
(1:500) and Anti-TRIB3 (1:200) were detected in cell lysate (35ug) from HEK
293T and PC-3 cells. Densitometry analysis was performed using ImageJ
software (U. S. National Institutes of Health, Bethesda, Maryland).
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Results:
Differential gene expression influenced by miR-186 inhibition and overexpression
To identify potential miR-186 targets in PCa, gene expression profiles
were evaluated in total RNA extracted from transiently and stably miR-186
inhibited PC-3 cells and transiently and stably miR-186 overexpressing RWPE1
cells. The PC-3 cells were chosen as a cell model for miR-186-5p inhibition for
the microarray analysis due to their pronounced expression of miR-186-5p
relative to normal epithelial cells (Figure 9). Also, RWPE1 cells were used as a
cell model for miR-186-5p overexpression in the analysis to provide information
on the dysregulation of gene profiles impacted by miR-186 in the normal prostate
cellular phenotype. Gene profiles were identified as potential miR-186 target
based on the following selection criteria: 1.2 fold change, false discovery rate
(FDR) p-value ≤ 0.05 and unique and/or common genes in PC-3 and RWPE1
cells (Figure 22). After filtering profiles according to the selection criteria, 222
genes were identified as up-regulated by ≥ 1.2-fold change in transient miR-186
inhibited PC-3 relative to scramble control (Data not shown). Before adjusting for
multiple hypothesis testing, 344 targets were down-regulated (≥ 1.2-fold change)
in transient miR-186-5p over-expressing RWPE1 cells relative to scramble
control (Data not shown). However, gene profiles in the transient RWPE1 cells
did not survived multiple hypothesis testing. In contrast, a total of 2,898 genes
were down-regulated in stable RWPE1 cells and 4009 targets were up-regulated
in stable PC-3 relative to the empty vector controls (Figure 23). After filtering
according to the selection criteria for 2,343 genes were down-regulated in stable
RWPE1 cells and 3,454 genes were up-regulated in stable PC-3 cells relative to
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empty vector (Figure 23). Gene expression profiles altered in stable PC-3 and
stable RWPE1 cells were further examined due to a larger selection of genes
and being more physiological cell models compared to the transient cell models.
Moreover, we identified potential miR-186 targets from microarray analyses using
previously validated miR-186 targets and miR-186 targets predicted by in silico
tools (e.g., miR Base, microRNA.org, Metacore and Ingenuity). A combination of
these predicted targets were used to further filter differentially expressed genes
from the human gene expression arrays. Twenty-three targets were selected for
further validation via qRT-PCR, and western blot analysis (Figure 24).

miR Target Selection
The microarray analysis for the physiological cell models (i.e., stable antimiR-186 PC-3 and stable miR-186 RWPE1 cells) revealed a wealth of
informative gene expression profiles. Twenty-three genes (JUN, FN1, p53,
WNT5A, CASP9, FOXO3, VEGFA, c-Myc, EGR1, AKAP12, FOXG1, STAT4,
CCL20, PTEN, SMAD4, WASL, PAK1, YY1, TDG, IL1RL1, TRIB3) were selected
as predicted targets of miR-186 from the gene expression profiles that survived
multiple hypothesis testing and further filtering on gene targets predicted by in
silico tools (11,000 genes), validated mRNA transcript targets and biological role
in cancer. Previous reports demonstrated that miR-186 directly target genes
involved in tumor suppression (i.e., FOXO1, NR5A2), oncogenesis (ROCK1),
stimulation of cell migration and/or invasion, cell cycle regulation (i.e., CDK2,
CDK6, cyclin D1), meschymal phenotype regulation (TWIST1) and apoptosis
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(i.e., P2X7) [100, 101, 103, 105-108]. These twenty-three genes included two
possible indirect targets of miR-186, IL1RL1 and TRIB3, due to their significant
up-regulation (8 and 11-fold) in stable anti-miR-186 PC-3 cells. Furthermore, the
microrna.org database was utilized to determine the binding sites of miR-186 for
all 23 genes (Data not shown). This database uses mirSVR and PhastCons
scoring methods to determine potential direct gene targets of miR-186. The
PhastCons score is a probability that each nucleotide belongs to a conserved
element. A negative value indicates faster-than expected evolution and a positive
value imply conservation (threshold minimum = 0.566). mirSVR is a regression
model that assesses a weighted sum of a number of sequence and context
features of the predict miRNA-mRNA duplex to aid in the prediction of target sites
of 6-mer or better seed site, or a mirSVR score ≤ -0.1. (www.microrna.org). The
gene and protein expression of selected potential targets were further validated
via qRT-PCR and western blot analyses.
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Figure 22. Gene selection criteria for miR-186 potential targets. Human GeneChip
Primeview Human gene expression array contained 49,395 genes. Gene expression
profiles were evaluated using the 3’UTR region of each gene via qRT-PCR. In silico
tools (i.e., MetaCore, Mirbase.org, Ingenuity) were used to determine about 11,000
predicted targets for miR-186. Gene expression profiles of predicted targets that ± 1.2
fold change and false discovery rate (FDR) p-value ≤ 0.05 were identified as potential
miR-186 targets in PC-3 and RWPE1 cells. Common and unique targets were identified
in each cell line as well. Additional target selection was performed using identified and
validated miR-186 targets in from miR databases and published reports to produce a list
of 21 targets. Genes not identified as putative targets, but highly up-regulated in PC-3
cells were selected as potential indirect targets (≥ 5 fold change and FDR p-value ≤
0.05).
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Figure 23. Identification of potential miR-186 targets in PCa. Gene expression profiles of
50,000 targets in stable miR-186 overexpression in RWPE1 cells and stable miR-186
inhibition in PC-3 cells were evaluated by human gene expression Affymetrix
microarrays. The down-regulation of 2343 differentially expressed gene targets were
identified in RWPE1 cells relative empty vector. In stable PC-3 cells, 3454 gene targets
were up-regulated relative to empty vector. There were 555 common genes identified as
potential targets of miR-186 between PC-3 and RWPE1 cells.
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Figure 24. Gene list of predicted direct targets of miR-186. In the microarray analysis, a
total of 21 targets (JUN, FN1, p53, WNT5A, CASP9, FOXO3, VEGFA, c-Myc, EGR1,
AKAP12, FOXG1, STAT4, CCL20, PTEN, SMAD4, WASL, PAK1, YY1, TDG) were
identified as differentially expressed genes due to alternate miR-186-5p expression
based on the gene selection criteria (± 1.2 fold change and false discovery rate (FDR)
p-value ≤ 0.05). The above common and unique gene targets in PC-3 and RWPE1 cells
were identified as direct miR-186 targets via in silico tools (Ingenuity, MetaCore,
www.microrna.org, MirBase). In addition, we identified as a potential indirect miR-186-5p
target, TRIB3, due to its significant up-regulation (8-fold) in stable PC-3 cells.
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AKAP12 is a direct target of miR-186 in metastatic PCa
Only a select number of miR-186 targets (p53, PTEN, CASP9, FOXO3,
AKAP12, PTEN, TRIB3, IL1RL1) were validated from the microarray analysis
based on time and budget constraints. Gene expression of potential miR-186
targets were analyzed in miR-186-5p inhibited PC-3 cells and miR-186-5p
overexpressing RWPE1 cells. PC-3 cells were transiently transfected with miR186-5p inhibitor (33 nM) and scramble control (33 nM). RWPE1 cells were
transiently transfected with miR-186-5p mimic (19 nM) and scramble control (19
nM). Cell lysates were collected 24, 48, 72, and 96 hrs post transfection. Total
RNA was isolated from cells at the indicated time points using the mirVana
microRNA isolation kit. Total RNA was reverse transcribed into cDNA and
expression of miR-186-5p and selected genes were validated by qRT-PCR. Next,
whole cell protein lysates from transient miR-186-5p inhibited PC-3 cells and
miR-186-5p overexpressing HEK 293T cells were collected 24, 48, 72, 96hrs
post transfection to measure the endogenous protein expression of gene targets.
No significant difference was detected in the transcript expression of p53,
CASP9, FOXO3, PTEN, and IL1RL1. The gene expression of pro-apoptotic
gene, TRIB3, was up-regulated after 48 hrs post-transfection in metastatic PC-3
cells relative to scramble control (Figure 25A). However, this up-regulation was
not significant. Tumor suppressor, AKAP12, was up-regulated by 1.78-fold 72 hrs
post-transfection in PC-3 cells relative to scramble controls (Figure 25B).
Additionally, miR-186 has three different binding sites on the AKAP12 transcript
(Figure 26). In stable anti-miR-186 PC-3 cells, AKAP12 gene expression was upregulated by 1.6-fold relative to empty vector (Figure 27A). Furthermore, AKAP12
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transcript expression was extremely under-expressed in metastatic MDA PCa 2b
and LNCaP cells relative to normal epithelial RWPE1 cells (Figure 27B).
However, AKAP12 was up-regulated by 2-fold in PC-3 cells relative to RWPE1
cells (Figure 28B). Although AKAP12 was up-regulated in PC-3 cells, miR-1865p expression in PC-3 cells (16-fold) is 8 times more than the expression of
AKAP12 expression.
To determine the effect of miR-186-5p expression on the endogenous
protein of AKAP12 and TRIB3, immunoblotting analyses were performed in HEK
293T and PC-3 cells. HEK-293T cells were transiently transfected with miR-186
mimic (19 nM) and scramble control (19 nM) for 24-72 hrs. After 72hrs post
transfection, AKAP12 protein expression was decreased in HEK 293T cells
(Figure 28A). Transient miR-186-5p inhibition in PC-3 cells with miR-186 inhibitor
(33nM) and scramble control (33 nM) resulted in the slight up-regulation of
AKAP12 protein expression in PC-3 cells 48hrs post-transfection relative to
scramble control. Unfortunately, TRIB3 exhibited no protein expression changes
in HEK293T and PC-3 cells (Figure 28B).
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Figure 25. Expression of potential miR-186 targets, TRIB3 and AKAP12, in metastatic
PC-3 cells. Transiently transfected PC-3 cells with miR-186 inhibitor and scramble
negative control. Cell lysates were collected 24, 48, 72, 96 hrs post-transfection and total
RNA was isolated from lysates using mirVana microRNA isolation kit. TRIB3 and
AKAP12 gene expression in PC-3 cells was examined by qRT-PCR. A) Pro-apoptotic
gene, TRIB3, expression was up-regulated by 1.72-fold increase after 48 hrs relative to
negative control (p-value = 0.0769). B) Tumor suppressor AKAP12 gene expression
was up-regulated 1.78-fold increase after 72 hrs relative to negative control (p-value =
0.0346). Data was quantitated from at least three independent experiments. Statistical
analysis was performed using an Unpaired Student’s T test and significance cut-off pvalue ≤ 0.05.
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Figure 26. Predicted binding sites for hsa-miR-186 on the AKAP12 transcript. Mir-186
has three potential binding sites for the AKAP12 gene as predicted by in silico tool
www.microrna.org. mirSVR score is the result of a regression model that computes a
weighted sum of a number of sequence and context features of the predicted
miRNA::mRNA duplex [144]. Context features are divided into duplex, sequence and
global. The duplex features include base pairing at the seed region, and 3'end of the
miRNA. The sequence features include A/U composition near the target sites and
secondary structure accessibility. Global features are the length of the UTR, relative
position of the target site in the UTR and conservation score. PhastCons score is a
probability that each nucleotide belongs to a conserved element. A negative value
indicates faster-than expected evolution a positive value imply conservation (Threshold
minimum = 0.566) (www.microrna.org).
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Figure 27. Endogenous AKAP12 expression in stable anti-miR-186 PC-3 cells and
metastatic PCa. Total RNA was isolated from cell lysates collected from stable anti-miR186 PC-3 cells and normal epithelial and PCa cells using mirVana microRNA isolation
kit. A) AKAP12 expression was up-regulated by 1.66-fold change in stable PC-3 cells
relative to empty vector (p-value= 0.0006). B) Relative to RWPE1 cells, AKAP12 was
under-expressed in androgen sensitive metastatic PCas cells (i.e., LNCaP, MDA PCa
2b). However, AKAP12 was up-regulated by 2.0 in PC-3 cells. Data was quantitated
from at least three independent experiments. Statistical analysis was performed using an
Unpaired Student’s T test and significance cut-off p-value ≤ 0.05.
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Figure 28. Protein expression of AKAP12 and TRIB3 in 293T and PC-3 cell lysates. A)
Hek-293T cells were transiently transfected with miR-186 mimic (19 nM) and scramble
control (19 nM). Protein expression of AKAP12 was decreased (70%) to scramble 72 hrs
post-transfection. Next, TRIB3 protein expression was examined in HEK 293T cells,
however no significant difference was detected between scramble and miR-186 mimic.
B) PC-3 cells were transiently transfected with miR-186 inhibitor (33nM) and scramble
control (33 nM). AKAP12 protein expression was slightly up-regulated by 11% in PC-3
cells 24 hrs post-transfection relative to scramble. However, no difference was detected
for TRIB3 protein expression. Data was quantitated from at least two independent
experiments. Densitometry analysis was performed using ImageJ software.
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Discussion:
Nearly 2,000 human miRNAs promiscuously regulate 30-60% of gene
expression, which proposes a great dilemma for miRNA target selection and
validation. Although multiple miRNAs may regulate the same mRNA transcript,
the utilization of in silico tools (i.e., MetaCore, Ingenuity MirBase, TargetScan
and

MicroRNA.org),

deep

sequencing

technologies

and

transient/stably

transfected cell models aid in the identification of direct miRNA targets. In the
current study, microarray analyses, in silico tools, specific statistical parameters,
published reports and PCa in vitro studies in Chapter 3 were utilized to identify
23 putative miR-186 targets using physiological stable miR-186 overexpressing
RWPE1 and miR-186 inhibited PC-3 cell models. Although over 2,000 targets
were either up-regulated or down-regulated in the transfected RWPE1 and PC-3
cell lines, respectively, we only focused on 23 targets due to their biological
function in cancer as well as time and budget constraints. To our knowledge, our
lab is the first to demonstrate AKAP12 as a direct target of miR-186-5p in a
metastatic PCa cell line (PC-3). Following miR-186 inhibition, we demonstrated
AKAP12 protein was up-regulated by 11% in the PC-3 cells. Although this upregulation of AKAP12 was modest, AKAP12 is known to be hypermethylated in a
number of cancers including prostate [145-151]. It is possible this may partially
attribute to the modest up-regulation of AKAP12 in PC-3 cells.
AKAP12 (A-kinase anchor protein 12) also known as the mouse
homolog SSecKS functions as a scaffold protein in signal transduction that
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associates with protein kinases A (PKA) and C and phosphatase [152].
Specifically, it binds to the regulatory subunit of protein kinase A and presumably
alters various cancer hallmarks [143, 153-155]. Previously, several investigators
demonstrate the down-regulation of AKAP12, a tumor suppressor, in several
cancers, including prostate [145-151]. Overexpression of AKAP12 in vitro
corresponds with a decrease in cell invasion, and anchorage independent growth
of mouse PCa cell models, MLL [143, 153]. Furthermore, AKAP12 knockout in
vivo resulted in prostatic hyperplasia [156]. However, additional studies are
warranted to elucidate the impact of loss of AKAP12 on tumor growth and cellular
behavior using PCa cell models. Also, AKAP12 was identified as a direct target
of miR-186 in only one other report other than the current study. A study by
Goppert et al reported a down-regulation of the AKAP12 transcript due to miR186 overexpression in HEK 293T cells [105].
In the current study, we demonstrate miR-186-5p overexpression downregulates endogenous AKAP12 protein for the first time to our knowledge.
Additionally, miR-186-5p inhibition in metastatic PC-3 cells resulted in an upregulation of the AKAP12 transcript and endogenous protein as well. We
speculate AKAP12 may partially, but not exclusively mediate the biological
effects of miR-186 on tumor behavior. Therefore, additional studies are needed
to identify other miR-186-5p targets that may contribute to the effect of miR-186
inhibition on cell proliferation, anchorage independent growth and invasion.
Collectively, the findings of our study and other studies suggest miR-186-5p
expression impacts the tumor aggressive phenotype.
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Fourteen studies have identified and validated miR-186s as either an
oncomiR or tumor suppressor in several different cancers (Table 3). It’s specific
role in cancer appears to be tumor specific. Seven out of 14 reports suggest
miR-186-5p plays a tumor suppressor role and targets oncogenic-related genes
for which cancers [106-112, 130, 131]. For instance, two independent studies
revealed ectopic expression of miR-186-5p in NSCLC cell models has led to the
down-regulation of oncogenic ROCK1 and motility promoting PTTG1 protein
expression [106, 107]. However in both studies, the β-actin loading controls (i.e.,
b-actin, GAPDH) were not evenly distributed comparing the negative control and
miR-186 over-expressing cell lines. In contrast, six studies support an oncogenic
role for miR-186-5p and have validated tumor-suppressor-related genes as miR186-5p targets as well. Overexpression of miR-186-5p resulted in the repression
of tumor suppressors, FOXO1, N5RA2, and PPM1B in endometrial, pancreatic
and bladder cancer cell models [100, 105, 130]. Additionally, these targets have
been shown as down-regulated at same time miR-186-5p was up-regulated in
tumor tissue relative to normal tissue.

We have considered the limitations, strengths and future directions of this
study. Although we hypothesized that primarily tumor suppressor genes would be
altered by oncogenic miR-186, a mixture tumor suppressor and oncogenicassociated genes were affected by miR-186 expression. Microarray analyses
revealed ectopic expression of RWPE1 cells led to the down-regulation of tumor
suppressor genes, namely (i.e., PTEN, FOXO3, AKAP12, FOXG1, SMAD4),

141

transcription factor (YY1), pro-angiogenic (VEGFA), oncogenic (c-Myc) and
chemokine (i.e., CCL20) genes. In contrast, miR-186 inhibition led to the upregulation of tumor suppressor (i.e., FOXO3, p53), oncogenic (i.e., JUN, P300, cMyc), cell adhesion (i.e., WNT5A), cytokine (i.e., IL1R1), pro-apoptotic (i.e.,
TRIB3) and cellular death-related (CASP9) genes. We speculate that the upregulation and down-regulation of oncogenic genes in both PC-3 and RWPE1
cells may represent a residual effect of normal epithelial and tumor cells
attempting to retain their original phenotype. For instance, well known
oncogenes, c-Myc and JUN, were slightly up-regulated in stably miR-186
inhibited PC-3 cells. We speculate up-regulation of these oncogenes may trigger
a survival mechanism to help this metastatic PC3 cell line retain its tumor
phenotype. Unfortunately, in our study the up-regulation tumor suppressor genes
involved in cell proliferation, anchorage independent growth and cellular invasion
apparently outweighed the tumor promoting properties of up-regulated
oncogenes. In the case of the over-expressing miR-186 normal epithelial cell
lines,

we evaluated whether miR-186 over-expression or inhibition would

modulate a limited number of mRNA transcripts (n = 11,000). However, future
analyses of the entire human transcriptome may elucidate novel miR-185-5p
targets using RNA-seq or next generation sequencing of transfected PCa cell
models and micro-dissected tissue-based studies.
Based upon the aforementioned reports and our study findings, AKAP12
may be a potential therapeutic target against PCa using pre-clinical studies.
Based on the direct impact of AKAP12 on cell proliferation, invasion and
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anchorage independent growth [143, 153-155], future studies may assess
whether ectopic or knock-in AKAP12 expression alone and/or in combination with
chemopreventive and/or chemotherapeutic agents may inhibit prostate tumor
growth and metastasis. Ultimately, we speculate that ectopic expression of
AKAP12 will reduce tumor growth and the metastatic potential of prostate tumor
cells as well as demonstrate a synergistic interaction with PCa therapeutic
agents.

In closing, miRNAs may serve as valuable tools to find potential

therapeutic targets for the effective monitoring and treatment of aggressive PCa.
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CHAPTER V
DISCUSSION, STRENGTHS AND LIMITATIONS AND CLINICAL RELEVANCE
Discussion
Aberrant expression of miRNAs is commonly associated with various
malignancies, including PCa. MiRNAs regulate a vast number of cancer-related
genes that regulate cell survival, proliferation, differentiation, migration, epithelial
mesenchymal transition, immune surveillance, angiogenesis, invasion and
metastasis [53, 54]. Their expression is not only detectable in mammalian cells
and tumor tissue, but also biological fluids (e.g., serum, plasma, urine) [52-54,
117, 121].

Consequently, miR expression in biological specimens offers an

opportunity to find and validate new clinical biomarkers as ideal cancer
diagnostic, prognostic and ultimately clinical management tools.

The primary objectives of the current study were to identify, validate and
characterize an oncogenic miRNA, miR-186-5p, using serum and cancer cell
models collected from PCa patients and appropriate controls.

We assessed

whether 377 miRNAs were differentially expressed comparing non-cancerous
controls to PCa patients with non-metastatic and bone-specific metastatic
disease

using

Taqman

array

and
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qRT-PCR

data.

Out

of

the

377 miRNAs, miRNA-106b-5p and -186-5p were up-regulated in the serum of
European American men diagnosed with PCa (tumor stage I, III, IV) relative to
disease free individuals. Since the literature on the role of miR-186 and PCa was
understudied relative to miR-106b, we focused on the quantitation and
characterization of miR-186 in immortalized PCa cell models and normal
epithelial cells. Relative to normal epithelial cells, miR-186 was significantly upregulated in a few metastatic PCa cell lines (i.e., PC-3, MDA PCa-2b and
LNCaP), especially the PC-3 cells. In addition, inhibition of miR-186-5p in PC-3
and MDA-PCA-2b cells resulted in the reduction of cell proliferation, colony
formation and cell invasion by 27-66% relative to appropriate controls for
transient transfections. In terms of a putative miR-186 target, we demonstrate
inhibition of miR-186 in PC-3 cells corresponds with an upregulation of a tumor
suppressor gene AKAP12 based on micro-array data, quantitative real time PCR
and western blot analysis. These findings were further confirmed upon ectopic
expression of miR-186, which led to down-regulation of AKAP12 in HEK 293T
cells. Lastly, previous empirical, text mining or in silico studies suggest AKAP12
is

a

likely

miR-186

target

based

on

bioinformatics

analysis,

immunohistochemistry staining, micro-array, qRT-PCR western blot and a
luciferase reporter assay [105] (mirtarbase.mbc.nctu.edu; microrna.org).

There is a lot of controversy surrounding the role of miR-186 in relation to
tumorigenesis. Six published studies suggest miR-186 has tumor suppressing
potential; where as other studies indicate an oncogenic role [106-112]. Six other
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studies propose miR-186 has oncogenic potential. MiR-186 expression is upregulated in endometrial, pancreatic, esophageal, cervical, head/neck and nonmelanoma skin cancer [99-104]. Controversy for miR-186 also exists for PCa
[63, 113]. In 2008, Ambs et al. observed miR-186 expression was up-regulated
in PCa relative to controls; whereas, Erdmann and co-workers (2014) indicate
miR-186 was down-regulated in PCa patients with non-organ confined PCa and
metastases. Neither of these two studies characterized the role of miR-186 in
PCa using pre-clinical models. We addressed this gap in the literature by
inhibiting the expression of miR-186 in metastatic PCa cell lines and monitoring
the effects on several aggressive cancer phenotypes. Commensurate with the
Ambs et al. report, our results are consistent with miR-186’s role as an oncomiR.
In short, inhibition of miR-186 leads to a reduction of cell proliferation, colony
formation and invasion as well as re-expression of a tumor suppressor gene,
(i.e., AKAP12), which is intimately involved in the aforementioned transformative
tumor processes.

AKAP12 as a miR-186 gene target based on empirical and in silico evidence
from published reports and our own studies
AKAP12 has been identified as a putative target of miR-186 in two studies
including this study. Additionally, we observed an increase in the transcript and
protein expression levels of AKAP12 after miR-186-5p inhibition in metastatic
PC-3 cells. Our findings and published reports on AKAP12 taken together
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suggest AKAP12 may be partially responsible for the suppression of proliferation,
invasion and anchorage independent growth in PC-3 cells [143, 153-155].
The Role of AKAP12 in Tumorigenesis
Based on our data, several published reports and in silico evidence, we
speculate AKAP12, a miR-186 gene target, may contribute to the observance of
significant reductions in cell proliferation, anchorage independent growth and cell
invasion in MiR-186 inhibited metastatic PCa cell models.

AKAP12 (a.k.a.,

SSeCKs), a major protein kinase C substrate, is a tumor suppressor gene that is
down-regulated in many solid tumors, including PCa [145-151].
independent studies demonstrate AKAP12’s ability to

Several

suppress cancer

phenotypes such as cell proliferation, anchorage independent growth, and cell
invasion [143, 153-155].

Transient co-expression of AKAP12 significantly

reduced colony formation and focus formation in v-Src NIH3T3 cell lines
(genetically modified to have enhanced anchorage independent growth) [154,
155].
Six out of seven published reports indicate AKAP12 plays a role in cell
proliferation [145, 152, 156-160]. Early passaged AKAP12 -/- or knock out MEFs
cells exhibited a higher cellular proliferation than wild type MEFs [158]. However
in later passages, AKAP12 KO MEFs lost capacity to proliferate and underwent
pre-mature senescence due to the hyperactivity of PKC α isoform, which induces
p16Ink4a/Rb via the mitogen-activated protein kinase kinase 1 (MEK) signaling
pathway. In another study, overexpression of AKAP12 significantly reduced cell
proliferation in S2-6 cells (i.e., equine fibroblasts transformed with the BPV-1
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genome), after 6 -10 days relative to Tet-regulated S2-6 clone [157]. This
overexpression of AKAP12 also leads to G1 cell cycle arrest via down-regulation
of the cyclin D transcript. Moreover, AKAP12 null mice had higher levels of
cellular proliferation within the anterior and ventral prostatic lobes relative wild
type mice [156]. Although higher levels of cell death within the anterior prostatic
lobe were detected in knock out mice, the number of newly proliferated cells far
exceeded the apoptotic cells.

Two studies suggest ectopic expression of SSeCKS (AKAP12 in humans)
reduces tumor invasion in vitro [143, 153]. In one study, ectopic expression of
SSeCKS in v-Src NIH3T3 cells (genetically modified to have enhanced
aggressive cancer behavior) significantly reduced the cellular invasion of NIH3T3
cells relative to v-Src NIH3T3 cells with basal levels of AKAP12 via RhoA- and
Cdc42-Dependent Pathways [153]. Notably, activated RhoA and Cdc42 could
reverse SSeCKS suppression of cytoskeletal architecture. In another study, reexpression of SSeCKS in MAT-LyLu (MLL) PCa cell line derived from rodents
decreased the chemotaxis and cell invasion through a matrigel by 4-6-fold
relative to MLL cells with endogenous levels of SSeCKS [143]. This increased
invasive potential mediated through overexpression of AKAP12 in MLL cells is
primarily dependent on MMP-2 expression and to a lesser extent MMP-9.
Treatment of MML cells with MMP inhibitor, GM6001, reduces cellular invasion
and the activity of MMP-2/9 [143]. Moreover, SSeCKS re-expression reduces
chemotaxis, cell invasion and MMP-2 transcript levels in MML cells. Matrix
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metalloproteinases (MMPs), including MMP2, play a role in the degradation of
the extracellular matrix proteins, necessary for the initiation of aggressive cellular
behaviors, including cell proliferation, migration, invasion, differentiation,
angiogenesis and apoptosis. The SSeCKS mediated reductions in chemotaxis
and cell invasion appear to be influenced by SSeCKS’s inhibitory effect on MEK,
which in turn blocks MEK/ERK signaling activation and subsequently MMP2
transcription. SSeCKS appears to regulate MEK/ERK signaling via inhibition of
PKC-induced activation of Raf, presumably through direct scaffolding of PKC by
SSeCKS [143].

The influence of SSeCKS (AKAP12) on aggressive cancer

behavior can be reversed by co-expressing

CA-MEK1, MEK2 or ERK2 in

constitutively SSeCKS expressing MLL cells, which increases chemotactic
motility. Re-expression of SSeCKS in MLL cells does not appear to alter RNA
levels of MMP-14 and TIMP-2, which are both required for MMP-2 activation
[143].

Collectively, these findings suggest SSeCKS potentially inhibit motility

parameters related to metastasis, presumably by deactivating Raf/MEK/ERK
pathways, which result in the down-regulation of MMP-2.

Commensurate with the aforementioned in vitro studies, our results
demonstrate that transient inhibition of miR-186 leads to an increase in AKAP12
transcript expression as well as a decrease in cell proliferation (PC-3, MDA PCa
2b), anchorage dependent growth (PC-3, MDA PCa 2b) and cell invasion (PC-3,
MDA PCa 2b) in metastatic PCa cells. The influence of miR-186 inhibition on
cellular behavior was more pronounced for the PC-3 cells and MDA PCa 2b cells
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derived from European-American and African-American men diagnosed with
bone-specific metastatic PCa, respectively. Interestingly, miR-186 inhibition did
not significantly influence anchorage independent growth of the MDA PCa 2b
cells unless cells were treated with DHT. This suggests androgen sensitivity may
increase susceptibility of cells to the tumor suppressing effects of miR-186-5p
inhibition. This androgen receptor-mediated change in anchorage independent
growth for MDA PCa 2b cells did not reach the level of significance observed for
miR-186-5p inhibited PC-3 cells. Although androgen-insensitivity may contribute
toward the cancer cell lines responsivity to miR-186 inhibition, we cannot rule out
the possibility of other genomic differences between these two cell lines. We
speculate the presence of a mutant P53 and null PTEN tumor suppressor genes
within PC-3 may make this cell line more dependent on miR-186’s oncogenic
potential to maintain a metastatic phenotype.

Future studies will test this

hypothesis by inhibiting or re-expressing P53 and/or PTEN within PC-3 cells,
respectively.

Limitations and Strengths
We have considered the strengths, limitations and future directions of the
current study. The current study demonstrates that over expression of miR-1865p in serum collected from PCa patients relative to controls, even in the presence
of a small sample size. Our limited sample size may have compromised our
capacity to detect other oncomiRs that were differentially expressed in serum
from PCa patients. Future studies are needed to confirm up-regulation of miR-
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186 in serum and matched micro-dissected PCa tissue specimens collected from
ethnically/racially diverse populations. Such studies require appropriate sample
sizes to have adequate statistical power to detect significant differences in miR186 expression comparing lethal and non-lethal PCa.
Moreover, we may have limited our capacity to identify additional
oncomiRs, since we did not include an acceptable internal control (i.e., C.
elegans miR-39) within the Taqman array cards designed to analyze 377 miRs.
We attempted to address this issue using a global normalization technique.
Global normalization is a technique that takes the median Ct value of all miRNA
profiles and screens for differentially expressed miRNAs that are down- or upregulated relative to the median Ct values. Although global normalization led us
to two important oncomiRs detected in our cell models transiently transfected
with a miR-186 inhibitor, global normalization can lead to false positives and false
negatives.

For instance, miR-186 upregulated in serum collected from PCa

patients relative to disease-free individuals following normal globalization of the
array data; however, this same miR was down-regulated during validation using
qRT-PCR and normalization with an external control (i.e., C. Elegans miR-39).
To minimize discordant findings attributed to varied normalization methods, we
will add miR-39 as an external control prior to serum processing and analysis
using taqman array and qRT-PCR.

However, given what we learned about

serum-based miRNAs, miR-39 is an appropriate control.

Since there is no

appropriate internal control for serum-based miRNAs, we used a non-human
derived miRNA (miR-39) for our qRT-PCR validation of miR-186, prior to the
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isolation of total RNA and conversion of RNA to cDNA [52]. C. Elegans miRNAs
(e.g., miR-39) may serve as ideal external controls for the analysis of serumbased human miRNAs because they help to account for any miRNA losses
during biospecimen processing [52, 122]. The use of miR-39 was ideal for our
serum based analysis, since C. elegans miR-39 is not detected in humans and is
unaffected by disease states.
Despite the aforementioned limitations, we demonstrated miR-186-5p was
significantly up-regulated in three metastatic PCa cell lines (i.e., PC-3, MDA PCa
2b and LNCaP cells) relative to normal epithelial cells. More importantly, we
established a link between miR-186 and several hallmarks of cancer (i.e.,
proliferation, anchorage independent growth and invasion). Inhibition of mIR-1865p reduced cellular proliferation, anchorage independent growth and cell invasion
in metastatic PCa cells. This decrease in aggressive cancer behavior may be
partially attributed to up-regulation of AKAP12 via miR-186 inhibition. However,
the up-regulation of other miR-186-5p gene targets may also contribute this
decrease in aggressive behavior as well.

Our data demonstrates an over-

expression of AKAP12 following inhibition of miR-186 in vitro. Since AKAP12
appears to regulate cellular proliferation, anchorage independent growth, and cell
invasion in other cancers, we speculate its loss in PCa may contribute toward
enhanced

cellular

tumorigenesis.

proliferation,

hyperplasia

and

ultimately

prostate

However, additional studies are needed to assess whether

ectopic expression of AKAP12 leads to a decrease in cell proliferation,
anchorage independent growth, and cell invasion using various PCa pre-clinical
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studies.

In addition, future pre-clinical or human tissue-based will assess

whether AKAP12 expression levels are inversely related to markers involved in
cellular proliferation (e.g., e-Cadherin, PTK2), anchorage independent growth
(e.g., PTK2), and cell invasion (e.g., MMP-2, MMP-9) in cell models with ectopic
expression of AKAP12 or immunohistochemistry staining of cancerous tissue
derived from animal models or humans. In addition, we will assess whether over
expression of AKAP12 will inhibit tumor growth and metastasis using a PCa
animal model.
In closing, we added new insights toward a definitive role of miR-186 in
PCa. Commensurate with previously mentioned studies [143, 145, 152, 153,
156-160], we provide convincing data that reveals miR-186 inhibition leads to upregulation of AKAP12 as well as a 27-46% reduction of cell proliferation,
anchorage independent growth and invasion in metastatic PC-3 and/or MDA
PCa-2b cells. Ultimately, our study findings serve as a foundation for future
studies focused on the identification and characterization of a new miRNA
biomarkers needed to distinguish between lethal and non-lethal PCa. In addition,
we offer guidance toward potential targets (e.g., AKAP12) that can be tested as a
therapeutic target for the effective treatment of aggressive PCa. These efforts, if
successful, may help to reduce the burden of PCa among all men.

Clinical Relevance
MiRNAs differentially expressed in cancer are steadily beginning to be
accepted as potential prognostic and diagnostic tools in PCa. Due to their
regulation of a vast number of gene targets and stable expression in biological
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fluids and tissue, miRNAs show great promise as potential biomarkers to aid
current screening tools. Clinical trial studies have yet to identify a procedure that
can completely replace the PSA test and digital rectal exam.
PCa detection has been solely dependent on procedures such as the PSA
test, digital rectal exam (DRE) and tumor biopsies. Unfortunately, alone the PSA
test is not a reliable tool in disease due to various biological stimulants [39, 40,
44, 46, 161]. The DRE is an invasive technique that also is insufficient alone to
detect PCa [40, 44, 46]. The combinatorial effort of both tools do not drastically
improve detection and can lead to false positive test results. Consequently, there
is a great need for biomarkers to aid in PCa detection and improve the overall
accuracy of these tools. To definitively diagnose PCa, physicians must collect a
biopsy from the prostate for histological evaluation. Tumor biopsies are very
invasive for patients and associated with urological problems. The measurement
of miRNA expression in routinely collected biological fluids may serve as an
alternative to these extremely invasive procedures.
The research presented in this dissertation is clinically relevant due to the
number of phase I and II clinical trials evaluating the miRNA expression in
various malignancies including PCa [NCT01220427, NCT02366494,
NCT01503229, NCT02471469, NCT01444820, and NCT02391051]. Some trials
are even investigating the use of tumor suppressor miRNA mimics as therapeutic
agents in cancer [NCT01829971, NCT02369198]. In the current study, miR-186
has been identified as a potential oncogenic miRNA in PCa. Furthermore,
inhibition of this miRNA has shown to repress the cellular behavior associated
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with the tumor phenotype. Ultimately, therapeutic agents that inhibit miR-186
expression may impede disease progression in PCa.
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CURRICULUM VITA
Dominique Z. Jones-Reed, M.S.
Dzjone01@exchange.louisville.edu
919-428-0273 (cell)

PROFESSIONAL SUMMARY
•

Research scientist with experience in developing, leading, and conducting

multi-disciplinary scientific studies in the areas of cancer and genetic
epidemiology.
•

Proficient communicator with the ability to provide results by preparing

comprehensive written and oral summaries of research development and
research findings.
•

Adept at evaluating research studies through collaborations with basic

scientists and community partners.
•

Skilled at training and providing guidance to colleagues and students in

research-related tasks.

EDUCATION
University of Louisville, Louisville, KY
Ph.D., Pharmacology and Toxicology
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May 2016

M.S., Pharmacology and Toxicology

December 2014

Smith College, Northampton, MA

May 2010

B.A., Biochemistry
RESEARCH AND PROFESSIONAL EXPERIENCE
Doctoral Candidate, Pharmacology and Toxicology Department
08/2011-05/2016
University of Louisville, Louisville, KY
P.I.: Dr. LaCreis Kidd
•

Received training in statistical analysis software (SAS), Linux operating

system programming, Collaborative Institutional Training Initiative (CITI) in
Human Subject Research, Health Insurance Portability and Accountability Act
(HIPPA) Privacy, Bloodborne Pathogens, and Laboratory Safety and Hazardous
Waste
•

Developed written evaluations and peer-reviewed manuscripts to

disseminate research findings and study progress
•

Developed laboratory protocols and facilitated the training of

undergraduates and medical students
•

Mentored and aided in the development of research projects for summer

research students
•

Investigating inflammatory and immune response related genetic variants

linked to PCa risk through data mining techniques (e.g., logistic regression and
multi-factor dimensionality reduction (MDR) modeling)
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•

Evaluating miRNA expression profiles in PCa serum and cell lines as

potential prognostic tools for PCa through the utilization of molecular and cellular
biology techniques to examine the impact of microRNA expression on cellular
behavior in normal prostate and PCa cells
•

Presenting research findings at local/national scientific meetings

•

Managing and maintaining human cell culture lines for experiments,

laboratory inventory, and administrative documents

Summer Research Intern, James Graham Brown Cancer Center
06/2011—08/2011
University of Louisville, Louisville, KY
P.I.: Dr. LaCreis Kidd
•

Evaluated chemokine-associated genetic variants as predictors of PCa

risk among men of African Descent though SAS programming and MDR
modeling
•

Routinely met with research team members and principal investigator to

discuss study progress and propose solutions to methodological problems in
order to achieve research goals in a timely manner
•

Presented research findings at the regional Research Louisville

symposium

Research Technician, Biomedical and Biotechnology Research Institute (BBRI)
11/2010-05/2011
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North Carolina Central University, Durham, NC
PIs: Dr. Maxwell Gyamfi and Dr. Sean Kimbro
•

Received American Association for Laboratory Animal Science (AALAS)

certification training in animal care for research and education through the
AALAS Learning Library
•

Evaluated the role of mouse and human xenobiotic nuclear receptor

pregnane X receptor (PXR) in obesity in vivo through protein analysis of targets
involved in S-Adenosyl methionine (SAM) synthesis and metabolism,
measurement of triglyceride, cholesterol and non-esterified free fatty acid in
hepatic tissue as well as glucose tolerance, lipid profiling (triglycerides, HDL,
LDL, and VDL) and liver toxicity (ALT/AST levels) in the serum

AWARDS AND HONORS
•

Dean’s Citation, University of Louisville

2016

•

AACR MICR Scholar in Cancer Research Travel Award

2016

•

ASPET Dolores C. Shockley Best Abstract Award 2nd Place

2016

•

ASPET Underrepresented Graduate Student Travel Award

2016

•

ASPET Dolores C. Shockley Best Abstract Award 1st Place

2015

•

ASPET Underrepresented Graduate Student Travel Award

2015

•

Alice Eaves Barns Award, University of Louisville

2014

•

Dean’s Citation, University of Louisville

2014

•

Fall Graduate Research Symposium Poster Winner,
University of Louisville

2014
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•

Southern Regional Education Board Doctoral Scholar Fellowship,
University of Louisville

•

2012-2015

Integrated Programs in Biomedical Sciences Fellowship (IPIBS),
University of Louisville

2011-2012

•

Dean’s List, Smith College 2009-2010

•

Jackie Robinson Foundation Scholar, Smith College

2006-2010

•

American Chemical Society Scholar, Smith College

2006-2010

PROFESSIONAL MEMBERSHIP
•

Sigma Xi, The Scientific Research Society, Member, 2010

•

American Association of Cancer Research (AACR), Member, 2012-2016

•

Black Biomedical Graduate Student Organization (BBGSO), President,
2012-2016

•

Golden Key International Honour Society, Member, 2012-2016

•

Minority Association of Graduate Students (MAGS), Vice President,
2015-2016

•

Society of Toxicology, Member, 2014-2016

•

American Society for Pharmacology and Experimental Therapeutics
(ASPET), Member, 2014-2016

INVITED ORAL PRESENTATIONS
•

American Society of Investigative Pathology (ASIP)/ American Association

of Anatomists (AAA) Career Development & Mentoring Program and Lunch:
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Fundamentals of Success: How to Give an Award Winning Presentation, March
29, 2015.
•

American Society of Investigative Pathology (ASIP), Breast and

PCa Mini-Symposium, March 30, 2015.
•

Translating MicroRNA Cancer Biology to Therapy Symposium, April
6, 2016.

PEER REVIEWED MANUSCRIPTS
•

Kidd L.R., Jones D.Z., Beache S., Rogers E.N., Ragin C., Jackson M.,

McFarlane-Anderson N., Tulloch-Reid M, Flores-Obando R., Barve S.S., Rudd
J.E., and Kimbro K.S.. Chemokine Ligand 5 (CCL5) and Chemokine Receptor
(CCR5) Genetic Variants and PCa Risk among men of African Descent.
Hereditary Cancer in Clinical Practice, 10(1):16, 2012.
•

Rogers E.N., Jones D.Z., Yeyeodu, S.T, Ragin C., Jackson M.,

McFarlane-Anderson N., Tulloch-Reid M, Kimbro K.S., and Kidd L.R. Toll-like
Receptor (TLR)-Associated Sequence Variants as Predictors of PCa Risk Among
Men of African Descent. Genes and Immunity, 10.1038/gene.2013.22, 2013.
•

Kidd, L.R., Rogers, E.N., Yeyeodu, S.T., Jones, D.Z., Kimbro, K.S.

Contribution of Toll-like Receptor Signaling Pathways to Breast Tumorigenesis
and Treatment. Breast Cancer: Targets and Therapy, 10.2147/BCTT.S29172,
2013.
•

Jones D.Z., Ragin C., Jackson M.,Kidd N.C., Flores-Obando

R.E.McFarlane-Anderson N., Tulloch-Reid M, Kimbro K.S., and Kidd L.R. The
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Impact of Genetic Variants in Inflammatory-related Genes on PCa Risk among
men of African Descent. Hereditary Cancer in Clinical Practice,11(1):19, 2013.
•

Spruiell K., Jones D.Z., Cullen J.M., Awumey E.M., Gonzalez F. J., and

Gyamfi, M.A. Role of human pregnane X receptor in high fat diet-induced obesity
in pre-menopausal female mice. Biochemical Pharmcology, 2014 Apr 7. pii:
S0006-2952(14)00207-X. doi: 10.1016/j.bcp.2014.03.019.

ABSTRACTS AND PRESENTATIONS: NATIONAL/LOCAL MEETINGS
•

Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N., Morrison S.,

Flores-Obando F., Kimbro K.S., and Kidd, L.R. Chemokine-associated genetic
variants as predictors of PCa risk among men of African Descent. Research
Louisville!, Louisville, Kentucky, September 28, 2011.
•

Kidd L.R., Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N.,

Morrison S., Flores-Obando F., Kimbro K.S. Chemokine-associated genetic
variants as predictors of PCa risk among men of African Descent. American
Association for Cancer Research (AACR) Cancer Health Disparities,
Washington, D.C. July 19, 2011.
•

Ragin C., Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N.,

Morrison S., Flores-Obando F., Kimbro K.S., Kidd L.R. Inflammatory Cytokine
SNPs and PCa in Black men. Caribbean Exploratory Research Center (CERC)
Health Disparities Institute, St. Thomas Virgin Islands, USA, October 19-21,
2011.
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•

Kidd L.R., Jones D.Z., Ragin C., Jackson M., McFarlane-Anderson N.,

Morrison S., Flores-Obando F., Kimbro K.S. Chemokine-associated Loci and
PCa Among Men of African Descent. American Association for Cancer Research
(AACR), Chicago, IL, November 15, 2011.
•

Jones D.Z., Anene D., Aloway A., Anene P., Avila D.V., Gobejishvili L.,

Barve S.S., McNally L.R., and Kidd L.R. Potential micro-RNA Biomarkers
Associated with Cell Migration and Metastasis. Research Louisville!, Louisville,
Kentucky, August 24, 2012.
•

Anene D., Jones D.Z., Aloway A., Anene P., Avila D.V., Gobejishvili L.,

Barve S.S., McNally L.R., and Kidd L.R. Are Cell Adhesion Associated MicroRNAs Linked With Metastatic PCa? Research Louisville!, Louisville, Kentucky,
August 24, 2012.
•

Aloway A., Jones D.Z., Anene D., Anene P., Avila D.V., Gobejishvili L.,

Barve S.S., McNally L.R., and Kidd L.R. Cell Survival miRNAs (29a, 29c, and
221) and Pre-metastatic PCa? Research Louisville!, Louisville, Kentucky, August
24, 2012.
•

Jones D.Z., Anene D., Aloway A., Anene P., Avila D.V., Gobejishvili L.,

Barve S.S., McNally L.R., and Kidd L.R. Potential micro-RNA Biomarkers
Associated with Cell Migration and Metastasis. James Graham Brown Cancer
Center Retreat, Louisville, Kentucky, October 3, 2012.
•

Jones D.Z., Anene D., Aloway A., Anene P., Avila D.V., Gobejishvili L.,

Barve S.S., McNally L.R., and Kidd L.R. Reduced Expression of miR-342-3p in
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stage I, III, and IV PCa. American Association for Cancer Research (AACR),
Washington, D.C., November 15, 2012.
•

Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt M.L.,

Hobbing K., Clark G., and Kidd L.R. TGF-beta Signaling in PCa cell lines derived
from European- and African-American men. Research Louisville!, Louisville,
Kentucky, September 24, 2013.
•

Linder J., Jones D.Z., Avila D.V., Gobejishvili L., Barker D., Schmidt M.L.,

Hobbing K., Clark G., and Kidd L.R. microRNA-885-5p and its role in the TGFbeta pathway using PCa cell lines derived from European- and African-American
men. Research Louisville!, Louisville, Kentucky, September 24, 2013.
•

Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt M.L.,

Hobbing K., Clark G., and Kidd L.R. TGF-beta Signaling in PCa cell lines derived
from European- and African-American men. James Graham Brown Cancer
Center Retreat, Louisville, Kentucky, October 25, 2013.
•

Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. The Effect

of miR-186 Inhibition on Cell Viability and Colony Formation in PCa. Research
Louisville!, Louisville, Kentucky, September 16, 2014.
•

Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. The Effect

of miR-186 Inhibition on Cell Viability and Colony Formation in PCa. James
Graham Brown Cancer Center Retreat, Louisville, Kentucky, October 17, 2014.
•

Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. The Effect

of miR-186 Inhibition on Cell Viability and Colony Formation in PCa. Fall 2014
Graduate Research Symposium, Louisville, Kentucky, November 14, 2014.
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•

Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. MicroRNA-

186 inhibition alters cell proliferation and colony formation in PCa. Experimental
Biology Meeting, Boston, MA, March 29, 2015.
•

Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. MicroRNA-

186 inhibition alters cell proliferation and colony formation in PCa. American
Association for Cancer Research (AACR), Philadelphia, PA, April 21, 2015.
•

Jones D.Z., Hobbing K., Schmidt M.L., Clark G. and Kidd L.R. MicroRNA-

186 inhibition alters cell proliferation and colony formation in PCa. Ohio Valley
Society of Toxicology (OVSOT), Cincinnati, OH, June 29, 2015.
•

Packer T.A., Jones D.Z., and Kidd, L.R. Impact of Quercetin on miR-21,

Cell Proliferation and Migration of Metastatic and Non-Metastatic PCa Cell lines.
Undergraduate R25 Poster Session, Louisville, Kentucky, July 30, 2015.
•

Jones, D.Z., Schmidt M. Lee, Hobbing, K.R., Clark G. and Kidd L.R. miR-

186 suppresses cell proliferation and anchorage-independence in a metastatic
PCa cell line. Research Louisville!, Louisville, Kentucky, October 27, 2015.
•

Jones, D.Z., Schmidt M. Lee, Hobbing, K.R., Clark G. and Kidd L.R. miR-

186 inhibition suppresses cell proliferation and anchorage-independence in a
metastatic prostate cancer cell line. Experimental Biology Meeting, San Diego,
CA, April 4, 2016.
•

Jones, D.Z., Schmidt M. Lee, Hobbing, K.R., Clark G. and Kidd L.R.

Inhibition of miR-186 and repression of aggressive prostate cancer phenotype
using a metastatic cell model. American Association for Cancer Research
(AACR) Meeting, New Orleans, LA, April 18, 2016.
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SERVICE TO UNIVERSITY
•

University of Louisville School of Medicine Diversity Committee,
Graduate Student Representative

2014-2016

SERVICE TO PROFESSION
•

American Society for Pharmacology and Experimental Therapeutics

(ASPET) Mentoring and Career Development Committee, Graduate Student
Representative

2015-2016
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